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Abstract 
 
Bariatric surgery such as Roux-en-Y gastric bypass (RYGB) is increasingly performed 
in obese patients with type 2 diabetes (T2DM) due to its beneficial metabolic effect. 
RYGB is distinct from non-bariatric surgery as it improves glycaemic control 
immediately post-surgery. Most bariatric centres also use a low calorie diet 
preoperatively which also impacts on glycaemic control before surgery. Glycaemic 
management of these patients therefore needs to be reviewed perioperatively to avoid 
hypoglycaemia. To date, no study has assessed how best to manage this group of 
patients preoperatively and postoperatively. GLUCOSURG-pre and GLUCOSURG-
post studies were designed to assess the effect of intensive glucose management 
before and after RYGB on glycaemic outcome. 
 
Moreover, patients with difficult controlled diabetes are more at risk of complications 
of diabetes. Given the rapid improvement in glucose control following RYGB, its effect 
on microvascular complications needs to be assessed. In this thesis, I measured the 
changes in diabetic nephropathy, retinopathy and neuropathy; and compared the 
changes in nephropathy and retinopathy to a control group. 
 
My study showed that 3 months of intensive management of glycaemia before surgery, 
or the first 2 weeks after surgery had not resulted in better glycaemic control at 1 year. 
RYGB has substantial effects on glucose control, and additional intensive glucose-
lowering interventions do not confer clinical benefits compared to conservative 
approaches. In the case-control study, RYGB patients showed substantial reductions 
in albuminuria, while the rates of retinopathy progression were similar to those 
observed in a medically treated group. There was no change in peripheral nerve 
function 1 year after RYGB surgery. My study was limited by small sample size and 
short duration of follow up. Nonetheless, the result would reaffirm the importance of 
annual surveillance for diabetic retinopathy and neuropathy after RYGB. 
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Introduction 
 
1.1 Prevalence of obesity 
1.1.1 The obesity epidemic 
Obesity has become the major public health problem in developed and developing 
countries due to its rising prevalence and association with obesity related diseases. 
The prevalence of obesity began in 1970, and had seen a significant increase since 
1999. In 2008, it was estimated that 1.4 billion adults worldwide were overweight, of 
which 500 million were obese. Overweight is defined as body mass index of ≥ 25kg/m², 
and obese is defined as body mass index of ≥30kg/m² (Organisation), 2012). In 
England, 26% of adult were classified as obese (The NHS Information Centre, 2012). 
Wang et al used a simulation model to project the health and economic consequences 
of obesity in UK and US at 20 years’ time (Wang et al., 2011). The projection showed 
prevalence of obesity would increase from 26% in 2007- 8 to 41- 48% in men in 2030; 
similarly, there is an increase from 26% to 35- 43% in women, an estimate of 11 million 
more obese adults in the UK by 2030. (Wang et al., 2011). Alarmingly, children are 
also affected by this epidemic. More than 40 million children under the age of five are 
classified as overweight globally. (WHO, 2010). In England, 30 % of children aged 2-
15 were classed as overweight or obese (The NHS Information Centre, 2012). 
1.1.2 Aetiology of obesity 
The development of obesity is led by chronic excess of energy intake over expenditure. 
Obesogenic environment, fuelled by easy accessibility of sugar-dense food, increased 
in mechanised work and reduction in physical work; led to inactivity and sedentary 
lifestyle. However, not everyone within the same environment becomes obese. 
Genetic predisposition to fat accumulation, or the drive to overeat, coupled by the 
obesogenic environmental factors exacerbate the extent of obesity. Advancement in 
food technology and expansion of food industry also played a part. Cultural differences 
such as body size preferences could also modulate the prevalence of obesity 
(Swinburn et al., 2011). 
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1.1.3 Treatment of obesity 
The conventional treatment of obesity encompassed physical activity (Shaw et al., 
2006), diet (Thomas et al., 2007) and pharmacotherapy(Bray, 2008). Comparing with 
low intensity exercise, high intensity exercise had better weight loss result. In addition, 
combined exercise and diet was shown to yield better weight loss than diet alone. 
Pharmacotherapy was once a popular option to control weight loss. However, the 
availability of these medications is restricted since the beginning of year 2000 due to 
drug safety issues. For example, Sibutramine are now withdrawn from sales in many 
countries due to its associated increased risk with cardiovascular and cerebrovascular 
events. Rimonabant were linked to increased risks of severe depression and suicidal 
thoughts and hence been withdrawn from the America and European market. 
Orlistat is now the only medication licensed for weight loss intervention in United 
Kingdom. It works by inhibiting the breakdown of ingestible fat by pancreatic lipase. It 
causes weight loss and had been shown to reduce incidence of diabetes in those with 
impaired glucose tolerance (Torgerson et al., 2004).  These interventions could 
achieve weight loss of about 10% but the success of these interventions is limited by 
long term adherence (Bray, 2008). 
More recently, weight loss surgery or bariatric surgery is shown to be more effective 
in losing weight and maintain the weight loss long term. It also has positive effect on 
hypertension and hyperlipidaemia; and had shown to reduce obesity related diseases 
such as obstructive sleep apnoea and cardiovascular event (Colquitt et al., 2009, 
Buchwald et al., 2004, Sjostrom et al., 2012). 
1.1.4 Relationship between obesity and chronic diseases 
Obesity is now the major public health problem because of its association with 
metabolic syndrome and chronic diseases. Obesity related conditions are projected to 
increase significantly. Consequently, it is estimated that by 2030 there will be an 
additional 544 000- 668 000 cases of diabetes, 331 000- 461 000 of coronary heart 
disease and strokes, and 87 000-130 000 of cancer in UK and US combined (Wang 
et al., 2011). 
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Obesity and obesity related diseases such as T2DM, hypertension and dyslipidaemia 
are risk factors for cardiovascular disease, and are associated with atherogenesis 
(Husain et al., 2015). Atherosclerosis and endothelial dysfunction are discussed at 
Chapter 1.2.2.1. Endothelial dysfunction, reduction in nitric oxide, activation of renin 
angiotensin system and inflammation are the proposed mechanisms for 
atherosclerosis. Similar mechanisms have also been proposed to link between obesity 
and chronic kidney disease (Wahba and Mak, 2007).    
Animal study had shown that obesity was associated with increased abdominal 
pressure, and hence increased systemic blood pressure and vascular resistance, 
which impairs renal perfusion and activates juxtaglomerular apparatus and the renin, 
angiotensin system. Chronic activation of renin angiotensin system eventually leads 
to hypertension, glomerulopathy, and proteinuria (Heneghan et al., 2013, Currie et al., 
2011).  
 
1.1.4.1 Relationship between obesity and diabetes 
There are two main classifications of diabetes. Type 1 diabetes is autoimmune in origin 
and is characterised by insulin deficiency and it is not usually associated with obesity; 
its treatment is insulin injection. Type 2 diabetes (T2DM) forms 90% of the population 
of diabetes (UK, 2012). Risk factors of T2DM include obesity, metabolic disease, and 
increased abdominal adiposity. Its aetiology is multifactorial, with genetic makeup, 
environment, and prevalence of obesity all played the key part (Kahn, 2003). ‘Diabesity’ 
(Zimmet et al., 2001) is a term referred to diabetes resulted from obesity. There are 
346 million patients with diabetes worldwide ((WHO), 2011) and the prevalence of 
diabesity populations is on an increasing trend. 
T2DM is a progressive disease. It is associated with impaired insulin sensitivity and 
beta cell dysfunction. Insulin sensitivity is influenced by genetics, lifestyle measures 
such as diet and exercise, medications and body fat composition. Central body fat or 
visceral adiposity has shown to impair insulin sensitivity. 
Beta cell dysfunction including loss of beta cell mass and diminished first phase insulin 
response occur at an early stage of the disease (Kahn, 2003). The normal pulsatile 
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insulin secretion is also disrupted. Consequently, there is failure in suppression of 
hepatic glucose production, leading to postprandial glycaemic excursion. 
1.2 The diabetes epidemic 
The prevalence of T2DM for all age-groups worldwide was estimated to be 2.8% in 
2000 and 4.4% in 2030. The total number of people with T2DM is projected to rise 
from 171 million in 2000 to 366 million in 2030 (Wild et al., 2004). In UK, T2DM affects 
2.61 million adults in 2011, this number is estimated to rise to 4.5 million in 2025 (UK, 
2012). Following the increase in childhood obesity, a rise in T2DM in children was 
noted in United States, Australia, and Japan. In UK, incidence of T2DM in children 
was 0.53/100,000 per year(Haines et al., 2007). Incidence of diabetes is higher in 
ethnic minority such as blacks and South Asians. Of these, 95% of children were 
overweight and 83% obese (Haines et al., 2007). Onset of childhood obesity is 
associated with 24 times of Hba1c≥ 7% in adulthood, at age 45   (Power and Thomas, 
2011). 
1.2.1 Natural history of T2DM 
T2DM used to be disease that affects middle-aged and elderly, increasingly it is 
diagnosed in younger generations. It may present as polyuria, polydipsia, and 
recurrent infection (Organisation, 1999). Frequently, patients may be asymptomatic. It 
is estimated that 850,000 people in UK have undiagnosed diabetes. At diagnosis, 25% 
of the patients would have diabetes retinopathy, and 8% would have developed 
nephropathy(Astrup and Finer, 2000). Despite treatments, T2DM is a progressive 
disease; with time, patients will progress to combination therapy including insulin, 
which often lead to weight gain, exacerbating insulin resistance. 
1.2.2 Complications of diabetes 
Exposure to hyperglycaemia was known to increase risk of developing macrovascular 
and micorvascular complications of diabetes. Management of macrovascular 
complications such as coronary artery disease and stroke; microvascular 
complications such as retinopathy, nephropathy and neuropathy have significant 
impact on morbidity and mortality, both at personal level and population level (Remuzzi 
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et al., 2002, Watkins, 2003, Young et al., 1993). Cardiovascular death was the 
commonest cause of mortality in T2DM population. 
1.2.2.1 Macrovascular complications 
Atherosclerosis 
Atherosclerosis is the central pathological mechanism of cardiovascular disease. It 
results from accumulation of oxidised lipids in the endothelial wall of arteries in 
response to endothelial injury and inflammation. This oxidised lipids form foam cells 
which stimulate macrophages proliferation and attract T-lymphocytes. T-lymphocytes 
in turn induce smooth muscle proliferation in the arterial walls and collagen 
accumulation. This leads to formation of a lipid-rich atherosclerotic lesion with a fibrous 
cap (Brownlee, 2001, Fowler, 2008). 
Endothelial dysfunction 
Although the mechanisms of which diabetes increases the risk of atherosclerotic 
plaques formation are not known, endothelial dysfunction involving hyperglycaemia 
and pathway specific insulin resistance has been implicated in its pathogenesis 
(Brownlee, 2001). The reduction in endothelial production of nitric oxide, and 
increased proliferation of vascular smooth muscle cells lead to atheroma formation; 
while production of plasminogen activator inhibitor-1 (PAI-1) increased platelet 
adhesion and hypercoagulability, as well as impaired fibrinolysis(Fowler, 2008). This 
results in diffuse narrowing of arterial walls. 
T2DM is a strong independent risk factor for ischaemic heart disease, stroke and death 
(Fowler, 2008). Being female, and presence of microvascular complications are risk 
factors for coronary heart disease (Fowler, 2008). 
Contrary to Type 1 diabetes study which showed intensive glycaemic control is 
associated with preventing cardiovascular event; studies in T2DM had not conclusively 
shown that intensive glycaemic control is associated with statistically significant 
reduction in cardiovascular event. The inconsistencies might be related to the complex 
relationship between hyperglycaemia and cardiovascular risk in T2DM. While 
hyperglycaemia had implications on endothelial dysfunction and proinflammatory 
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state, effects of improving glycaemia maybe less profound than blood pressure (BP) 
and lipid management. 
1.2.2.2 Micorvascular complications 
This is a disease of small vessel affecting eye, kidney and nervous system. They have 
pronounced effect on morbidities and mortality such as visual loss, amputation, renal 
failure and cardiovascular death. Diabetes is the leading cause for blindness and end-
stage renal diseases(Brownlee, 2001). The risk of developing these complications 
increases with poor glycaemic control, and intensive glycaemic control had shown to 
reduce the risk.(DCCT, 1995, 1998c) (Stratton et al., 2000). 
Mechanisms of hyperglycaemia induced damage: 
Polyol Pathway 
In the polyol pathway, aldose reductase is the first enzyme that catalyses the NADPH- 
dependent reduction of glucose to the polyalcohol sorbitol in event of 
hyperglycaemia(Brownlee, 2001). Osmotic stress from sorbitol accumulation has been 
postulated as an underlying cause of microvascular complications(Fowler, 2008). In 
animal studies, sorbitol accumulation has been linked to microaneurysm formation, 
thickening of basement membranes, and loss of pericytes. However, treatment studies 
with aldose reductase inhibitors have been disappointing(Fowler, 2008). The decrease 
in NADPH which is also requires for glutathione reductase activity resulted in increase 
in oxidative stress and activates pathways that increase cellular damage(Cumbie and 
Hermayer, 2007). 
Formation of advanced glycation end products (AGEs) 
Hyperglycaemia promotes the nonenzymatic formation of AGEs. AGEs are a 
heterogeneous group of modified proteins, lipids and nucleic acids implicated in the 
aging process and diabetes (Cumbie and Hermayer, 2007). Hyperglycaemia may also 
influence production of AGEs through polyol pathway and oxidative stress(Cumbie 
and Hermayer, 2007). AGEs were noted in increased level in diabetes retinopathy and 
nephropathy(Brownlee, 2001). It has been associated with formation of 
microaneurysms and pericyte loss in animal studies(Fowler, 2008). 
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Reactive oxygen species 
Hyperglycaemia can stimulate reactive oxygen species formation; oxidative stress 
may play a role in cellular injury. Treatment with antioxidants has yet to show any 
benefit in the disease progression(Fowler, 2008). 
Vascular endothelial growth factor production 
Vascular endothelial growth factor (VEGF) stimulates angiogenesis, enhances 
collateral vessel formation, and increases the permeability of the 
microvasculature(Ray et al., 2004). VEGF production is known to be stimulated by 
hyperglycaemia, advanced glycosylation end products, IGF-I, angiotensin II, and 
hypoxia(Ray et al., 2004). 
Diabetic Retinopathy 
Diabetic retinopathy is the commonest cause of blindness. It may develop as early as 
seven years before the diagnosis of T2DM. Duration of diabetes, hyperglycaemia and 
hypertension are risk factors for retinopathy (Fowler, 2008). Presence of 
microalbuminuria and duration of diabetes are independent variables for the presence 
of proliferative diabetic retinopathy (Ray et al., 2004). 
Hyperglycaemia has been shown to induce apoptosis of retinal pericytes. Pericytes 
are essential in protecting endothelial cells of retinal capillaries, its loss is associated 
with microaneurysms formation, herald the initial stages of diabetic retinopathy.  This 
is worsen by frequent fluctuation of blood glucose between high and low (Cai and 
Boulton, 2002). The retinal increases its vascular permeability, leading to swelling 
through macular oedema, or formation of new vessels (Ciulla et al., 2003). This results 
in reduction or loss of vision. 
The early stage of retinopathy is characterised by microaneurysms, dot 
haemorrhages, and hard exudate which may appear due to retinal capillary dilatation, 
occlusions or leaks. This progresses to cotton wool spots which are microinfarctions 
of the nerve fibre layer.  This heralds the development of new vessels, or proliferative 
retinopathy. It carries a high risk of blindness as a result of vitreous haemorrhage and 
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ﬁbrosis (Ciulla et al., 2003). Laser photocoagulation was often used to prevent the 
progression of proliferative retinopathy to visual loss. 
Diabetic Neuropathy 
Martyn and Hughes found that diabetic neuropathy presented in 4 % of diabetic 
population diagnosed within 5 years of diagnosis and the prevalence rose to 15% in 
20 years (Martyn and Hughes, 1997). Population study showed that up to a third of 
patients with diabetic neuropathy were asymptomatic (Fowler, 2008). Diabetic 
neuropathy is associated with duration of diabetes, poor glycaemic control (Martyn 
and Hughes, 1997) and often co-existing with other microvascular complications. 
Chronic sensorimotor distal symmetric polyneuropathy is the commonest form of 
neuropathy in diabetic patients. Sensory loss is most prominent bilaterally in stocking 
distribution. Electrophysiology studies showed a more pronounced decrease in 
sensory and motor compound action potential amplitude, which is suggestive of axonal 
degeneration as the underlying pathology (Martyn and Hughes, 1997). Pure sensory 
neuropathy is relatively rare. Mononeuropathy affecting femoral nerve is common, and 
it is often rapid onset and reversible. Compression neuropathies involving entrapment 
of nerves such as median and ulnar nerves are also more common in diabetes 
population. Autonomic neuropathy such as gastroparesis, postural hypotension, and 
silent myocardial ischaemia could occur in patients with long duration of poorly 
controlled diabetes. 
Positive symptoms of neuropathy are distressing. Management include symptomatic 
control with medication, and improvement in glycaemic control with avoidance of 
glycaemic excursion. 80% of amputations occur after foot ulceration or injury, which 
can result from diabetic neuropathy (Fowler, 2008). 
Diabetic Nephropathy 
Diabetic nephropathy is the leading cause of renal failure. Seven per cent of patients 
with T2DM had nephropathy by the time of diagnosis. The incidence of nephropathy 
in UKPDS was 2 % per year and its prevalence at 10 years was 25% (Fowler, 2008). 
It is characterised by presence of persistent albuminuria, progressive decline in 
21 
 
glomerular filtration rate, and elevated blood pressure. Presence of albuminuria is 
defined in stages: microalbuminuria, albumin creatinine ratio (ACR)> 2.5 mg/mmol for 
men, > 3.5 mg/mmol for women; macroalbuminuria (ACR >30mg/mmol). Detection of 
persistent microalbuminuria is defined as the early marker of diabetes renal disease; 
it is also a predictor for cardiovascular morbidity and mortality (Fowler, 2008). 
Microalbuminuria is potentially reversible; while macroalbuminuria is progressive. With 
increasing albuminuria, glomerular filtration rate (GFR) elevated and eventually 
declined as it progressed to end stage renal failure. 
Diabetic nephropathy is characterised by increased glomerular basement membrane 
thickness, microaneurysm formation, mesangial nodule formation (Fowler, 2008). The 
underlying mechanisms of diabetic nephropathy are similar to retinopathy. VEGF is 
implicated in the development of diabetic nephropathy. Use of anti-VEGF antibodies 
to neutralise effect of VEGF in experimental models has signiﬁcantly reduced 
hyperﬁltration, microalbuminuria, and glomerular hypertrophy (Ray et al., 2004). 
Management of diabetes nephropathy stresses importance of glycaemic and blood 
pressure control. ACE inhibitor has been shown to reduce the risk of developing 
diabetic nephropathy and cardiovascular events in patients with T2DM (Fowler, 2008). 
Renin angiotensin blockade appeared to have renoprotective effect which is 
independent of its effect on blood pressure lowering (Fowler, 2008).  Screening for 
diabetic nephropathy is carried out annually in United Kingdom using spot urine 
measurement. 
1.3 Type 2 diabetes treatments 
1.3.1 Diet and Lifestyle 
Treatment of diabetes has also evolved, although at a much slower pace compared to 
the expansion of obesity and diabetes epidemic. T2DM is largely regarded as a 
lifestyle disease. Lifestyle and dietary changes was the treatment for T2DM since 1800 
(K, 2009). Today, it remained the first line treatment for T2DM. Dietary input and 
physical activity has shown to maintain weight loss of 2.0-3.3 kg over a six year period 
in patients with T2DM and impaired glucose tolerance (IGT); leading to 53.8% of 
remission of diabetes, and 75.8% of normalisation of oral glucose tolerance tests 
(Eriksson and Lindgarde, 1991, Heymsfield et al., 2000) . Individualised dietary 
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therapy and physical activities have also been supported by American Association of 
Clinical Endocrinologists/American College of Endocrinology/ American Diabetes 
Association (AACE/ ACE/ ADA) as part of treatment algorithm for T2DM. Calorie 
restriction such as use of low calorie diet (LCD) has also shown to improve insulin 
sensitivity and beta cell function (Lim et al., 2011). 
1.3.2 Pharmacotherapy 
T2DM is a progressive disease, hence polypharmacy is not uncommon. Patients’ 
compliance to medications is therefore often limited by its side effect, hypoglycaemia 
and weight gain. 
Biguanide 
Metformin, from the biguanide family, has been recommended as first line oral agent 
for T2DM due to its safety and efficacy. It is effective at decreasing both fasting plasma 
glucose and postprandial glucose levels (Goldman-Levine, 2011). It improves insulin 
sensitivity at peripheral tissues, reduces hepatic glucose production, and increases 
intestinal glucose uptake and utilization (Bergenstal et al., 2010). Metformin does not 
stimulate insulin production and therefore has a very low risk for hypoglycaemia. It is 
weight neutral, and may also result in weight loss. It has also been shown to lower 
mortality and improved heart failure (Goldman-Levine, 2011). 
Sulphonylurea 
Sulphonylureas was first discovered in 1956. It works by stimulating glucose 
independent release of insulin from the pancreas. The effect of sulphonylureas relies 
on the functioning of pancreatic islets. Primarily effective at reducing fasting plasma 
glucose. It could cause hypoglycaemia and weight gain (Goldman-Levine, 2011). 
Thiazolidinediones 
Pioglitazone is the only licensed thiazolidinedione available since rosiglitazone was 
withdrawn due to cardiovascular risks. It decreases peripheral insulin resistance by 
improving insulin sensitivity in adipose tissue, skeletal muscle, and the liver. This 
results in increase insulin-dependent glucose disposal and decreased hepatic 
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gluconeogenesis. It works by reducing fasting glucose. It could cause weight gain 
(Goldman-Levine, 2011). 
Glinides 
Glinides stimulate the release of insulin from the pancreas. They are primarily effective 
at decreasing postprandial glucose (Goldman-Levine, 2011). 
Alpha-Glucosidase Inhibitors 
The alpha-glucosidase inhibitors delay the digestion of polysaccharides in the proximal 
small intestine and decrease the rise in plasma glucose concentrations postprandial. 
It is effective in patients whose diet contains large amounts of complex carbohydrates. 
It is weight neutral (Goldman-Levine, 2011). 
Glucagon-Like Peptide-1 Receptor Agonists 
The GLP-1 receptor agonists mimic effect of gut hormone GLP-1 which is elevated 
post RYGB surgery. Its binding to GLP-1 receptor exerts incretin effect, leading to 
increased glucose-dependent insulin secretion, glucose dependent suppressed 
glucagon secretion, reduced hepatic glucose production, delayed gastric emptying, 
and greater satiety. Animal studies have shown that use of GLP-1 receptor agonist 
lead to an increase in β-cell mass, and β-cell preservation. It has effects on 
postprandial glucose or/and fasting glucose. It is also associated with weight loss of 
up to 5kg (Goldman-Levine, 2011). 
Dipeptidyl Peptidase-4 Inhibitors 
The DPP-4 inhibitors prevent endogenous GLP-1 and gastric inhibitory polypeptide 
inactivation, therefore prolong the physiologic levels of endogenous GLP-1. It is 
effective at decreasing postprandial glucose levels. They are weight neutral (Goldman-
Levine, 2011). 
Sodium/glucose cotransporter 2 inhibitors 
SGLT-2 inhibitors are the competitive inhibitors of the renal SGLT-2 system, 
preventing glucose reabsorption from the glomerular ﬁltrate in the proximal tubules. Its 
24 
 
effect is therefore insulin independent. It is associated with weight loss (Vasilakou et 
al., 2013). 
 
Insulin 
Development of insulin has transformed diabetes management. Insulin is the third line 
medications, when oral medications and GLP-1 agonist had been exhausted. It 
improves glycaemic control by inhibiting hepatic gluconeogenesis and glycogenolysis. 
Its use is limited by its mode of delivery, and its effect on weight gain and 
hypoglycaemia. The weight gain associated with insulin use often led to worsening of 
insulin resistance and ẞ cell dysfunction (Goldman-Levine, 2011). 
1.3.3 Bariatric surgery 
Increasingly, bariatric surgery has been seen as a treatment for patients with T2DM 
and severe and complex obesity defined as a body mass index above 35 kg/m² with 
life or limb threatening co-morbidities (Schauer et al., 2012a). The International 
Diabetes Federation’s (IDF) position statement in 2011 recommend bariatric surgery 
to be included in future algorithms for treatment of complex obese T2DM (Dixon et al., 
2011). 
Obesity surgery originated as a form of gastrointestinal surgery, which was first 
performed in 1954. The jejuno-intestinal bypass strived for weight loss by 
circumventing the middle section of the small intestine (Pories, 2008). Over time, this 
has evolved and today the three commonest weight loss surgeries are laparoscopic 
Roux-en-Y gastric bypass (RYGB), adjustable gastric banding (AGB) and vertical 
sleeve gastrectomy (VSG) (Buchwald et al., 2009). RYGB and biliopancreatic 
diversion (BPD) have also been termed as metabolic or diabetes surgery due to their 
effects in improving glycaemic control (Schauer et al., 2003, Pories et al., 1995, 
Buchwald et al., 2009).  They are also effective in improving BP, lipid and obstructive 
sleep apnoea. 
Biliopancreatic diversion, with or without duodenal switch (BPD and BPD-DS), is less 
commonly performed but remains to be considered in extremely obese individuals. All 
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procedures can be performed laparoscopically with a lower rate of complications such 
as wound infection and incisional hernias (Neff and le Roux, 2013). 
Roux-en –Y gastric bypass 
In RYGB, the gastric pouch is created from the stomach, approximately 15–30 ml in 
size. The gastric pouch is anastomosed to the jejunum after it has been divided 
approximately 30 to 75 centimetres distal to the ligament of Treitz; this distal part is 
brought up as a “Roux-limb”. The excluded biliary limb including the gastric remnant 
is connected to the bowel approximately 75 to 150 centimetres distal to the 
gastrojejunostomy (Figure 1. RYGB) (Neff and le Roux, 2013). The effect of RYGB on 
diabetes remission and its proposed mechanisms are discussed in more details in 1.4. 
Adjustable gastric banding 
In AGB, a band with an inflatable balloon is placed around the proximal stomach just 
below the gastroesophageal junction. (Figure 2. AGB) The band can be adjusted by  
filling the band with saline solution through a subcutaneous access port (Neff and le 
Roux, 2013) 
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Figure 1. Roux-en-Y gastric bypass 
(Karl Neff 2012) 
 
Sleeve gastrectomy 
In SG, approximately 80% of the stomach is removed. The stomach is transected 
vertically over a 34 or 36F bougie creating a gastric tube and leaving a pouch of 100-
200 mL (Figure 3. SG). Although many regard SG as a restrictive procedure, it is 
increasingly recognised as a metabolic procedure (Neff and le Roux, 2013). 
Biliopancreatic diversion 
The BPD involves a partial gastrectomy which results in a 400 mL gastric pouch. The 
small bowel is then divided 250cm proximal to the ileocaecal valve, and the alimentary 
limb is connected to the gastric pouch to create a Roux-en-Y gastroenterostomy. An 
anastomosis is performed between the excluded biliopancreatic limb and the 
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alimentary limb 50 cm proximal to the ileocaecal valve (see figure BPD) (Neff and le 
Roux, 2013). 
 
 
Figure 2. Adjustable gastric band 
(Karl Neff 2012) 
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Figure 3. Sleeve gastrectomy 
(Karl Neff 2012) 
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Figure 4. Bilioancreatic diversion 
(Karl Neff 2012) 
 
Recent development 
Non-surgical treatment such as Endobarrier has been developed to mimic some of the 
mechanism of bariatric surgery. It is a synthetic duodenojejunal bypass liner which is 
placed endoscopically, and lines the first 60cm of the duodenum, therefore achieving 
duodenal exclusion. It has positive effect on weight loss and improving glycaemic 
control in T2DM. The liner last for 12 months and therefore the durability of weight loss 
and long term data is yet to be reviewed. Other method such as insertion of intra-
gastric balloon is developed to achieve short term weight loss in patients that were too 
high risk to proceed to bariatric surgery. Long term data on benefits of these methods 
are currently unavailable for review. (Neff and le Roux, 2013). 
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1.3.4  Roux-en –Y gastric bypass and proposed mechanisms 
Both RYGB and BPD achieve excellent diabetes outcome. However, BPD is not 
commonly performed due to its higher complication rates. The impact of RYGB on 
diabetes remission could be influenced by weight loss and weight independent factors. 
Weight loss preoperatively while on liver shrinking diet; and in the long term follow up 
postoperatively would have contributed to the improved glucose homeostasis. 
However, the effect of gastric bypass on glucose control immediately postop, before 
significant weight loss is established suggested that mechanisms other than weight 
loss are at play. Despite similar weight loss, the rate of diabetes remission achieved 
by RYGB is disproportionately high compared to other procedures such as SG and 
AGB. Several weight independent mechanisms have been proposed: 
i) Small stomach 
Following the procedure, the stomach pouch is reduced to 15-30ml. This reduced 
gastric capacity limits the size of meals, as storage capacity of the stomach is reduced 
to 5% of its normal volume(Näslund and Kral, 2006). This leads to early satiety. The 
rapid reduction in calorie intake post-surgery leads to improved hepatic insulin 
sensitivity immediately after surgery, whereas peripheral insulin sensitivity only 
improves later in response to the postoperative weight loss. This was evidenced by 
the reduction in homeostasis model assessment of insulin resistance (HOMA-IR) 
(Dirksen et al., 2012). 
ii) Bypass of nutrients- foregut 
Ingested food bypasses 95% of the stomach, the duodenum, and a small portion (15–
20 cm) of the proximal jejunum (Näslund and Kral, 2006). This is supported by the 
rodent study where duodenal-jejunal bypass that excludes nutrient passage through 
the duodenum is compared with gastrojejunotomy with intact duodenal nutrient 
passage. Significant improvement in glucose metabolism was observed in the group 
that had duodenal-jejunal bypass. There was no difference in food intake, nutrient 
absorption, or weight loss between both groups (Rubino et al., 2006). This effect is 
independent of weight loss, as further supported by RYGB on T2DM with 
BMI<35kg/m² who did not showed excessive weight loss , despite significant 
improvement in glycaemic control (Rubino et al., 2010). 
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iii) Stimulation of hindgut 
Contrasting to the theory of bypassing foregut, a rapid stimulation of the hindgut by 
arrival of maldigested food may have affected the alterations in gastrointestinal peptide 
release. This activates mechanoreceptors and chemoreceptors (17) or neurohumoral 
mechanisms. This leads to changes in gut hormones. 
iv) Gut hormone changes 
Incretin hormones 
Fasting level of GLP-1 has not changed, whereas GLP-1 level was several fold 
increase postprandial. The exaggerated response of GLP-1 to nutrients was abolished 
when gastrotomy catheter was inserted in the gastric remnant and the nutrients 
passed through the excluded pathway, suggestive that the GLP-1 changes was 
related to changes in gastrointestinal nutrient transit. This was further supported by 
study with ileal transposition which showed improved glucose homeostasis in diabetes 
patients with BMI 24-35kg/m² (Dirksen et al., 2012). GLP-1 increases insulin and 
decreases glucagon secretion. It also has trophic effects on the pancreas via anti-
apoptotic and proliferative effects on β-cells (Dirksen et al., 2012). 
Increased GLP-1 might reverse the impaired first phase insulin response in T2DM. 
After RYGB, there was an earlier and exaggerated postprandial rise in insulin 
concentrations that reaches a higher peak than level before surgery. There was also 
a more rapid return of insulin to fasting levels. The total postprandial insulin AUC was 
unchanged or reduced suggestive of improved insulin sensitivity (Dirksen et al., 2012). 
 
Appetite regulating gut hormones 
Gut hormones including GLP-1 and peptide YY (PYY), oxytomodulin are released from 
the intestinal L-cells postprandially. They play a role in appetite regulation. Their 
increased levels postprandially have been shown to reduce hunger, decreasing food 
intake and therefore lowering plasma glucose levels (Dirksen et al., 2012). 
There was contradictory result on secretion of ghrelin post gastric bypass surgery. 
Ghrelin is an orexigenic hormone.  Exclusion of foregut and ghrelin producing cells 
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had been proposed as the cause of decreased ghrelin, and therefore lack of hunger. 
However, subsequent studies had not been able to reproduce similar results. There 
were also reports on ghrelin levels return to pre-operative level or even increase, years 
after RYGB (Dirksen et al., 2012). 
These gut hormone changes were the likely contributing factors to the postoperative 
weight loss and indirectly improve insulin sensitivity. 
 
v) Changes in food preferences 
Changes in food preferences had been observed in patients having bariatric surgery. 
Following RYGB, there was reduction in intake of sweet and fatty meal. This has been 
associated with change in sense of taste. The altered food preferences coincided with 
functional MRI studies which showed a corresponding reduction in activation of brain 
reward centres to high energy food (Behary and Miras, 2015).   
 
vi) Bile acids 
Cholestyramine, a bile acid sequestrant was shown to lower LDL- cholesterols and 
improve glycaemic control in T2DM in a short term study(Garg and Grundy, 1994). 
Further studies had shown that it has effect on lowering glucose in prediabetes 
(Handelsman et al., 2010), and early T2DM (Rosenstock et al., 2010). 
Altered bile flow after RYGB surgery, and the increased level of total plasma bile acids 
post-surgery may contribute to the improvement in glycaemic control. Bile acids 
inhibits gluconeogenesis through Farnesoid X receptor pathway. It also promotes 
insulin signalling and glycogen synthase activation, which influence the hepatic 
glucose metabolism. The binding of bile acid to the G-protein coupled receptor, TGR5, 
which is expressed on L cells might explain the increased secretion of GLP-1. 
Combination of food and bile was shown to increase gut hormone, GLP-1 and PYY 
secretion, therefore enhance insulin release, and satiety. Bile acids also have an effect 
on fibroblast growth factor (FGF) 19, which enhanced mitochondrial activity, and 
improves insulin resistance (Pournaras et al., 2012b). 
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vii) Vagal nerve fibres transection 
 
Gastrointestinal tract is extensively innervated by vagus nerve, which are mainly 
afferent sensory fibres. Vagus nerve is involved in the regulation of feeding.  The 
presence of nutrient in the stomach or intestine activates the stretch and 
chemoreceptors which then transmit information through vagal signalling. Apart from 
mechanosensor effect, there was evidence that gastrointestinal hormones acting on 
vagal afferent. Ghrelin and hyperglycaemia were shown to suppress, while gastric 
distension and cholecystokinin (CCK) increased the firing activity of vagal afferent 
(Thaisetthawatkul et al., 2004). The transection of vagus nerve during RYGB might 
offer explanation to disruption of ghrelin secretion post-surgery. This was supported 
by animal study which shows vagotomy eliminates the normal response of ghrelin to 
weight loss. It might also influence gastric emptying. 
 
viii) Changes in gut microflora 
Recent studies had shown that composition of gut microflora altered after RYGB. In 
rodent study, the population of gut microorganisms changes after RYGB. The transfer 
of gut microflora from the RYGB mice to the non-operated germ-free mice resulted in 
weight loss and decreased body fat. RYGB induced significant changes to the gut 
microbial communities that was independent of changes in diet. The change in 
microflora distributions has been postulated to alter energy expenditures, and 
therefore weight loss (Kugelberg, 2013) 
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1.4 Diabetes and surgical outcome 
1.4.1 Diabetes and general surgery outcome 
Patients with T2DM have 2 to 4 fold increase in cardiovascular disease (Stamler et al., 
1993, Dhatariya et al., 2011). Most diabetic patients planning for surgery are likely to 
have 1 or more cardiovascular risk factors and a significant number will have 
microvascular disease (retinopathy, nephropathy or neuropathy). They are at high risk 
of perioperative complications and even mortality (Dhatariya et al., 2011), with  
perioperative mortality rate reported to be up to 50% higher than that of the non-
diabetic population (Dhatariya et al., 2011, Clement et al., 2004).  Diabetic patients 
are more at risk of poor wound healing, respiratory infection, myocardial infarction, 
admission to intensive care, and increased length of stay in hospital(Frisch et al., 2010, 
Sehgal et al., 2011, Dhatariya et al., 2011). Perioperative poor glycaemic control has 
significant impact on postoperative infection (Clement et al., 2004). The UK national 
guideline recommended that all patients with diabetes undergoing elective surgery 
should have their glycaemic control optimised preoperatively (Dhatariya et al., 2011). 
This recommendation was made based on the majority of evidence on morbidity and 
mortality of T2DM patients undergoing surgery, which were from the setting of cardiac 
surgery and to a lesser extent non-cardiac surgery. There was no specific evidence 
for bariatric surgery (Chuah and le Roux, 2013). 
Distinction between non-bariatric surgery and bariatric surgery 
Bariatric surgery such as RYGB should be distinguished from general surgery 
because of its immediate beneficial effect on glycaemic control postoperatively. The 
rapid glycaemic improvement appears independent of weight loss (Pournaras et al., 
2010). Moreover, these patients often followed low calorie diets preoperatively 
(Adrianzen Vargas et al., 2011, Van Nieuwenhove et al., 2011) which lead to 
improvement in glycaemia immediately before surgery. General surgery does not alter 
glycaemic control postoperatively; neither does it require patients to follow low calorie 
diet preoperatively. The question thus arises whether bariatric patients should follow 
a distinct pathway from the general surgical population and that their diabetes should 
be managed differently. There was also lack of prospective study to assess if 
preoperative, perioperative and postoperative glucose management would impact on 
improvement and remission of diabetes (Chuah and le Roux, 2013). 
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Management of diabetes on pre-operative low calorie diet 
Low calorie diet (800-1200 kcal/day) lead to rapid weight loss and improvement in 
T2DM (Anderson et al., 2003). The diet is used preoperatively in many bariatric 
centres to induce acute weight loss before surgery. LCD has shown to reduce visceral 
fat, liver volume and intrahepatic fat, facilitates the use of laparoscopic approach in 
obesity surgery (Colles et al., 2006). 
Despite the wide use of preoperative diet, studies has reported no differences in mean 
operating time, estimated blood loss and intraoperative complications when compared 
to the groups received LCD and those without preoperatively, except the 30 days 
postop complications was lower in the LCD group (Adrianzen Vargas et al., 2011, Van 
Nieuwenhove et al., 2011). The use of LCD in patients with T2DM improves glycaemic 
control, and increased the risk of hypoglycaemia. There is no data on management of 
glucose during the perioperative period whilst on LCD. 
Management of diabetes post -surgery 
Although remission of diabetes after gastric bypass surgery is well recognised, there 
is a paucity of data on management of diabetes postoperatively. Study reported that 
giving a low dose of long acting insulin analogue therapy for the first few weeks after 
BPD improves the number of patients achieving remission (Scopinaro et al., 2011). 
Another cohort study in patients with type 2 diabetes requiring insulin suggested that 
tight glycaemic control (fasting blood glucose <6.5 mmol/L for 1-2 week after surgery) 
after RYGB improves the remission rate of T2DM after one year (Fenske et al., 2012). 
It is possible that the pancreas undergoes a period of regeneration within the early 
postoperative period, and a healthy glucose environment is beneficial for β cell 
function not only in the short, but in the long term. This may be analogous to islet cell 
‘rest’ immediately post islet transplant in type 1 diabetes, where exogenous insulin is 
given to avoid glucotoxicity (Bretzel et al., 1999, Chuah and le Roux, 2013). 
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1.4.2 Diabetes and bariatric surgery outcome 
Mortality 
The Swedish Obesity Subject (SOS) Study, a prospective, controlled cohort study 
comparing bariatric surgery to medical treatment for long-term mortality found that the 
adjusted hazard ratio was 0.71 in the surgery group (p=0.01) as compared with the 
control group (Sjostrom et al., 2007). McDonald et al had also reported that mortality 
in patients with T2DM who underwent gastric bypass surgery was 9% compared to 
28% of diabetes control group at 9 years follow up (MacDonald et al., 1997). The most 
common cause of death was myocardial infarction. SOS study had also reported that 
surgery was associated with a reduced number of cardiovascular death compared to 
the control group (28 vs 49 events, adjusted HR 0.47, p=0.02) (Sjostrom et al., 2012). 
The benefit of surgical treatment was significantly associated with a raised baseline 
plasma insulin above the median of 17 IU/L, with greater relative treatment benefit in 
subjects with higher insulin (p for interaction <0.001). 
These are also supported by Adams et al. which showed that patients with T2DM who 
undergo bariatric surgery have a 92% relative risk reduction compared to the matched 
control group at a mean follow up of 7.1 years (Adams et al., 2007).  The acute 
improvement in glycaemic control and other metabolic co-morbidities together with the 
significant weight loss after gastric bypass may play a significant role in the decreased 
mortality after bariatric surgery (Chuah et al., 2013). 
Morbidity 
Perioperative complications 
A prospective study of diabetic patients under RYGB reported overall major 
complication rate was 13.6% and minor complication rate of 24.9%. Early major 
complications included pneumonia, gastrojejunal leaks, small bowel obstruction and 
deep vein thrombosis; minor complications included wound infections, prolonged 
emesis and marginal ulcers (Schauer et al., 2003). The longitudinal assessment of 
bariatric surgery reported that of the 2975 subjects who undertook LRYGB, the 
composite end point of death, venous thromboembolism, reintervention, or failure to 
be discharged by 30 days after surgery was 4.8%. History of pulmonary embolic event, 
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obstructive sleep apnoea, extreme body mass index were associated with increased 
risk of the composite end point (2009, Chuah et al., 2013). 
Impact of pre and postoperative glycaemic control on outcome of bariatric 
surgery 
Elevated HbA1c preoperatively has been associated with increased hospital LOS and 
worsen postoperative outcome in non-bariatric surgery patients (Perna et al., 2011). 
However, there is no data on whether preoperative glycaemic control could influence 
the outcome of bariatric surgery and remission of diabetes, especially as many units 
use a 2 week pre-operative very low calorie diet which will improve glycaemic control 
substantially. A retrospective study reviewed 468 patients scheduled for bariatric 
surgery and grouped them into three categories based on HbA1c preoperatively. Poor 
preoperative glycaemic control was associated with worse glucose control 
postoperatively, as well as less weight loss and fewer cases of complete remissions 
of their T2DM at 18 months. An elevated postoperative glucose was independently 
associated with wound infection (p= 0.008), and acute renal impairment (p= 0.04) 
(Perna et al., 2011). A cohort study in patients with type 2 diabetes requiring insulin 
suggested that after gastric bypass surgery tight glycaemic control (fasting blood 
glucose < 6.5 mmol/L for 1-2 week after surgery) can improve the remission rate of 
T2DM after 1 year (Chuah et al., 2013, Fenske et al., 2012). 
Bariatric surgery and diabetes remission 
T2DM is a progressive disease, and the aim of treatment is to prevent macrovascular 
and microvascular complications, as this had significant impact on morbidity and 
mortality of patients. Reversal of diabetes has not been possible with 
pharmacotherapy in the past, the emergence of bariatric surgery has now offered a 
new dimension to diabetes management as it offers the opportunity of diabetes 
remission. RYGB and BPD  were shown to achieve 75% and 95% of diabetes 
remission respectively when compared to best medical therapy (Mingrone et al., 
2012b). A meta-analysis showed that diabetes resolution was achieved in 80.3% of 
those undergoing RYGB (Buchwald et al., 2009). It is important to note that the 
definitions used for remission of T2DM in all the above studies varied significantly. 
Pournaras et al. reported 34.4 % of surgery cohort achieved complete remission of 
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diabetes when the American Diabetes Association guideline was used (Pournaras et 
al., 2012a). While longer term data on remission of diabetes is awaited, the evidence 
of its effect on complications of diabetes is less well known. 
1.4.3 Bariatric surgery and macrovascular complications 
Macrovascular complications such as cardiovascular disease were reduced following 
bariatric surgery (MacDonald et al., 1997) with improvements in coronary heart 
disease (CHD) (Iaconelli et al., 2011, Adams et al., 2007).  Bariatric surgery was also 
associated with a reduced number of cardiovascular death compared to the control 
group (28 vs 49 events, adjusted HR 0.47, p=0.02) (Sjostrom et al., 2012). Metabolic 
complications such as hypertension, hyperlipidaemia, and obstructive sleep apnoea 
were all improved following bariatric surgery (Buchwald et al., 2004). 
1.4.4 Bariatric surgery and microvascular complications 
A case-controlled study with 10-years' follow-up had shown that microalbuminuria and 
glomerular filtration rate (GFR) improved in diabetic patients having BPD; whereas 
microalbuminuria progressed in non-operated subjects (Iaconelli et al., 2011). Some 
more studies had recently reported improvement in diabetic nephropathy as evidenced 
by reduction in microalbuminuria at 1 to 5 years post bariatric surgery (Heneghan et 
al., 2013, Miras et al., 2011, Brethauer et al., 2013). Most studies on diabetic 
retinopathy changes post bariatric surgery were retrospective except 1, all reported no 
significant change in retinopathy. Risk of progression of retinopathy was higher in 
those with pre-existing moderate to severe background retinopathy (Singh et al., 2015, 
Murphy et al., 2015, Miras et al., 2012, Thomas et al., 2014). There is no prospective 
study reporting objective changes in diabetic neuropathy post bariatric surgery so far. 
One study reported neuropathy symptom score and neuropathy deficit score which 
improved 6 month post-surgery (Muller-Stich et al., 2013). 
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1.5 Relationship between glycaemic control and complications 
1.5.1 Glycaemic control and macrovascular complications 
Despite UKPDS showing beneficial long term protective effect on macrovascular 
complications following early intensive management of type 2 diabetes; recent studies 
on patients with established diabetes had found no effect on major cardiovascular 
events (Patel et al., 2008, Duckworth et al., 2009). One study had shown increased 
risk of death in intensively treated group (Gerstein et al., 2008). Meta-analysis that 
included large, randomised controlled trials (Gerstein et al., 2008, Duckworth et al., 
2009, Patel et al., 2008, 1998c, 1998b) observed overall 16% reduction in risk of non-
fatal myocardial infarction associated with intensive glucose control after pooling the 
relative risk across all trials(Kelly et al., 2009). In contrast, no association was 
observed between intensive glucose control, fatal myocardial infarction, nonfatal 
stroke, fatal stroke, or peripheral artery disease(Kelly et al., 2009). 
The differences in results between UKPDS 33 and 34, as compared to recent studies 
could partly be explained by the different study cohorts, as the UKPDS studies 
included only newly diagnosed T2DM, whereas recent studies recruited patients with 
longer duration of diabetes, some with known cardiovascular risk factors. The rate of 
reduction in HbA1c may also played a part, with 1 trial reported a reduction of 1.4% 
over 4 months (Gerstein et al., 2008). The post intervention median HbA1c in intensive 
treatment group in UKPDS   studies were also higher than the recent studies. The 
recent trials also reported increased risk of hypoglycaemia in intensively treated group. 
Overall, the intensive glucose control showed evidence for a beneficial effect on 
cardiovascular disease, particularly on nonfatal myocardial infarction, but not on 
cardiovascular death and all-cause mortality(Kelly et al., 2009). 
1.5.2 Glycaemic control and microvascular complications 
United Kingdom Prospective Diabetes Study (UKPDS) demonstrated that early 
intensive glycaemic control reduced the risk of developing microvascular 
complications in patients with T2DM (1998c, Pitale et al., 2005). The UKPDS follow 
up study further demonstrated that early intensive glycaemic control has long term 
beneficial effects on both micro and macrovascular complications (Holman et al., 
2008). However, there is concern of the risk of rapid intensive glycaemic management 
on progression of retinopathy and neuropathy. Diabetes Control and Complications 
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Trial (DCCT) reported an early deterioration in retinopathy in the intensively treated 
T1DM cohort at 6 and or 12 months which resolved by 18 months (DCCT, 1995). 
Rapid improvement in glycaemic control during pregnancy is known to cause 
deterioration in diabetic retinopathy (Rasmussen et al., 2010). There was also a case 
report of worsening retinopathy 1 month after RYGB (Silva et al., 2013). There were 
reports of worsening neuropathy after rapid glucose lowering in diabetes (Leow and 
Wyckoff, 2005), and bariatric surgery (Miras et al., 2011). It is therefore important to 
ascertain the effect of rapid improvement in glycaemic control observed in bariatric 
surgery such as RYGB on the progression of diabetes complications. 
Effect of glycaemic control on reversibility of retinopathy 
In T2DM, UKPDS showed that the intensive treated group has a significant 25% 
reduction of risk in developing microvascular complications, most of which was due to 
reduction on photocoagulation(1998c). The Kumomata study on non-obese T2DM 
patients had also demonstrated that intensive treatment with insulin in the cohort with 
no diabetes retinopathy and the cohort with simple retinopathy reduced the cumulative 
percentages of the development and progression of diabetes retinopathy after 6 
years(Ohkubo et al., 1995). Study in T1DM had shown that in the group that already 
had retinopathy at baseline, the cumulative incidence of sustained progression of 
retinopathy worsened at 1 year in the intensive treatment group; but the incidence 
reduced after third year. Intensive therapy had shown to reduce the average risk of 
progression of retinopathy by 54%. The deterioration of retinopathy in intensive 
treatment group within the first 18 months was transient(1998a). 
Effect of glycaemic control on reversibility of neuropathy 
Four out of 5 studies on intensive glycaemic control in T2DM had not shown significant 
improvement in neuropathy (Gaede et al., 2008, Azad et al., 1999, Duckworth et al., 
2009, Ismail-Beigi et al., 2010, 1998c). UKPDS study only showed statistically 
significant effect of glycaemic control on progression of neuropathy at 15 years follow 
up. This is in contrast with studies in Type 1 diabetes patients, where both DCCT and 
Stockholm Diabetes intervention study reported a reduction in rate of progression of 
diabetes neuropathy at 5 to 7 years of follow up in intensive glycaemic control 
compared to  standard treatment group(Reichard et al., 1993). It is therefore 
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suggestive that glycaemia may not be as critical in progression of neuropathy in T2DM 
as compared to T1DM, and that factors other than glycaemic is at play. 
Effect of glycaemic control on reversibility of nephropathy 
Effect of intensive glycaemic control on diabetic nephropathy in T2DM are consistently 
shown in all studies (1998c, Ohkubo et al., 1995, Patel et al., 2008, Duckworth et al., 
2009). The reversibility of diabetic nephropathy was also observed in DCCT of T1DM, 
where intensive glucose control reduced the incidence of microalbuminuria by 39% 
(1993). It also reported a long-lasting reduction in the risk for development of 
microalbuminuria and hypertension  7-8 years after the end of the trial(2003). 
In a small study of T1DM with known diabetic nephropathy after pancreas transplant, 
microalbuminuria improved after 5 years of normalisation of glycaemic control; while 
basement membrane thickness and mesangial volume improved at 10 years (Fioretto 
et al., 1998). Glycaemic control therefore had a role in reversal of diabetes 
nephropathy. 
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1.6 Relationship between weight loss and complications 
Effect of weight loss on retinopathy 
Some studies had demonstrated relationship between high BMI and retinopathy, 
although the results were inconsistent. Studies on type 1 diabetes showed that higher 
BMI was associated with earlier development of retinopathy (Henricsson et al., 2003). 
Underweight (BMI<20kg/m2 ) was also shown to be a risk factor for retinopathy 
(Cheung and Wong, 2007). There is no report on effect of weight loss on retinopathy. 
Effect of weight loss on neuropathy 
There was evidence that obesity was associated with subclinical neuropathy as shown 
in the study of 21 obese non-diabetic subjects underwent bariatric surgery (Singleton 
et al., 2014). The validated neuropathy scale and skin biopsy showed that there was 
presence of asymptomatic neuropathy compared to lean subjects. A study on cohort 
with impaired glucose tolerance demonstrated reversibility of intraepidermal nerve 
fibre density on skin biopsy 1 year following lifestyle and diet intervention (Smith et al., 
2006). There was a retrospective study compared subjects who had bariatric surgery 
to the group who had cholecystectomy which reported increased peripheral 
neuropathy post bariatric surgery, nutritional deficiency was shown to be the main 
cause (Thaisetthawatkul et al., 2004). Similar findings were also reported in the case 
series (Maryniak, 1984, Feit et al., 1982). 
Effect of weight loss on nephropathy 
Obesity is known to be independent risk factor for chronic kidney disease (Wahba and 
Mak, 2007). Renal dysfunction associated with obesity included hyperfiltration, 
proteinuria, followed by hypofiltration eventually. Obesity related glomerulomegaly is 
increasing in prevalence. It presents with proteinuria without nephrotic 
syndrome(Darouich et al., 2011), and is characterised by presence of 
glomerulomegaly and glomerulosclerosis on renal biopsy. Study compared obese non 
diabetic subject underwent bariatric surgery to healthy weight control showed 
significant reduction in BMI, BP, 24 hour proteinuria and albuminuria at 1 year; and 
continue reduction in BMI and 24 hour albuminuria at second year (Navarro-Diaz et 
al., 2006). A systematic review of weight loss interventions in chronic kidney disease 
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reported that non-surgical weight loss interventions reduce proteinuria and blood 
pressure; whereas bariatric surgery normalise glomerular hyperfiltration, reduced BP, 
and microalbuminuria (Navaneethan et al., 2009) . 
 
Objectives 
RYGB surgery is distinct from other gastrointestinal surgery because of its effect on 
improving glucose control and maintaining weight loss post-surgery. Glycaemic 
management of this group of patient therefore should not be generalised with other 
gastrointestinal surgery. There is no prospective study that assesses management of 
this challenging group of complex obese diabetes patients pre-operatively and post-
operatively. There is also lack of data to support whether intensive glucose control 
pre-operatively and postoperatively (which was the common practice in most 
cardiothoracic and gastrointestinal surgeries), would have any added benefit on the 
surgical complications and glycaemic outcome postoperatively.  Diabetes 
microvascular complications, such as retinopathy is known to deteriorate with rapid 
improvement in glucose. Given the rapid improvement in glucose control following 
RYGB, it is therefore important to study its effect on all microvascular complications. 
There is no prospective study assessing all microvascular complications of T2DM 
using objective measurement. My study therefore aims: 
1.   to determine the impact of preoperative glycaemic control on remission of T2DM 
and progression of microvascular complications (retinopathy, nephropathy and 
neuropathy) 1 year after RYGB. 
2.   to determine the impact of postoperative glycaemic control on remission of T2DM 
and progression of microvascular complications (retinopathy, nephropathy and 
neuropathy) 1 year after RYGB. 
3. to determine the impact of RYGB on progression of diabetic nephropathy, 
retinopathy and neuropathy 1 year after surgery 
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Hypotheses 
1. Intensive glucose control before gastric bypass surgery results in better 
medium term glycaemic control and is beneficial for the microvascular 
complications of T2DM. 
2. Intensive glucose control post gastric bypass surgery results in better 
medium term glycaemic control and is beneficial for the microvascular 
complications of T2DM. 
3. Gastric bypass surgery is beneficial for the microvascular complications of 
T2DM. 
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Chapter 2. Clinical Methodology 
2.1. Study 1: GLUCOSURG-pre 
Participants and informed ethical consent 
This was a single- centre, non-blinded, randomised, controlled trial studying obese 
patients with T2DM undergoing RYGB. Forty-one suitable subjects were recruited 
between July 2011 and August 2012 from the obesity clinic at Charing Cross Hospital, 
London. All subjects gave written informed consent. The study was conducted 
according to the principles of the Helsinki declaration. 
Ethics was granted from the West London 2 Research Ethics Committee, 
(Ref11/H0711/1). The trial was registered on the ClinicalTrials.gov NCT01353118. 
 
Randomisation 
Using a computer generated block-randomization method with a 1:1 ratio; subjects 
were randomised to intensive glucose management or conservative management 
preoperatively. 
 
Inclusion criteria: 
1. Informed consent obtained before any trial related activities. 
2. T2DM according to clinical judgement. 
3. BMI ≥35 kg/m2 
4. Age between 18 and 70 years. 
5. HbA1c of greater or equal to 69mmol/mol (8.5%). 
6. Able and willing to complete the trial. 
 
Exclusion criteria: 
1. Type 1 diabetes mellitus 
2. Pregnancy 
3. Failure to proceed to surgery 
4. Proliferative retinopathy that has required acute treatment within last three 
months. 
5. Inability to participate in capillary glucose testing 
6. Inability to titrate glucose lowering pharmacotherapy 
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2.1.1 Study preparation 
 
Forty-one subjects were screened for inclusion and participation in the study. The 
screening, randomisation, and allocation process are shown in figure 5. Three did not 
meet inclusion criteria. 38 subjects gave written informed consent and were 
randomised. Four subjects dropped out. Thirty-four subjects had completed one year 
follow up. The study was analysed by intention to treat and as per protocol analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Recruitment, randomisation and follow up for GLUCOSURG-pre 
subjects. 
 
41 assessed for eligibility    
3 withdraw before 
randomisation or did not meet 
inclusion criteria 
(n=  3  ) 
  not yet proceeded to surgery 
Analysed (n=18) 
 
Lost to follow-up (n=2) 
    
Non-optimized group (n=20) 
Lost to follow-up (n=2) 
    
Optimized group (n=18) 
Analysed (n=16) 
 
Allocation 
Analysis 
Follow-Up 
Enrollment 
Block Randomisation 1: 1 
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Preoperative care 
 
Following randomisation, subjects in the intensive management group were assessed 
in a clinic by chief investigator. Their glucose-lowering therapy was optimised based 
on the American Diabetes Association (ADA) and European Association for Study of 
Diabetes (EASD) guidelines 3 months prior to surgery (Murphy et al., 2015). Intensive 
management was defined as an absolute reduction in HbA1c≥1% after 3 months and 
or before surgery. Subjects were asked to check their capillary glucose (CG) levels 
pre-meals every day. Adjustments were made every 2-3 days apart to reduce the 
incidence of hypoglycaemia. Subjects randomised to the conservative group did not 
undergo any glycaemic optimisation pre-surgery. Preoperative investigations included 
2 urine albumin creatinine ratio (ACR), nerve conduction study and thermal threshold 
testing were organised. Subjects were reminded to attend their retinal screening or 
ophthalmology appointment before surgery. 
 
Perioperative care 
 
All subjects underwent a standard low-calorie diet of 800kCal for 2 weeks before 
admission for surgery in order to decrease their liver size. All glucose-lowering 
medications were discontinued on admission. Subcutaneous short-acting insulin was 
given as necessary according to capillary glucose monitoring using an insulin sliding 
scale (Table 1), as per standard operating procedure at Charing Cross Hospital 
bariatric unit. The target capillary glucose (CG) during the admission was 5.0-
8.0mmol/L. RYGB was performed laparoscopically as described on Chapter 1.3.4.1 
RYGB (Figure1). Subjects were allowed oral fluids the day after surgery, and were 
discharged 2 days after surgery, unless they developed a post-operative complication. 
Metformin 1g bd was routinely started on day 3 unless subjects had a known 
intolerance or evidence of kidney impairment. In addition, patients were prescribed a 
once daily long-acting insulin analogue at a dose equivalent to their total insulin 
requirements during the 24 hour prior to discharge. 
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Table1. Standard bariatric insulin sliding scale. 
Postoperative care 
 
Following discharge, subjects emailed or texted (via short messages service) the chief 
investigator to report their morning fasting CG levels obtained using Accu-Chek 
Advantage® (Roche Diagnostics Ltd, Hertfordshire, England, UK). Insulin dosages 
were adjusted based on a titration schedule (Table 2), aiming for fasting CG levels 
between 5.5 and 7.5 mmol/L. The daily contact was discontinued once fasting CG 
values were documented between 5.0 and 7.5mmol/L for at least 3 consecutive days. 
Subjects were advised to contact their physician if their fasting CG levels were <4.5 or 
>7.5 mmol/L. Glycaemic control and the use of glucose-lowering medication were 
assessed at 10 days, 3 months, 6 months and 1 year after surgery. Metformin was 
reviewed and discontinued if fasting glucose levels were ≤5.6 mmol/L. 
Follow up 
All subjects were reviewed at one year in bariatric clinic. Weight, medication usage 
and glycaemic control were assessed. Follow up investigations including 2 urine ACR, 
nerve conduction study and thermal threshold testing were arranged. Subjects were 
reminded to attend retinal screening or ophthalmology follow up. 
 
 
 
Bariatric 4 Hourly s.c. Sliding Scale Prescription
Check BM 4 hourly. Give Actrapid 4 hourly s.c.
BM Stix Range Sub.Cut Actrapid Dose
1 2 3
< 4.0 Call Doctor 0 Units 0 Units 0 Units
4.1 - 8.0 Perfect 0 Units 2 Units 4 Units
8.1 - 11.0 2 Units 4 Units 6 Units
11.1 - 14.0 4 Units 6 Units 8 Units
14.1 - 17.0 Call Doctor and ask to consider changing scales 6 Units 8 Units 10 Units
17.1 - 20.0 Call Doctor, a senior review is needed. 8 Units 10 Units 12 Units
Signature of Doctor
Bleep Number
Date Signed ___/____/___ ___/____/___ ___/____/___
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Table 2. Daily insulin titration schedule in insulin-requiring type 2 diabetes after gastric 
bypass surgery.  
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2.2 Study 2: GLUCOSURG-post 
 
Participants and informed ethical consent 
This was a single- centre, non-blinded, randomised, controlled trial studying obese 
subjects with T2DM undergoing RYGB. Forty-two suitable subjects were recruited 
between December 2010 and October 2012 from the obesity clinic at Charing Cross 
Hospital, London. All subjects gave written informed consent. The study was 
conducted according to the principles of the Helsinki declaration. 
Ethics was granted from the West London 2 Research Ethics Committee, 
(Ref10/H0711/69). The trial was registered on the ClinicalTrials.gov NCT01257087. 
 
Randomisation 
Using a computer generated block-randomisation method with a 1:1 ratio; subjects 
were randomised to intensive glucose management or conservative management for 
2 weeks following RYGB. 
Inclusion criteria: 
1. Informed consent obtained before any trial related activities. 
2. T2DM according to clinical judgement. 
3. BMI ≥35 kg/m2 
4. Age between 18 and 70 years. 
5. Insulin treated T2DM. 
6. Able and willing to complete the trial. 
Exclusion criteria: 
The same exclusion criteria as outlined in study 1. 
2.2.1 Study preparation 
Forty-two subjects were screened for inclusion and participation in the study. The 
screening, randomisation, and allocation process are shown in figure 6. One did not 
meet inclusion criteria. 41 subjects gave written informed consent and were 
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randomised. Six subjects dropped out. Thirty-five subjects had completed one year 
follow up. The study was analysed by intention to treat and as per protocol analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Recruitment, randomisation and follow up for GLUCOSURG-post 
subjects.  
42 assessed for eligibility    
1 did not meet inclusion criteria 
Analysed (n=17) 
 
Lost to follow-up (n=5) 
    
Conservative group (n=22) 
Lost to follow-up (n=1) 
    
Intensive group (n=19) 
Analysed (n=18) 
 
Allocation 
Analysis 
Follow-Up 
Enrollment 
Block Randomisation 1: 1 
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Preoperative care/ Perioperative care 
All subjects were seen in a specialist medical clinic prior to surgery. They shared the 
similar preoperative, perioperative, inpatient and postoperative care pathway as 
described in study 1, with exception to their target fasting CG 
readings. Postoperatively, intensive glucose management aimed for a fasting CG of 
5.5 - 6.5mmol/L, and conservative glucose management aimed for fasting CG of 6.5-
7.5mmol/L. 
Postoperative care 
Following discharge, subjects contacted the chief investigator with their daily fasting 
CG up to post-operative day 15, in the same way as GLUCOSURG-pre. The dose of 
the long-acting insulin analogue and metformin was adjusted to achieve target fasting 
CGs of 5.5-6.5mmol/L in the intensively treated group and 6.5-7.5mmol/L in the 
conservative treated group. Thereafter, subjects were advised to contact their 
physician if their fasting CG levels were <4.5 or >7.5 mmol/L. Glycaemic control and 
the use of glucose-lowering medication were assessed at 10 days, 3 months, 6 months 
and 1 year after surgery. Metformin was reviewed at follow up and discontinued if 
fasting glucose levels were ≤5.6 mmol/L. 
Follow up 
Follow up care as discussed in study 1. 
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2.3 Study 3: GLUCOSURG-combine 
 
Surgical and Medical groups 
Subjects from GLUCOSURG -pre and GLUCOSURG -post were collated into surgical 
group. The surgical subjects were matched with 25 diabetic patients with BMI ≥35 
kg/m2 receiving best medical care. These patients were matched for gender, age, 
HbA1c and duration of diabetes. They were under the care of tertiary centre diabetes 
specialist clinic. The patients were seen by diabetes physicians who provided the 
routine diabetes care including optimisation of glycaemia, cardiovascular risk and 
weight. The patients were also reviewed within a year. 
2.4. Data collection and analysis  
Data Collection (GLUCOSURG-pre and GLUCOSURG-post) 
Demographic information, duration of diabetes, body weight, height, blood pressure, 
HbA1c, fasting plasma glucose were collected at baseline and 12 months. Data on 
diabetes microvascular complications (urine ACR, retinal photography, nerve 
conduction study, thermal threshold testing) were collected before and a year after 
surgery. Data on capillary glucose readings and insulin requirement were collected up 
to 14 days post- surgery. Data on glucose and blood pressure lowering medications 
were collected before and a year after surgery. Length of stay, 30 days surgical 
complications, and postoperative hypoglycaemic episodes were also collected. 
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2.4.1 Analysis(GLUCOSURG-pre and GLUCOSURG-post) 
Analysis were carried out comparing the outcomes between the conservative and 
intensive groups.  Data were analysed with intention to treat analysis, and as per 
protocol analysis. 
As per protocol analysis (GLUCOSURG -pre) 
Subjects who were randomised to intensive group but did not achieve at least 1% 
reduction in HbA1c before surgery were reassigned to conservative group and vice 
versa. 
As per protocol analysis (GLUCOSURG -post) 
Subjects who were randomised to intensive group but did not achieve fasting CG of 
5.5-6.5mmol/L within two weeks post- surgery were reassigned to conservative group, 
and vice versa. 
2.4.2 Data collection and analysis (GLUCOSURG-combine) 
Demographic information and data on surgical group as collated previously. Data 
collected on medical comparative group include demographic information and duration 
of diabetes. BMI, HbA1c, blood pressure, medication usage and microvascular 
complications were also collected within the 6 months before and at 12-18 months 
after intervention. 
2.5 Glycaemic control 
Glycated haemoglobin (HbA1c) was measured at 1 month before, and 12 months after 
surgery or inclusion in the trial. Remission of diabetes was based on the ADA criteria. 
Partial remission is defined as HbA1c of less than 6.5% for at least 1 year without 
active pharmacologic therapy. Complete remission is defined as HbA1c level of less 
than 6% of at least 1 year’s duration without active pharmacologic therapy (Buse et 
al., 2009). 
Further analysis included collating all surgical patients in GLUCOSURG -pre and 
GLUCOSURG -post together as surgical group, and compared the change in HbA1c 
to the comparative group who received best medical treatment only. 
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2.6 Renal function 
Albuminuria was assessed using 2 early morning ACR collected within the 6 months 
preceding surgery and 10 - 14 months after surgery. Albuminuria was defined as an 
ACR value of ≥ 2.5 mg/mmol in males or ≥ 3.5 mg/mmol in females. Improvement or 
deterioration after surgery was defined as a decrease or increase in the ACR value 
respectively. Normalisation was defined in those patients with pre-existing albuminuria 
who subsequently had a reduction in their urine ACR result to below the 
aforementioned cut off. The changes in albuminuria before and within 1 year of surgery 
were assessed between the intensive and conservative treated groups. 
Further analysis included collating all surgical patients in GLUCOSURG -pre and 
GLUCOSURG -post together as surgical group, and compared the change in urine 
ACR to the comparative group who received best medical treatment only. 
2.7 Retina 
Retinal photographs within 6 months preceding surgery and within 9 to 15 month post-
surgery were obtained from the national retinal screening centre or ophthalmology 
department. Retinal images were graded according to the English National Screening 
Programme for Diabetic Retinopathy and the results confirmed by an independent 
ophthalmologist who was blinded to the patient clinical information. The final decision 
on scoring was taken from the ophthalmologist’s score. 
The retinal photographs were graded and given a retinal score according to features 
described at each stage of retinal disease (Table 3). In cases where score was 
different in both eyes, the higher score was taken for the purpose of analysis. 
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Table 3. Retinal grading and score (Adapted from International clinical disease 
severity scale for diabetic retinopathy)(Wilkinson et al.) 
 
Proposed disease severity level Description Retinal score 
No apparent retinopathy No abnormalities 0 
Mild non-proliferative diabetic 
retinopathy 
Microaneurysms only 1 
Moderate non-proliferative 
diabetic retinopathy 
More than just microaneurysms but less 
than severe nonproliferative diabetic 
retinopathy 
2 
Severe nonproliferative diabetic 
retinopathy 
Any of the following: 
More than 20 intraretinal haemorrhages in 
each of 4 quadrants; definite venous 
beading in 2+ quadrants; prominent 
intraretinal microvascular abnormalities in 
1+ quadrantand no signs of proliferative 
retinopathy 
3 
Proliferative diabetic retinopathy One or more of the following: 
Neovascularization, vitreous/preretinal 
haemorrhage 
4 
 
 
Improvement or worsening was defined as a decrease or an increase of at least two 
steps in the same grading system respectively (i.e. at least two steps in one eye or 
one step in each eye). Normalisation was defined in the patients with pre-existing 
diabetic retinopathy, who showed no signs of diabetic retinopathy after surgery or best 
medical care. 
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The changes in retinal images before and after surgery were compared between the 
intensively treated group and conservative treated group. 
Further analysis included collating all surgical patients in Glucosurg-pre and 
Glucosurg-post together as surgical group, and compared the change in retinal images 
to the comparative group who received best medical treatment only. 
2.8 Peripheral nervous system function 
Nerve Conduction studies (NCS) and thermal threshold testing (TTT) were only 
performed on subjects who had bariatric surgery due to cost limitation. The studies 
were performed within 3 months preceding and 12-15 months after surgery. 
Nerve conduction study 
Nerve conduction study is the gold standard for evaluation of myelinated large nerve 
fibres. The study of motor and sensory nerves was performed with standard 
techniques of stimulation and recording using Dantec EMG machine. This test was 
conducted by a single operator on the right upper and lower limb. The motor nerves 
tested include median, ulnar, common peroneal and tibial nerves.  The sensory nerves 
include median, ulnar, superficial radial and sural. Upper limb assessment included 
superficial radial sensory nerve action potential (SNAP), superficial radial conduction 
velocity (CV); and lower limb assessment included sural SNAP and sural CV, common 
peroneal CV, tibial compound muscle action potential (CMAP), minimal latency tibial 
F-response. Nerve conduction study was analysed quantitatively. P value was 
adjusted with Bonferroni correction to correct for multiple comparisons. 
The data was also analysed qualitatively by a neurophysiologist. Table 5 showed 
normal values for motor nerve (standard operating procedure for Charing Cross 
Hospital neurophysiology department). Table 6 showed normal values for sensory 
nerve (standard operating procedure for Charing Cross Hospital neurophysiology 
department). Reference range for minimal latency tibial F response is height 
dependent, medium stature 54-58ms. 
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Table 4 Normal range for motor nerve values 
Nerve  DL (ms) Amp. (mV)         CV (m/s) 
Median 4.2  4.5-17.5   49 
Ulnar  4.0  5.0-17.5   47 
Radial  5.2  4.0-9.0    50 
Peroneal 6.5  2.5-11.0   39 
Tibial  7.0  2.5-14.0   37 
 
 
 
Table 5. Normal range for sensory nerve values 
 
Amp. (µV) CV (m/s) 
 
Median (index) 6-26  44-66 
Ulnar (little finger) 4-24  45-71 
Radial (1st webspace) 4-20  50-64 
Sural   4-26  39- 54 
 
2.9.2 Thermal threshold testing 
Thermal threshold testing is used to evaluate small sensory nerve fibres. The test was 
conducted on upper limb (dorsum of hand) and lower limb (dorsum of foot). This was 
carried out by a single operator in an ambient temperature controlled (24 ± 1 ºC) room 
to ensure consistency. P value was adjusted with Bonferroni correction to correct for 
multiple comparison. 
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The data was also analysed qualitatively by a neurophysiologist. Patients thermal 
threshold values were compared to healthy controls reference ranges (Table 7(Nicotra 
A, 2012)). 
Table 6. Thermal thresholds values in the upper and lower limbs in healthy controls subjects. 
(mean ± standard error of mean) 
 Controls ( n=17) 
Hand 
Cool perception threshold(ºC) 30.0 ± 0.7 
Warm perception threshold (ºC) 34.2 ± 1.0 
Feet 
Cool perception threshold(ºC) 29.3 ± 1.3 
Warm perception threshold (ºC) 36.1 ± 1.9 
 
2.9. Surgical complications 
Surgical complications included any surgical related complications within 30 days of 
surgery. This was obtained from patient case notes, and confirmed with patients at 1 
year review. 
2.10 Hypoglycaemic episodes 
Hypoglycaemia is defined as capillary glucose readings of < 4.0mmol/L. This was 
assessed between day 3 to day 15 post-surgery. 
2.11. Study Endpoints 
The primary end point was the proportion of patients achieving remission of diabetes 
as defined by ADA criteria at 12 months after surgery(Buse et al., 2009). Secondary 
endpoints included microvascular complications such as nephropathy, retinopathy, 
and neuropathy. Other secondary end points included length of stay, 30 days surgical 
complications, hypoglycaemic episodes, and medication usage. 
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2.11 Statistical analysis 
 
Presentation of data 
Descriptive statistics were expressed as mean ± standard error of the mean or median 
(interquartile range) depending on normality distribution or as percentages. Within 
group comparisons were made using the paired sample student t-test or the Wilcoxon 
matched pairs test, and between group comparisons using the unpaired Student t-test 
or the Mann Whitney U test depending on the normality distribution. Categorical data 
were compared using the chi square test (Graphpad PRISM software version 5.01, 
GraphPad Software Incorporation, USA). Bonferroni correction for multiple 
comparisons was applied to the neurophysiological measurements. The Pearson 
methodology was used to test correlations between two variables at a time. Statistical 
significance was accepted as p<0.05. 
2.12 Power calculation 
Study 1: GLUCOSURG -pre 
The criteria variable selected to determine statistical power are HbA1c. There are no 
data on the effects of pre-operative glycemic optimisation on average glycaemia at 1 
year after bariatric surgery and as such the GLUCOSURG -pre trial was a pilot. 
Study 2 GLUCOSURG -post 
Based on our data , with an absolute reduction in HbA1c of -3.0% in the group whose 
glucose control was optimised for 2 weeks after surgery and -1.2% in the group that 
underwent no optimisation, with a standard deviation of 1.7 around the mean, a 
sample size of 16 patients in each group was needed for a proposed RCT in order to 
have 80% power to show significant differences between the groups at α=0.05(Chuah 
et al., 2015). 
Study 3: GLUCOSURG -combine 
The criteria variable selected to determine statistical power are HbA1c. At the design 
of the study, there were no data on the effects of RYGB on diabetic nephropathy, 
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retinopathy and neuropathy at 1 year after bariatric surgery and as such the 
GLUCOSURG -combine trial was a pilot. 
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Chapter 3. Methods/ Techniques 
3.1. Glycaemic measurement 
Point of care measurement of blood glucose 
Point of care measurement of glucose was obtained using Accu-Chek Advantage® 
(Roche Diagnostics Ltd, Hertfordshire, England, UK).This is the most common glucose 
monitoring available at home. It allows measurement of glucose throughout the day. 
It involves placing a blood sample on a chemically coated test strip, which is then 
placed in a glucose meter. The glucose in the blood reacts with the chemicals on the 
test strip, producing a small electrical current. This current is measured, and a result 
displayed on the screen. The size of the current depends on the amount of glucose in 
the blood sample. This could be affected by temperature. Quality control solution is 
used to ensure quality control. 
Assessment of accuracy demonstrates excellent correlation with a value of 0.994 with 
1.000 as the optimum value. The linear regression shows a slope of 1.025 with a 95% 
confidence interval of (1.009, 1.040). The intercept is 3.6 mg/dL (0.2 mmol/L). The 
data presented 97% of the individual glucose results shall fall within ± 0.83 mmol/L of 
the results of the manufacturer’s measurement procedure at glucose concentrations 
less than 4.2 mmol/L and all individual glucose results were within ± 20% at glucose 
concentrations greater than or equal 4.2 mmol/L. 
Plasma glucose 
 
ADVIA® 2400 Chemistry systems are used for in vitro diagnostic quantitative 
determination of glucose in human serum, plasma, urine and cerebrospinal fluid. It 
works by enzymatic method based on the method by Slein utilizing hexokinase and 
glucose-6-phosphate dehydrogenase enzymes. The Glucose Hexokinase II method is 
a two-component reagent. Sample is added to Reagent 1, which contains the buffer, 
ATP, and NAD. Absorbance readings of the sample in Reagent 1 are taken and are 
used to correct for interfering substances in the sample. Reagent 2 is added, which 
initiates the conversion of glucose and the development of absorbance at 340 nm. The 
difference between the absorbance in Reagent 1 and Reagent 2 is proportional to the 
glucose concentration. 
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Glucose is phosphorylated by adenosine triphosphate (ATP) in the presence of 
hexokinase. The glucose-6-phosphate that forms is oxidized in the presence of 
glucose-6-phosphate dehydrogenase causing the reduction of NAD to NADH. The 
absorbance of NADH is measured as an endpoint reaction at 340 nm. 
 
The imprecision for glucose has an inter-assay coefficient variation of <2.9%. 
HbA1c 
 
The principal haemoglobin (Hb) consists of two alpha chains and two beta chains. 
These chains can be glycated. Glycated haemoglobins consist of HbA1a (fructose-1, 
6-diphosphate), HbA1b (glucose-6-phosphate) and HbA1c (glucose). HbA1c consists 
of a labile and a stable form.The formation of stable glycated Hb is irreversible and the 
blood level depends both on the blood glucose concentration and the life span of the 
red blood cells. Thus the level of HbA1c represents the integrated values for glucose 
over the preceding 6-8 weeks. 
HbA1c is measured using the Menarini HA-8160. The HA 8160 differentiates stable 
HbA1c from HbA1a, HbA1b, and labile HbA1c and stable Hba1c as well as from the 
non-glycated ‘parent’ haemoglobin A0. Reversed phase partition chromatography is 
used to elute HbA1a, HbA1b, HbF, labile HbA1c and stable HbA1c by Eluant A. Ion 
exchange chromatography is then used to elute HbA by Eluant B and HbA2, HbS and 
HbC by Eluants C and D.  Detection relies upon dual-wave length spectrophotometry. 
The International Federation for Clinical Chemistry (IFCC) has produced an 
international reference standard. It has been agreed that the new IFCC standardised 
HbA1c will be reported as mmol per mol of unglycated haemoglobin. 
The imprecision for HbA1c has an inter-assay coefficient variation of <2.4%. 
3.2 Retinal assessment 
Retinal photography 
Diabetic eye disease was assessed using two field (nasal view and macular view) 
digital retinal images taken at the same time points. Patients received 1% tropicamide 
64 
 
eye drop for mydriasis, prior to retinal photograph. Photographs were obtained though 
fundus camera. This is part of national screening programme for diabetic retinopathy; 
hence the minimum accepted standards for the quality of images, the maximum 
accepted technical failure rate of the screening system were as specified by the 
national programme. The retinal grader also attended monthly online test and training 
session as part of quality assurance. 
3.3 Renal assessment 
Urine albumin creatinine ratio 
 
ADVIA® 2400 Chemistry systems are used for in vitro diagnostic quantitative 
determination of human albumin in urine. This microalbumin method is based on the 
work of Fielding and Hellsing, and it measures very small levels of albumin in urine 
samples. Albumin is a plasma protein that is responsible for much of the osmotic force 
of the blood. In healthy population, only a small amount of albumin (up to 20 mg/L) is 
excreted in the urine. 
Elevated levels of urinary albumin indicate a high probability of damage of the 
glomerular filtration capacity of the kidney. During the progression of renal disease in 
type I diabetes mellitus, stage III or incipient nephropathy is characterized by the 
elevation in urinary albumin. Elevated results in urinary albumin may also be 
associated with hypertension, some lipid abnormalities, and several immune disorders 
as well as other conditions such as vigorous exercise, blood in the urine, urinary tract 
infection, dehydration, and some drugs. 
 
The microalbumin method is a PEG enhanced immunoturbidimetric assay. Sample 
containing human albumin is suitably diluted and then reacted with specific antiserum 
to form a precipitate that can be measured turbidimetrically at 340 nm. By constructing 
a standard curve from the absorbances of standards, the albumin concentration of the 
sample can be determined. 
The imprecision for urine ACR has inter-assay coefficient variation of <5.3%. 
 
3.4 Peripheral nervous system assessment 
Nerve Conduction studies and thermal threshold testing (TTT) were performed before 
and 12 months after surgery or inclusion in the trial respectively. 
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Nerve conduction studies 
 
Nerve conduction studies (motor and sensory) were performed with standard 
techniques of stimulation and recording using Dantec EMG system (Copenhagen, 
Denmark). Motor conduction is performed by stimulating the nerve at two points and 
recording form one of the distal muscles supplied by the nerve. Sensory conduction is 
performed either orthodromically (stimulating the nerve distally and recording 
proximally along the course) or antidromically (stimulating the nerve proximally and 
recording distally).  The median and sensory nerves were tested orthodromically by 
stimulating the index (median) and little (ulnar) fingers distally and recording proximally 
at the wrists.  The superficial radial and sural nerves were tested antidromically; the 
radial nerve by stimulating the forearm and recording distally at the first web space and 
the sural by stimulating the lower leg and recording behind the lateral malleolus.  The 
motor measurements include distal motor latency (ms), conduction velocity (m/s), 
amplitude of the compound muscle action potential (mV) and the minimal latency of 
the F- responses.   The sensory measurements include amplitude (uV) and conduction 
velocity (m/s).The imprecision for NCS has a coefficient variation of <5.0%. 
 
Thermal threshold testing 
Thermal threshold testing to cool sensation and warm sensation was carried out with 
a SENSELab-THERMOTEST Modular Sensory Analyser (Sweden). A thermode (25 x 
50 mm) was applied to the skin of the dorsum of hands and feet. Cool and warm 
perception thresholds were measured using the method of limits:  subjects received five 
successive thermal stimuli, decreasing or increasing from a starting temperature of 32oC 
at a rate of 1oC/second, and were required to arrest the changing stimulus by pressing a 
button as soon as the specific modality (cool or warmth) being tested was perceived. The 
cut-off temperature limit for cool perception threshold was 10 0C and for warm perception 
threshold was 50 0C; if those limits are reached, the machine would automatically revert 
to the baseline temperature of 32 0C. Thresholds were taken as the average of five 
successive readings for each thermal modality. (Nicotra A, 2012, Chuah et al., 2015) 
Threshold from left and right limb were averaged, and taken for analysis. The test 
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combined objective physical sensory stimuli and subject’s response to stimuli, it is 
therefore a psychophysical testing, which has greater inherent variability. There is 
interoperator variability and its reproducibility is yet to be established. 
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Chapter 4. Results for GLUCOSURG -pre study 
4.1 Participants characteristics 
Thirty-four subjects had completed one year follow up. The subject baseline 
characteristics are shown in Table 7. 
There were 11 males, 7 females in the conservative group. The group had mean age 
of 48.9± 1.8, duration of diabetes 9.2± 1.5 years, and BMI of 42.1(39.4-50.8) kg/m2. 
HbA1c was 10.3 (9.5-11.0) % [89.1 (80.3-96.7)] mmol/mol at randomisation. 
There were 9 males, 7 females in the intensive group. The mean age was 49.3± 2.1, 
duration of diabetes 10.5± 1.9 years, and BMI of 46.2 (38.4-55.3) kg/m2. HbA1c was 
9.9 (8.9-10.4) % [84.7 (73.8-90.2) mmol/mol] at randomisation. HbA1c was reduced 
to 8.4 (7.1-9.3) % [68.3 (54.1-78.1)mmol/mol] following intensive treatment prior to 
RYGB. The number of glucose lowering medications was similar in both groups, 2.0 
(2.0-2.0). 
Following randomisation, the age, gender distribution, BMI, HbA1c, duration of T2DM 
and number of glucose lowering medications were similar between the groups. 
Body mass index 
BMI at 1 year following surgery showed significant reduction from 42.1 (39.4-50.8) to 
32.1 (29.9-34.4) kg/m2 in the conservative group (p<0.0001); and from 46.2 (38.4-
55.3) to 36.2 (28.8-38.3) kg/m2 in the intensive group (p=0.008). There was no 
significant difference between the 2 groups (p=0.62). 
Blood pressure 
There was significant reduction in systolic blood pressure (SBP) from 149(139-157) 
mmHg to 125 (116-142) mmHg in the conservative group (p<0.05). No significant 
reduction in SBP was observed in the intensive group, 146 (136-157) mmHg to 129 
(122-145) mmHg (p=0.21). The change in SBP between the two groups was not 
significant (p=0.21). 
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There was no significant change in diastolic blood pressure (DBP) in conservative and 
intensive groups at follow up, 83(80-91) mmHg to 82 (74-89) mmHg (p=0.16); 86 (80-
93) mmHg to 80 (77-91) mmHg (p=0.57) respectively. 
Effectiveness of the intervention on pre-operative glycaemic control 
In the intensive group HbA1c was reduced significantly in the three months pre-
surgery from 9.9% (85mmol/mol) to 8.4% (68.3mmol/mol) (p=0.003), whilst the HbA1c 
of the conservative group did not change significantly, 10.3% (89.1mmol/mol) to 9.7% 
(82.5mmol/mol)  (p=0.25). HbA1c of the intensive group on the day of surgery was 
significantly lower than the conservative group (p<0.005). 
4.2 Glycaemic control at 1 year 
Both groups achieved significant reductions in HbA1c 1year after surgery. The 
conservative group achieved HbA1c of 6.3 (5.9-6.8) % [45.4 (41.0-50.8)] mmol/mol, 
(p=0.0002) and the intensive group achieved 6.9 (5.9-7.8) % [51.9 (41.0-61.7)] 
mmol/mol (P=0.0001). The difference in reductions in HbA1c between both groups 
was not significant (p=0.07). 
Remission of diabetes 
Five (27.8%) subjects from the conservative group achieved HbA1c<6.0%, 2 subjects 
were not on any glucose lowering medication, and 3 were on metformin. Four (25%) 
subjects from the intensive group achieved HbA1c<6.0%, 1 subject was not on any 
glucose lowering medication, 3 were on Metformin. Overall 3 subjects achieved 
complete remission of diabetes at 1 year post surgery, as defined by ADA criteria. 
Medication usage 
Glucose lowering medications 
Glucose lowering medications was reduced from 2.0 (2.0-2.3) to 1.0 (1.0-1.0) 
(p=0.0001), and 2.0 (2.0-2.0) to 1.0 (1.0-2.0) (p=0.004) in conservative and intensive 
group respectively. 
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BP lowering medications 
BP lowering medications was reduced from 1 (1-2) to 1 (0-1), (p=0.007); and 2 (1-2) 
to 1 (0-2) (p=0.007) in conservative and intensive group respectively. 
Incidence of hypoglycaemia 
Two subjects in the intensive group had CG readings <4.0 mmol/L but did not have 
symptoms of severe hypoglycaemia during the two weeks monitoring post-surgery. 
No hypoglycaemia was noted in the conservative group. 
Length of stay 
The median length of stay was 3 days for both groups (p=0.73). 
Surgical complications 
There was no significant difference in the incidence of surgical complications between 
the 2 groups. One subject from the intensive group had a post-operative stroke on day 
1 and made a full recovery. One patient developed abdominal pain post-surgery which 
resolved spontaneously. One subject from the conservative group vomited post- 
surgery, but settled after a prolonged inpatient stay. 
4.3 Microvascular complications 
4.3.1 Albuminuria 
Thirteen subjects from conservative group and 11 subjects from intensive groups had 
complete urine ACR datasets.  Median urinary albumin creatinine ratio reduced from 
6.9 (1.3-14.3) to 1.8 (0.7-5.6) mg/mmol at one year in conservatively managed group 
(p<0.05). The change in urine ACR was not significant in the intensive treatment 
group, 6.1 (1.9-14.0) to 1.7 (0.8-6.8) mg/mmol, (p=0.58).  There was no significant 
difference in the change in albuminuria between the conservative and intensive group. 
Subgroup analysis of the overall cohort showed 9 subjects had normal ACR, 15 had 
pre-existing albuminuria at baseline. At 1 year after surgery, 13 subjects improved, 3 
deteriorated, 8 had no change. 
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Of the 15 subjects with pre-existing albuminuria, 13 improved of which 8 normalised, 
2 had deteriorated. Of the 9 normal albuminuria subjects, 8 had no change, and 1 had 
deteriorated. 
4.3.2 Retinopathy 
Fifteen subjects from conservative group and twelve subjects from intensive group had 
complete retinal datasets. The conservative group had a median retinal score of 1.0 
(0.0-1.0) before surgery, and 1.0 (0.0-2.0) at one year follow up (p=0.46). The retinal 
score was 1.0 (0.0-3.0) before surgery and 0.5 (0.0-1.8) at one year follow up (p=0.55) 
for intensive group. There was no significant different changes in retinal score between 
both groups (p=0.45). 
Subgroup analysis of overall cohort showed 11 subjects had no retinopathy, 12 had 
mild to moderate non-proliferative retinopathy, and 4 had severe non proliferative 
retinopathy. At 1 year after surgery, 20 (74.1%) patients had no change, 5 (18.5%) 
patients improved by at least two steps, and 2 (7.4%) deteriorated by at least two steps 
in retinopathy severity grading. 
Of the 16 subjects with pre-existing retinopathy, 5 improved, 1 deteriorated, 10 were 
stable. Of the 11 subjects with normal retinal, 1 deteriorated, 10 remained stable. 
4.3.3 Peripheral neuropathy 
Nerve conduction study 
Thirteen subjects from the conservative group and 14 subjects from the intensive 
group underwent nerve conduction studies (Table 8). There were no statistically 
significant changes in any of the nerve conduction parameters at 1 year. There was 
no significant difference between the intensive and conservative treated group. 
Qualitative analysis showed 11 of the overall cohort had pre-existing peripheral 
neuropathy, 16 had normal NCS at baseline. At 1 year after surgery, 2 who had pre-
existing neuropathy showed deterioration, 25 subjects had no change. 
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Thermal threshold testing 
Thirteen subjects completed thermal threshold testing in the intensive and 
conservative groups (Table 9). There was worsening of cool perception threshold on 
lower limbs in conservative group after surgery, from 30.1 (29.2-30.6) to 28.6(26.8-
30.3) ºC (P= 0.008). There were no statistically significant changes in other perception 
threshold after surgery. There was no difference in changes between both groups. 
Postoperative glucose management 
Both conservative and intensive groups of patients were monitored and managed with 
the aim of maintaining blood glucose within the range of 5.5 – 7.5 mmol/L. Figure 7 
showed glucose trend postoperatively in both optimised and non-optimised groups. 
Postoperative glucose trend was not significantly different between both groups 
(p=0.13). 
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Table 7. GLUCOSURG-pre. Baseline and 1 year follow-up results of the conservative and intensive group. (Intention to treat analysis) 
 
 
 
Conservative 
(n=18) 
P value 
(within 
group) 
Intensive 
(n=16) 
P value 
(within 
group) 
P value 
(between 
groups at 
baseline) 
P value 
(of change 
between 
groups) 
 Pre-operatively Post-operatively  Pre-operatively Post-operatively    
Baseline variables 
Age ( year) 48.9± 1.8 N/A N/A 49.3± 2.1 N/A N/A 0.93 N/A 
Male (%,n) 61.1, 11 N/A N/A 56.3, 9 N/A N/A 1.00 N/A 
Duration of 
diabetes (years) 
9.2± 1.5 N/A N/A 10.5± 1.9 N/A N/A 0.55 N/A 
BMI (kg/m²) 42.1 (39.4-50.8) 32.1 (29.9-34.4) <0.0001 46.2 (38.4-55.3) 36.2 (28.8-38.3) 0.008 0.78 0.62 
SBP (mmHg) 149(139-157) 125 (116-142) 0.03 146 (136-157) 129 (122-145) 0.21 0.98 0.21 
DBP (mmHg) 83(80-91) 82 (74-89) 0.16 86 (80-93) 80 (77-91) 0.37 0.93 0.57 
Outcome variables 
HbA1c (%) 
 
10.3 (9.5-11.0) 
a9.7 ( 8.8-10.9) 
6.3 (5.9-6.8) 0.0002 9.9 ( 8.9-10.4) 
b8.4 (7.1-9.3) 
6.9 (5.9-7.8) 0.0001 0.41 
cp<0.005 
0.07 
HbA1c 
(mmol/mol) 
89.1 (80.3-96.7) 
a82.5 (72.7-95.6) 
45.4 (41.0-50.8) 0.0002 84.7 (73.8-90.2) 
b68.3 (54.1-
78.1) 
51.9 (41.0-61.7) 0.0001 0.41 
cp<0.005 
0.07 
Urine ACR 
(mg/mmol) 
6.9 (1.3-14.3) 1.8 (0.7-5.6) 0.03 6.1 (1.9-14.0) 1.7 (0.8-6.8) 0.58 0.74 0.64 
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Retinal score 1.0 (0.0-1.0) 1.0 (0.0-2.0) 0.46 1.0 (0.0-3.0) 0.5 (0.0-1.8) 0.55 0.29 0.45 
Length of stay 
(days) 
N/A 3.0 (3.0-4.3) N/A  3.0 (3.0-4.5) N/A  0.73 
30 days surgical 
complications 
(%,n) 
N/A 11.1, 2 N/A  6.3, 1 N/A   
Hypoglycaemic 
episodes (n) 
N/A 1 N/A  1 N/A   
glucose-lowering 
medications 
2.0 (2.0-2.3) 1.0 ( 1.0-1.0) 0.0001 2.0 (2.0-2.0) 1.0 (1.0-2.0) 0.004 0.70 0.16 
BP lowering 
medications 
1.0 (1.0-2.0) 1.0 (0.0-1.0) 0.007 2.0 (1.0-2.0) 1.0 (0.0-2.0) 0.007 0.57 0.94 
BMI body mass index, HbA1c glycated haemoglobin, a HbA1c post-randomisation, b HbA1c post-optimisation, cp value post-optimisation, N/A not 
applicable, SBP systolic blood pressure, DBP diastolic blood pressure. 
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Table 8. Result of nerve conduction study before and one year post RYGB surgery (Intention to treat analysis) 
 
 
 
Conservative 
(n=13) 
P value 
(within 
group) 
Intensive 
(n=14) 
P value 
(within group) 
P value 
(between 
groups at 
baseline) 
P value 
(of 
change 
between 
groups) 
 Pre-operatively Post-operatively  Pre-operatively Post-operatively    
Sup radial 
SNAP(mV)* 
21.6 ( 16.1-29.5) 21.0 ( 14.7-27.8) 1.00 14.6 (10.4-18.8) 16.5 ( 10.4-21.6) 0.14 0.06 0.22 
Sup radial 
CV(m/s) 
63.2 ± 1.1 61.7 ± 1.3 0.21 59.9 ± 2.3 60.1 ± 2.2 1.00 0.32 0.08 
Sural SNAP (mV) 9.8 ( 4.8-14.6) 11.1 ( 8.2-17.2) 0.98 7.8 ( 4.8-14.3) 9.4 ( 6.3-21.9) 0.56 0.88 0.72 
Sural CV (m/s) 50.4 ± 1.6 50.1 ± 1.6 1.00 49.0 ± 2.0 48.7 ± 2.3 1.00 0.56 0.62 
Common 
Peroneal CV 
(m/s) 
46.0 ± 1.4 45.9 ± 1.0 1.00 43.3 ± 1.3 44.5 ± 1.4 1.00 0.16 0.70 
Tibial CMAP 
(mV) 
5.2 ± 0.5 5.5 ± 0.6 1.00 4.0 ± 0.7 4.5 ± 0.8 1.00 0.19 0.82 
Minimal latency 
tibial F-response 
(ms) 
53.8 ± 1.5 55.2 ± 1.6 0.21 57.5 ± 2.0 57.6 ± 2.3 1.00 0.17 0.34 
SNAP sensory nerve action potential, CV conduction velocity, CMAP compound muscle action potential 
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Table 9. Result of thermal threshold testing before and one year post RYGB surgery (Intention to treat analysis). 
 
 
 
Conservative 
(n=13) 
P value 
(within 
group) 
Intensive 
(n=13) 
P value 
(within 
group) 
P value 
(of change 
between groups) 
 Pre-
operatively 
Post-
operatively 
 Pre-operatively Post-
operatively 
  
UL- WPT (ºC) 35.2 (34.6-
37.1) 
34.7 (33.7-36.8) 0.88 36.5 (35.2-37.9) 35.8(34.2-37.7) 0.84 0.50 
UL-CPT (ºC) 30.4 (29.0-
31.0) 
30.4 (29.3-30.8) 1.00 30.0 (29.5-30.8) 30.2 (30.0-30.8) 1.00 0.11 
LL-WPT (ºC) 37.8 (35.0-
42.0) 
38.8 (36.1-40.8) 1.00 41.3 (36.2-44.0) 40.5 (37.4-44.7) 0.80 0.18 
LL-CPT (ºC) 30.1 (29.2-
30.6) 
28.6(26.8-30.3) 0.008 29.4 (26.6-30.5) 26.9 (23.7-30.1) 0.12 0.33 
UL upper limb, LL lower limb, WPT, warm perception threshold, CPT cool perception threshold 
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Figure 7. Postoperative glucose trend of both optimised (intensive) and non-
optimised (conservative) groups (Intention to treat). 
 
The effect of optimisation was not statistically significant F (1, 268) =2.34, p 
=0.13 
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Chapter 5. Results of GLUCOSURG -pre (As per protocol 
analysis) 
5.1 Participants characteristics 
Criteria for as per protocol analysis was discussed previously. Of the 18 subjects 
randomised to conservative group, 2 met the criteria for intensive group; of the 16 
randomised to intensive group, 6 met the criteria for conservative group. With the 
reassignment, 22 subjects were in conservative group, and 12 subject in the intensive 
group. The subject baseline characteristics are shown in Table 10. 
There were 12 males, 10 females in the conservative group. The group had mean age 
of 47.7± 1.6, duration of diabetes 10.2± 1.4 years, and BMI of 42.5(39.4-47.8) kg/m2. 
HbA1c was 9.9± 0.2% (83.0± 2.6 mmol/mol) at randomisation. 
There were 8 males, 4 females in the intensive group. The mean age was 51.1± 2.4, 
duration of diabetes 8.4± 2.0 years, and BMI of 46.2 (41.0-55.8) kg/m2. HbA1c was 
10.3± 0.5 % (88.8± 5.2 mmol/mol) at randomisation. HbA1c improved to 8.4± 0.5 
(73.8± 5.1 mmolmol) following intensive treatment, prior to bariatric surgery.  The 
number of glucose lowering medications at baseline was 2.0 (2.0-2.3) in conservative 
group, and 2.0 (1.0-2.0) in intensive group. 
 
Following randomisation, the age, and gender distribution, duration of T2DM, BMI, 
HbA1c, and number of glucose lowering medications were similar between the groups. 
 
Body mass index 
 
BMI at 1 year following surgery showed significant reduction from 42.5 (39.4-47.8) 
kg/m2 to 32.5 (28.9-37.1) kg/m2 in the conservative group (p<0.0001); and from 46.2 
(41.0-55.8) to 33.5 (30.1-36.8) kg/m2 in the intensive group (p<0.0001). There was no 
significant difference between the two groups (p=0.79). 
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Blood pressure 
 
There was significant reduction in SBP from 148 (139-157) mmHg to 132 (118-143) 
mmHg in the conservative group (p=0.01). No significant reduction in SBP was 
observed in intensive group, 146 (132-152) mmHg to 124 (119-141) mmHg (p=0.29). 
The changes in SBP between the two groups was not significant (p=0.84). 
There was no significant change in DBP in conservative group and intensive groups 
at follow up, 85 (80-92) mmHg to 82 (75-89) mmHg (p=0.09); 84 (79-94) mmHg to 80 
(72-91) mmHg (p=0.39) respectively. 
 
Effectiveness of the intervention on pre-operative glycaemic control 
 
In the intensive group HbA1c was reduced significantly in the 3 months pre-surgery 
from 10.3± 0.5% (88.8± 5.2 mmol/mol) to 8.4±0.5% (73.8± 5.1 mmol/mol) (p<0.0001), 
whilst the HbA1c of the conservative group did not change significantly, 9.9± 0.2% 
(83.0± 2.6 mmol/mol) to 9.1 ± 0.4% (76.3± 3.8 mmol/mol)  (p=0.72). 
 
5.2 Glycaemic control at 1 year 
Both groups achieved significant reductions in HbA1c at 1 year. The conservative 
group achieved HbA1c of 6.8± 0.2% (50.9± 2.3 mmol/mol), and the intensive group 
achieved 6.7 ± 0.4% (49.6 ± 4.3 mmol/mol). 
 
Remission of diabetes 
Four (18.2%) subjects from the conservative group achieved HbA1c<6.0%, 2 were not 
on any glucose lowering medication, 2 were on metformin. Five (41.7%) subjects from 
the intensive group achieved HbA1c<6.0%, 1 was not on any glucose lowering 
medication 4 were on metformin. Overall 3 subjects achieved complete remission of 
diabetes at 1 year post-surgery, as defined by ADA criteria. 
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Medication usage 
Glucose lowering medication 
Glucose lowering medication was reduced from 2.0 (2.0-2.25) to 1.0 (1.0-2.0) 
(p<0.0001), and 2.0 (1.0-2.0) to 1.0 (1.0-2.0), (p<0.05) in conservative and intensive 
group respectively. 
BP lowering medication 
BP lowering medications was reduced from 1 (1-2) to 1 (0-1), (p=0.004); and 2 (1-3) 
to 1 (0-2) (p=0.01) in conservative and intensive group respectively. 
 
Incidence of hypoglycaemia 
Two subjects in the conservative group had CG readings <4.0 mmol/L but did not have 
symptoms of severe hypoglycaemia during the two weeks monitoring post-surgery. 
No hypoglycaemia was noted in the intensive group. 
 
Length of stay 
The median length of stay was 3 days for both groups (p=1.00, Table 9). 
 
Surgical complications 
Within the conservative group, 1 subject had a post-operative stroke on day 1 and 
made a full recovery. One subject developed abdominal pain post-surgery which 
resolved spontaneously, and 1 subject vomited post- surgery, but settled after a 
prolonged inpatient stay. There was no surgical complication in the intensive group. 
5.3 Microvascular complications 
5.3.1 Albuminuria 
Seventeen subjects from conservative group and 7 subjects from intensive group had 
complete urine ACR datasets. Median urine ACR reduced from 6.4 (1.5-12.9) to 1.6 
(0.8-4.5)mg/mmol in conservative group (p<0.05) at 1 year. No significant change in 
urine ACR was observed in intensive group, 7.6 (2.9-16.4) to 2.6 (0.7-93.5)mg/mmol, 
(p=0.34).  There was no significant difference in the change of albuminuria between 
both groups. 
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5.3.2 Retinopathy 
Eighteen subjects from conservative group and 9 subjects from intensive group had 
complete retinal dataset. The conservative group had a median retinal score of 1.0 
(0.0-1.3) at baseline, and 1.0 (0.0-1.3) at follow up (p=0.80). The retinal score was 0.0 
(0.0-3.0) before surgery and 1.0 (0.0-3.0) at follow up for the intensive group (p=0.56).  
There was no significant changes in retinal score between both groups (p=0.45). 
5.3.3 Peripheral neuropathy 
Nerve conduction study 
Twenty subjects from the conservative group and 7 subjects from the intensive group 
completed nerve conduction study (Table 11). There were no statistically significant 
changes in the nerve conduction parameters at 1 year. 
Thermal threshold testing 
Seventeen subjects in the conservative and nine subjects in the intensive groups 
completed thermal threshold testing (Table 12). There was reduction of lower limb cool 
perception threshold in conservative group from 29.9 (27.0-30.6) ºC to 28.5(24.4-30.0) 
ºC at follow up (p<0.05), but no significant changes in other perception thresholds 
were observed. There was no difference in changes between the groups. 
Postoperative glucose management 
Both conservative and intensive groups of patients were monitored and managed with 
the aim of maintaining blood glucose within the range of 5.5 – 7.5 mmol/L. Figure 8 
showed glycaemic control in the group that had achieved preoperative optimisation of 
glucose, reduction of HbA1c by 1% before RYGB (As per protocol analysis). 
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Table 10. GLUCOSURG-pre. Baseline and 1 year follow-up results (As per protocol analysis). 
 
 
 
Conservative 
(n=22) 
P value 
(within 
group) 
Intensive 
(n=12) 
P value 
(within 
group) 
P value 
(between 
groups at 
baseline) 
P value 
(of change 
between 
groups) 
 Pre-operatively Post-operatively  Pre-operatively Post-operatively    
Baseline variables 
Age ( year) 47.7± 1.6 N/A N/A 51.5± 2.4 N/A N/A 0.17 N/A 
Male (%,n) 54.5, 12 N/A N/A 66.7, 8 N/A N/A 0.72 N/A 
Duration of 
diabetes (years) 
10.2± 1.4 N/A N/A 8.4± 2.0 N/A N/A 0.46 N/A 
BMI (kg/m²) 42.5(39.4-47.8) 32.5 (28.9-37.1) <0.0001 46.2 (41.0-55.8) 33.5 (30.1-36.8) <0.0001 0.31 0.79 
SBP (mmHg) 148(139-157) 132 (118-143) 0.01 146 (132-152) 124 (119-141) 0.29 0.81 0.84 
DBP (mmHg) 85( 80-92) 82( 75-89) 0.09 84( 79-94) 80( 72-91) 0.39 0.72 0.77 
Outcome variables 
HbA1c (%) 
 
9.9± 0.2 
a9.1±0.4 
6.8 ± 0.2 <0.0001 10.3± 0.5 
b8.4 ± 0.5 
6.7 ± 0.4 <0.0001 0.36 
cp=0.72 
0.21 
HbA1c 
(mmol/mol) 
83.0±2.6 
a76.3±3.8 
50.9±2.3 <0.0001 88.8± 5.2 
b73.8± 5.1 
49.6± 4.3 <0.0001 0.36 
cp=0.72 
0.21 
Urine ACR 
(mg/mmol) 
6.4 (1.5-12.9) 1.6 (0.8-4.5) 0.008 7.6 ( 2.9-16.4) 2.6 (0.7-93.5) 0.34 0.26 0.97 
Retinal score 1.0 (0.0-1.3) 1.0 (0.0-1.3) 0.80 0.0 (0.0-3.0) 1.0 ( 0.0-3.0) 0.56 0.87 0.45 
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Length of stay 
(days) 
N/A 3.0 (3.0-4.3) N/A  3.0 (3.0-4.5) N/A  1.00 
30 days surgical 
complications 
(%,n) 
N/A 13.6, 3 N/A  0, 0 N/A 0.54  
Hypoglycaemic 
episodes (n) 
N/A 2 N/A  0 N/A 0.53  
glucose-lowering 
medications 
2.0 (2.0-2.3) 1.0 ( 1.0-2.0) <0.0001 2.0 (1.0-2.0) 1.0 (1.0-2.0) <0.05 0.28 1.00 
BP lowering 
medications 
1.0 (1.0-2.0) 1.0 (0.0-1.0) 0.004 2 .0(1.0-3.0) 1.0 (0.0-2.0) 0.01 0.52 0.55 
BMI body mass index, HbA1c glycated haemoglobin, a HbA1c post-randomisation, b HbA1c post-optimisation, cp value post-
optimisation. 
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Table 11. Result of nerve conduction study before and one year post RYGB surgery (As per protocol analysis) 
 
 
 
Conservative 
(n=20) 
P value 
(within 
group) 
Intensive 
(n=7) 
P value 
(within group) 
P value 
(between 
groups at 
baseline) 
P value 
(of change 
between 
groups) 
 Pre-operatively Post-operatively  Pre-operatively Post-operatively    
Sup radial 
SNAP(mV)* 
18.7 ( 11.0-28.0) 21.0 ( 11.2-27.2) 1.00 14.1 (13.0-15.1) 16.5 (11.9-17.4) 1.00 0.15 0.52 
Sup radial 
CV(m/s) 
62.5 (60.0-67.7) 61.4 (59.5-65.8) 1.00 60.9 (57.4-66.0) 61.3 (49.7-66.7) 1.00 0.45 0.52 
Sural SNAP (mV) 9.4 (4.9-15.5) 10.6 ( 7.4-17.8) 0.49 7.6 (4.5-12.1) 9.7 (6.1-20.1) 1.00 0.55 0.73 
Sural CV (m/s) 50.5 (46.1-55.0) 49.9 (45.0-53.6) 1.00 48.0 (43.7-53.8) 48.3 (43.5-57.3) 1.00 0.68 0.31 
Common 
Peroneal CV 
(m/s) 
44.2 (42.1-48.8) 45.3 (42.0-48.7) 1.00 42.1 (39.7-49.7) 47.1 (40.5-50.4) 0.42 0.62 0.24 
Tibial CMAP (mV) 4.8 (2.8-5.8) 4.7 (3.1-6.9) 1.00 4.5 (3.2-6.7) 6.0 (2.5-6.6) 1.00 0.97 0.86 
Minimal latency 
tibial F-response 
(ms) 
55.9 (49.0-59.9) 55.4 (50.6-60.9) 0.07 54.3 (51.0-66.9) 55.6 (51.4-65.1) 1.00 0.90 0.34 
SNAP sensory nerve action potential, CV conduction velocity, CMAP compound muscle action potential 
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Table 12. Results of thermal threshold testing before and one year post RYGB surgery (As per protocol analysis). 
 
 
 
Conservative 
(n=16) 
P value 
(within 
group) 
Intensive 
(n=9) 
P value 
(within 
group) 
P value 
(between 
groups at 
baseline) 
P value ( of 
change 
between 
groups) 
 Pre-operatively Post-
operatively 
 Pre-operatively Post-
operatively 
   
UL- WPT(ºC) 35.3 (34.7-36.3) 34.4 (33.6-37.1) 1.00 36.7 (36.0-39.6) 35.8(35.0-39.2) 0.28 0.04 0.16 
UL-CPT(ºC) 30.4 (29.7-31.1) 30.5 (29.5-31.1) 1.00 30.0 (29.0-30.6) 30.2 (29.5-30.4) 1.00 0.12 0.35 
LL-WPT(ºC) 37.8 (35.0-41.8) 38.2 (36.0-41.9) 1.00 42.6 (36.2-44.4) 39.9 (38.6-45.8) 1.00 0.08 0.20 
LL-CPT(ºC) 29.9 (27.0-30.6) 28.5(24.4-30.0) <0.05 29.8(26.5-30.3) 26.9 (25.9-30.3) 0.24 0.72 0.80 
UL upper limb, LL lower limb, WPT, warm perception threshold, CPT cool perception threshold 
 
85 
 
Figure 8. Postoperative glucose trend of optimised (intensive) and non-
optimised (conservative) groups (as per protocol). 
 
The effect of optimisation was not statistically significant F (1, 256) =0.79 p=0.37 
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Chapter 6. Result for GLUCOSURG -post study 
6.1 Participants characteristics 
Thirty-five subjects had completed one year follow up. The subject baseline 
characteristics are shown in Table 13. 
There were 10 males, 7 females in the conservative group. The group had a mean 
age of 50.1± 2.3, duration of diabetes was 9.2± 1.3 years. The median BMI was 
44.6(41.2-51.1) kg/m2, HbA1c was 8.5 (7.6-10.1) % [69.4 (59.6-86.9)] mmol/mol. 
There were 5 males, 13 females in the intensive group. Their mean age was 53.9± 
1.7, duration of diabetes 14.2± 1.5 years. Their median BMI was 43.7 (40.0-48.2) 
kg/m2, HbA1c was 8.6 (7.3-10.3) % [70.5 (56.3-89.1) mmol/mol]. 
Following randomisation, the age, gender distribution, BMI and HbA1c were not 
significantly different between the groups. Subjects in the intensive group had T2DM 
for 5 years longer than the conservative group (p= 0.02). The conservative group was 
on one more glucose lowering medications 3.0 (2.0-3.0) than the conservative group 
2.0 (1.0-2.0). 
 
Body mass index 
BMI at one year following surgery showed significant reduction from 44.6 (41.2-51.1) 
kg/m2 to 32.7 (28.5-40.3) kg/m2 in the conservative group (p=0.0003); and from 43.7 
(40.0-48.2) kg/m2 to 31.8 (27.7-37.7) kg/m2 in the intensive group (p<0.0001). There 
was no significant difference between the two groups (p=0.98). 
 
Blood pressure 
No significant reduction in SBP was observed in the conservative group, 140± 3 mmHg 
to 133± 5 mmHg (p=0.36).  There was significant reduction in SBP from 138 ± 23 
mmHg to 124± 5 mmHg in the intensive group (p<0.05). The change in SBP between 
the two groups was not significant (p=0.19). 
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There was no significant change in DBP in conservative group, 78± 3 mmHg to 82± 2 
mmHg (p=0.26). Significant reduction of DBP was observed in intensive group, 84± 3 
mmHg to 76± 2 mmHg (p=0.02). 
 
Effectiveness of the intervention on early post-operative glycaemic control 
Following surgery, both groups of patients were monitored and managed with the aim 
of achieving intensive (5.5-6.5mmol/L) or conservative (6.5-7.5 mmol/L) glucose 
control within first 2 weeks. Figure 9 showed postoperative glucose trend of both 
intensive and conservative managed group (intention to treat analysis). The effect of 
optimisation was not statistically significant (p=0.94). 
6.2 Glycaemic control at 1 year 
Both groups achieved significant reductions in HbA1c 1 year after surgery. The 
conservative group achieved HbA1c of 6.2 (5.8-6.8) % [44.3 (39.9-50.8)] mmol/mol, 
and the intensive group achieved 6.2 (5.7-7.1) % [44.3 (38.8-54.1)] mmol/mol. There 
was no significant difference between both groups (p =0.73). 
Remission of diabetes 
Five (29.4%) conservatively treated subjects achieved HbA1c<6.0%, 3 subjects were 
not on any glucose lowering medication, and 2 were on metformin. Six (33.3%) of the 
intensively treated group achieved HbA1c<6.0%, 1 was not on any medication, 3 
subjects were on metformin, 2 were on insulin. Overall 4 (11.4%) subjects achieved 
complete remission of diabetes at one year post surgery. 
Medication usage 
Glucose lowering medications 
There were significant reductions in glucose lowering medications from 3.0(2.0 -3.0) 
to 1.0 (0.0-1.0) (p=0.0002) and 2.0(1.0-2.0) to 1.0(0.0-1.0) (p=0.002) in conservative 
and intensive groups respectively. 
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Blood pressure lowering medications 
There were significant reductions in BP lowering medications from 1.0 (0.5-2.5) to 0.0 
(0.0-1.0) (p=0.008), and 1.0 (0.0-2.0) to 0.0 (0.0-1.0) (p=0.04) in conservative and 
intensive groups respectively. 
Incidence of hypoglycaemia 
One subject in the intensive group had CG readings <4.0 mmol/L but did not have 
symptoms of severe hypoglycaemia during the two weeks monitoring post-surgery. 
No hypoglycaemia was noted in the conservative group. 
Length of stay 
The median length of stay was 3 days for both groups (p=0.91). 
Surgical complications 
There was no significant difference in the incidence of surgical complication between 
the two groups (p=1.00). One subject from the intensive group had diarrhoea post-
surgery. No complication was observed in the conservative group. 
6.3 Microvascular complications 
6.3.1 Albuminuria 
Fifteen subjects from conservative group and 14 subjects from intensive group had 
complete urine ACR datasets. The changes in urine ACR post-surgery were not 
significant in both groups. Urine ACR reduced from 2.8 (1.8-4.8) mg/mmol to 1.7 (1.0-
6.3) mg/mmol in conservative group (p=0.69); and from 2.3 (1.4-7.5) mg/mmol to 1.6 
(1.0-3.9) mg/mmol in intensive group (p=0.09). There was no significant difference in 
the change in albuminuria between the conservative and intensive group (p=0.84). 
Subgroup analysis of the overall cohort showed 17 subjects had normal ACR, 12 had 
pre-existing albuminuria at baseline. At 1 year after surgery, 9 subjects improved (8 
normalised), 16 no change, 4 deteriorated. 
89 
 
Of the 12 subjects with pre-exiting albuminuria, 9 improved (8 normalised), 2 had 
deteriorated, 1 had no change. Of the 17 subjects with normal ACR, 4 had 
deteriorated, 13 had no change. 
6.3.2 Retinopathy 
Thirteen subjects from conservative group and 16 subjects from intensive group had 
complete retinal photograph datasets. The conservative group had a median retinal 
score of 1.0(1.0-2.0) before surgery, and 1.5(1.0-2.0) at one year follow up (p=0.43). 
The retinal score was 1.0 (0.5-2.0) before surgery and 1.0 (0.5-2.0) at one year follow 
up (p=0.34) for intensive group. There was no significant difference in the change of 
retinal score between both groups (p=0.98). 
Subgroup analysis of the overall cohort showed 6 subjects had no retinopathy, 20 had 
mild to moderate non-proliferative retinopathy, 1 had severe non-proliferative 
retinopathy, and 1 had proliferative retinopathy. At 1 year after surgery, 4 had 
deteriorated, 24 had no change, 1 improved. 
Of the 23 subject with abnormal pre-existing retinopathy, 3 deteriorated, 1 improved, 
19 had no change at follow up. Of the 6 subjects with normal retinal, 1 deteriorated, 5 
had no change at 1 year. 
6.3.3 Peripheral neuropathy 
Nerve conduction study 
Twelve subjects from the conservative group and 15 subjects from the intensive group 
completed nerve conduction study (Table 14). No significant change in the neuropathy 
parameters were observed in conservative group. In the intensive group, superficial 
radial conduction velocity reduced from 62.5 (57.4- 69.1) m/s to 60.1 (54.4- 63.6) m/s 
(p= 0.04). This change was also significant when compared to the conservative group 
(p=0.04). 
Qualitative analysis showed 10 of the overall cohort had pre-existing neuropathy, 17 
subjects had no neuropathy at baseline. At 1 year after surgery, 5 who had pre-existing 
neuropathy showed deterioration, the other 22 subjects had no change. 
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Thermal threshold testing 
Seven subjects in the conservative group and 8 subjects in the intensive group 
completed thermal threshold testing (Table 15). No significant changes in perception 
threshold parameters were observed in both groups. 
Postoperative glucose management 
Conservative and intensive groups of patients were monitored and managed with the 
aim of achieving conservative (6.5-7.5 mmol/L), and intensive (5.5-6.5mmol/L) 
glucose control post-surgery. Figure 5 showed postoperative glucose trend of both 
intensive and conservative managed group (intention to treat analysis). 
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Table 13. GLUCOSURG-post. Baseline and 1 year follow-up results of the conservative and intensive group (Intention to 
treat analysis). 
 
 
 
Conservative 
(n=17) 
P value 
(within 
group) 
Intensive 
(n=18) 
P value 
(within 
group) 
P value 
(between 
groups at 
baseline) 
P value 
(of change 
between 
groups) 
 Pre-operatively Post-operatively  Pre-operatively Post-operatively    
Baseline characteristics 
Age ( year) 50.1± 2.3 N/A  53.9± 1.7 N/A N/A 0.20  
Male (%,n) 58.8, 10 N/A  27.8, 5 N/A N/A 0.09  
Duration of 
diabetes (years) 
9.2± 1.3 N/A  14.2± 1.5 N/A N/A 0.02  
BMI (kg/m²) 44.6 (41.2-51.1) 32.7 (28.5-40.3) 0.0003 43.7 (40.0-48.2) 31.8 (27.7-37.7) <0.0001 0.37 0.98 
Outcome variables 
HbA1c (%) 
 
8.5 (7.6-10.1) 6.2 (5.8-6.8) 
 
0.001 8.6 (7.3-10.3) 6.2 (5.7-7.1) 
 
<0.0001 0.97 
 
0.73 
HbA1c 
(mmol/mol) 
69.4 (59.6-86.9) 44.3 (39.9-50.8) 0.001 70.5 (56.3- 89.1) 44.3 (38.8-54.1) <0.0001 0.97 
 
0.73 
SBP (mmHg) 140±  3 133±  5 0.36 138± 3 124±5 0.005 0.71 0.19 
DBP (mmHg) 78±  3 82 ±  2 0.26 84±  3 72 ±  2 0.02 0.16 0.01 
Urine ACR 
(mg/mmol) 
2.8 (1.8-4.8) 1.7 (1.0-6.3) 0.69 2.3 (1.4-7.5) 1.6 (1.0-3.9) 
 
0.09 0.87 0.84 
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Retinal score 1.0(1.0-2.0) 1.5 (1.0-2.0) 0.43 1.0 (0.5-2.0) 1.0 (0.5-2.0) 0.34 0.56 0.98 
Length of stay 
(days) 
N/A 3.0 (3.0-4.0) N/A N/A 3.0 (3.0-4.0) N/A N/A 0.91 
30 days surgical 
complications 
(%,n) 
N/A 0 N/A N/A 5.6 , 1 N/A 1.00  
Hypoglycaemic 
episodes (n) 
N/A 0 N/A N/A 1 N/A N/A  
glucose-lowering 
medications 
3.0( 2.0 -3.0) 1.0 (0.0-1.0) 0.0002 2.0( 1.0-2.0) 1.0( 0.0-1.0) 0.002 0.01 0.21 
BP lowering 
medications 
1.0 ( 0.5-2.5) 0.0 ( 0.0-1.0) 0.008 1.0 (0.0-2.0) 0.0 (0.0-1.0) 0.04 0.80 0.98 
BMI body mass index, HbA1c glycated haemoglobin, N/A not applicable. 
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Table 14. GLUCOSURG-post. Result of nerve conduction study before and one year post RYGB surgery (Intention to treat 
analysis) 
 
 
 
Conservative 
(N=12) 
P value 
(within 
group) 
Intensive 
(N=15) 
P value 
(within group) 
P value 
(between 
groups at 
baseline) 
P value 
(of change 
between 
groups) 
 Pre-operatively Post-operatively  Pre-operatively Post-operatively    
Sup radial 
SNAP(mV)* 
13.5 (11.0-23.9) 15.2 ( 12.0-22.5) 1.00 17.0 ( 10.8-22.0) 18.3 ( 12.2-25.6) 0.14 0.96 0.07 
Sup radial 
CV(m/s) 
60.6 ( 53.8-65.6) 62.0 (54.0-66.8) 1.00 62.5 ( 57.4- 69.1) 60.1 ( 54.4- 63.6) 0.04 0.40 0.04 
Sural SNAP (mV) 8.6 ± 2.0 8.7 ± 2.2 1.00 10.1 ± 1.0 11.9 ± 2.0 1.00 0.49 1.00 
Sural CV (m/s) 48.5 ( 40.8- 52.9) 49.5 (44.1-51.7) 1.00 47.1 (45.7- 49.5) 47.6 ( 46.9-49.0) 1.00 0.32 0.42 
Common 
Peroneal CV (m/s) 
45.4 ± 1.9 46.5 ± 1.1 1.00 44.0 ± 1.4 45.3 ± 2.0 1.00 0.58 0.98 
Tibial CMAP (mV) 6.8 ± 1.1 6.4 ± 1.2 1.00 4.6 ± 0.7 4.9 ± 0.8 1.00 0.09 0.45 
Minimal latency 
tibial F-response 
(ms) 
51.6 ± 1.6 55.8 ± 1.9 0.28 55.4 ± 2.0 57.4 ± 2.6 0.07 0.17 0.60 
SNAP sensory nerve action potential, CV conduction velocity, CMAP compound muscle action potential 
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Table 15. GLUCOSURG-post.  Results of thermal threshold testing before and one year post RYGB surgery (Intention to 
treat analysis). 
 
 
 
Conservative 
(N=7) 
P value 
(within 
group) 
Intensive 
(N=8) 
P value 
(within 
group) 
P value (between 
groups at 
baseline) 
P value 
(of change 
between 
groups) 
 Pre-operatively Post-
operatively 
 Pre-operatively Post-operatively    
UL-WPT(ºC) 35.0 ( 34.0-38.2) 35.1 ( 34.0-35.5) 0.72 37.5 ( 34.4-42.7) 34.2 ( 33.6-35.4) 0.24 0.54 0.54 
UL-CPT(ºC) 30.6 (30.2-31.1) 30.6 ( 29.9-31.2) 1.00 30.6 ( 28.6-31.1) 30.5 ( 29.5-31.4) 1.00 0.73 0.95 
LL-WPT(ºC) 37.0 ( 35.1-44.9) 38.7 ( 35.1-43.1) 1.00 43.7 ( 37.9- 45.9) 42.2 ( 36.1-45.0) 1.00 0.28 0.34 
LL-CPT(ºC) 29.5 ( 28.0-30.6) 25.4 ( 20.7- 
30.6) 
0.32 29.5 ( 23.7- 30.4) 25.3 ( 22.5-30.5) 1.00 0.69 0.61 
UL upper limb, LL lower limb, WPT, warm perception threshold, CPT cool perception threshold
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Figure 9. Postoperative glucose trend of intensive and conservative managed 
groups (intention to treat analysis) 
 
The effect of optimisation was not statistically significant, F(1,290)=0.005 p = 
0.94 
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Chapter 7. Result for GLUCOSURG -post study (As per 
protocol analysis) 
7.1 Participants characteristics 
Criteria for as per protocol analysis was discussed previously. Of the 17 subjects 
randomised to conservative group, 10 met the criteria for intensive group; of the 18 
randomised to intensive group, 3 met the criteria for conservative group. With the 
reassignment, 10 subjects were in conservative group, and 25 subjects were in 
intensive group. The subject baseline characteristics are shown in Table 16. 
There were 4 male, 6 female in the conservative group. The group had a mean age of 
50.6± 3.7, duration of diabetes 10.6± 2.0 years. The median BMI was 44.0(40.9-50.9) 
kg/m2, HbA1c was 8.5 (7.4-10.3) % [69.4 (57.4-89.1)] mmol/mol. 
There were 11 male, 14 female in the intensive group. Their mean age was 52.5± 1.5 
and duration of diabetes was 12.3± 1.3 years. Their BMI was 43.7 (40.9-49.0) kg/m2, 
HbA1c was 8.5 (7.3-10.1) % [69.4 (56.3-86.9) mmol/mol]. 
There were no significant different between both groups in age, gender distribution, 
BMI, duration of diabetes and HbA1c at baseline. Subjects in the intensive group had 
lower SBP than the conservative group (p= 0.008). 
Body mass index 
BMI at one year showed significant reduction from 44.0 (40.9-50.9) kg/m2 to 31.8 
(28.2-40.3) kg/m2 (p=0.007) in the conservative group; and from 43.7 (40.9-49.0) 
kg/m2 to 32.7 (28.3-37.8) kg/m2 (p<0.0001) in the intensive group. There was no 
significant difference between the two groups (p=0.97). 
Blood pressure 
There was significant reduction in SBP from 150(145-159) mmHg to 131(117-144) 
mmHg in the conservative group (p=0.007). No significant reduction in SBP was 
observed in the intensive group, 140 (126-144) mmHg to 124(109-147) mmHg 
(p=0.10).  The change in SBP between the two groups was not significant (p=0.45). 
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There were no significant changes in DBP in both groups, 81± 4 mmHg to 81± 3 mmHg 
(p=0.93), 81±2 to 79±2 mmHg (p=0.27) in conservative and intensive groups 
respectively. 
 
Effectiveness of the intervention on early post-operative glycaemic control 
Following surgery, both groups of patients were monitored and managed with the aim 
of achieving intensive (5.5-6.5mmol/L) or conservative (6.5-7.5 mmol/L) glucose 
control within first 2 weeks. Figure 10 showed postoperative capillary glucose trend of 
both intensive and conservative groups (as per protocol analysis). The effect of 
optimisation was statistically significant (p<0.0001). Of the 17 subjects randomised to 
conservative group, 10 achieved fasting capillary glucose of 5.5-6.5mmol/L, and hence 
were assigned to intensive group. Of the 18 subjects randomised to intensive group, 
3 achieved fasting capillary glucose of 6.5-7.5mmol/L, and were assigned to 
conservative group for the purpose of as per protocol analysis. 
7.2 Glycaemic control at 1 year 
Both groups achieved significant reductions in HbA1c 1 year after surgery. The 
conservative group achieved HbA1c of 6.5 (5.8-6.9) % [46.0 (40.0-50.3)] mmol/mol 
(p=0.0004), and the intensive group achieved 6.2 (5.8-7.0) % [43.5 (40.3-52.5)] 
mmol/mol (p<0.0001). There was no significant difference between both groups. 
Remission of diabetes 
Three (30.0%) subjects from conservative group achieved HbA1c<6.0%, 1 was not on 
any glucose lowering medication, 1 was on metformin, and 1 was on insulin. Eight 
(32.0%) subjects from the intensive group achieved HbA1c<6.0%, 3 subjects were not 
on any medication, 4 were on metformin, and 1 was on metformin and insulin. Overall 
4 subjects achieved complete remission of diabetes at one year. 
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Medication usage 
Glucose lowering medications 
There were significant reductions in glucose lowering medications, from 2.5(1.0 -3.0) 
to 1.0 (1.0-2.0) (P=0.009), and 2.0 (2.0-3.0) to 1.0 (0.0-1.0) (P<0.0001) in conservative 
and intensive groups respectively. 
Blood pressure lowering medication 
There was no significant change in BP lowering medications in conservative group, 
from 1.0 (0.0-1.3) to 0.0 (0.0-1.0) (p=0.34). Significant reduction in BP medications 
was seen in intensive group, from 1.5 (0.3-2.8) to 0.0 (0.0-1.0) (p=0.001). There was 
no difference between both groups (p=0.77). 
Incidence of hypoglycaemia 
One subject in the intensive group had CG readings <4.0 mmol/L but did not have 
symptoms of severe hypoglycaemia during the 2 weeks monitoring post-surgery. No 
hypoglycaemia was noted in the conservative group. 
Length of stay 
The median length of stay was 3 days for both groups (p=0.75). 
Surgical complications 
There was no significant difference in the incidence of surgical complications between 
the 2 groups (p=1.00). One subject from the intensive group had diarrhoea post-
surgery. No complication was observed in the conservative group. 
7.3 Microvascular complications 
7.3.1 Albuminuria 
Six subjects from conservative group and 23 subjects from intensive group had 
complete urine ACR datasets. The changes in urine ACR were not significant in both 
groups. Urine ACR reduced from 1.7 (1.2-3.2) mg/mmol to 1.6 (0.8-2.1) mg/mmol in 
conservative group (p=0.84); and from 3.3 (1.7-6.2) mg/mmol to 1.8 (1.0-5.5) in 
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intensive group (p=0.31). There was no significant difference in the change in 
albuminuria between both groups (p=0.59). 
7.3.2 Retinopathy 
Seven subjects from conservative group and 22 subjects from intensive group had 
complete retinal datasets. The retinal score was 2.0 (0.0-2.0) before surgery, and 2.0 
(0.0-3.0) at one year (p=0.62) in conservative group. Intensive group had retinal score 
of 1.0 (0.0-3.0) before surgery and 2.0 (2.0-2.8) at one year (p=0.12). There was no 
difference in the change of retinal score between both groups (p=0.55). 
7.3.3 Peripheral neuropathy 
Nerve conduction study 
Seven subjects from the conservative group and 20 subjects from the intensive group 
completed nerve conduction study (Table 17). There was no significant change in the 
sensory and motor nerves in both groups. 
Thermal threshold testing 
Four subjects in the conservative group and 11 subjects in the intensive group 
completed thermal threshold testing (Table 18). There were no significant changes in 
all perception thresholds. No difference in changes between both groups was 
observed. 
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Table 16. GLUCOSURG-post.Baseline and 1 year follow-up results of the conservative and intensive group (As per protocol analysis). 
 
BMI body mass index, HbA1c glycated haemoglobin,N/A not applicable. 
 
 
 
 
Conservative 
(n=10) 
P value 
(within 
group) 
Intensive 
(n=25) 
P value 
(within group) 
P value 
(between 
groups at 
baseline) 
P value 
(of 
change 
between 
groups) 
 Pre-operatively Post-operatively  Pre-operatively Post-operatively    
Baseline characteristics 
Age ( year) 50.6 ± 3.7 N/A  52.5 ± 1.5 N/A N/A 0.83  
Male (%,n) 40, 4 N/A  44, 11 N/A N/A 1.00  
Duration of diabetes 
(years) 
10.6 ± 2.0 N/A  12.3 ± 1.3 N/A N/A 0.47  
BMI (kg/m²) 44.0 (40.9-50.9) 31.8 (28.2-40.3) 0.007 43.7 (40.9-49.0) 32.7 (28.3-37.8) <0.0001 0.76 0.97 
Outcome variables 
HbA1c (%) 8.5 ( 7.4-10.3) 6.5 (5.8-6.9) 0.0004 8.5 (7.3-10.1) 6.2 (5.8-7.0) <0.0001 0.94 0.77 
HbA1c (mmol/mol) 69.4 (57.4-89.1) 46.0 (40.0-50.3) 0.0004 69.4 (56.3- 86.9) 43.5 (40.3-52.5) <0.0001 0.97 0.73 
SBP (mmHg) 150 (145-159) 131 (117-144) 0.007 140 (126-144) 124 ( 109-147) 0.10 0.008 0.45 
DBP (mmHg) 81.4± 3.8 80.9 ± 2.6 0.93 81.1± 2.4 78.5 ± 2.1 0.27 0.95 0.41 
Urine  ACR 
(mg/mmol) 
1.7 (1.2-3.2) 1.6 (0.8-2.1) 0.84 3.3 (1.7-6.2) 1.8 (1.0-5.5) 0.31 0.13 0.59 
Retinal score 1.0 (1.0-2.0) 1.0 ( 1.0-3.0) 0.77 1.0(0.8-2.0) 1.0( 0.8-2.0) 0.27 0.52 0.55 
Length of stay (days) N/A 3.0 (3.0-4.0) N/A N/A 3.0 (3.0-4.0) N/A N/A 0.75 
30 days surgical 
complications (%,n) 
N/A 0 N/A N/A 4.0 , 1 N/A 1.00  
Hypoglycaemic 
episodes (n) 
N/A 0 N/A N/A 1 N/A 1.00  
glucose lowering 
medications 
2.5(1.0 -3.0) 1.0 (1.0-2.0) 0.009 2.0( 2.0-3.0) 1.0( 0.0-1.0) <0.0001 0.91 0.21 
BP lowering 
medications 
1.0 (0.0-1.3) 0.0 (0.0-1.0) 0.34 1.5 (0.3-2.8) 0.0 (0.0-1.0) 0.001 0.16 0.77 
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Table 17. GLUCOSURG-post. Result of nerve conduction study before and one year post RYGB surgery (As per protocol 
analysis). 
 
 
 
Conservative 
(n=7) 
P value 
(within 
group) 
Intensive 
(n=20) 
P value 
(within group) 
P value 
(between 
groups at 
baseline) 
P value 
(of 
change 
between 
groups) 
 Pre-operatively Post-operatively  Pre-operatively Post-operatively    
Sup radial 
SNAP(mV)* 
19.0 (10.0-33.0) 18.5 (4.7-44.9) 1.00 15.5 (11.3-21.8) 17.0 (12.5-23.4) 0.35 0.72 0.98 
Sup radial 
CV(m/s) 
61.7 (50.0-65.8) 58.5 (38.3-68.5) 1.00 61.9 ( 57.4- 67.7) 60.9 ( 56.7- 63.7) 0.21 0.52 0.95 
Sural SNAP (mV) 14.0 (8.5-18.7) 13.0 (6.3-18.1) 1.00 8.7 (5.0-11.0) 8.5 (6.6-14.6) 1.00 0.12 0.90 
Sural CV (m/s) 52.4 (42.3-55.2) 50.3 (42.8-53.0) 1.00 47.6 (44.4- 50.0) 48.1 (46.2-49.6) 1.00 0.35 0.68 
Common 
Peroneal CV 
(m/s) 
47.0 (43.4-51.4) 47.1 (44.1-56.5) 1.00 43.8 (41.6-47.5) 44.9 (40.7-48.8) 1.00 0.35 0.97 
Tibial CMAP 
(mV) 
6.4 (4.1-9.9) 5.0 (2.8-10.5) 1.00 5.0 (3.3-6.9) 5.2 (2.8-7.6) 1.00 0.54 0.10 
Minimal latency 
tibial F-response 
(ms) 
48.7 (46.6-55.6) 53.0 (47.7-57.4) 1.00 53.2 (48.8-56.8) 55.8 (50.5-64.1) 0.07 0.35 0.82 
SNAP sensory nerve action potential, CV conduction velocity, CMAP compound muscle action potential 
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Table 18. GLUCOSURG-post. Results of thermal threshold testing before and one year post RYGB (As per protocol 
analysis). 
 
 
 
Conservative 
(n=4) 
P value 
(within 
group) 
Intensive 
(n=11) 
P value 
(within 
group) 
P value (between 
groups at 
baseline) 
P value 
(of change 
between 
groups) 
 Pre-operatively Post-
operatively 
 Pre-operatively Post-operatively    
UL-WPT(ºC) 35.0 ( 33.6-38.7) 33.9 (33.4-35.0) 1.00 35.3 (34.5-42.5) 35.1 (33.8-35.4) 0.20 0.40 0.84 
UL-CPT(ºC) 30.7 (28.7-31.2) 31.0 (30.5-31.3) 1.00 30.6 (28.9-31.1) 30.1 (29.3-31.2) 1.00 0.95 0.43 
LL-WPT(ºC) 36.6 (35.3-43.2) 39.7 (34.7-43.7) 1.00 43.1 (36.2- 45.6) 42.0 (35.6-43.1) 1.00 0.33 0.47 
LL-CPT(ºC) 30.1 ( 21.3-30.8) 28.9 (23.9- 30.8) 1.00 29.3 (27.3- 30.4) 25.3 (21.8-30.6) 0.20 0.56 0.40 
UL upper limb, LL lower limb, WPT, warm perception threshold, CPT cool perception threshold 
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Figure 10. Postoperative glucose trend of both postop intensive and 
conservative managed groups (as per protocol analysis) 
 
The effect of optimisation was statistically significant F(1, 302)=36.28 , p <0.0001 
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Chapter 8. Results of GLUCOSURG-combine (surgical and 
medical groups) 
8.1 Participants characteristics 
In the surgical group, 69 subjects had completed 1 year follow up. The subject baseline 
characteristics are shown in Table 19. There were 35 males, 34 females in the surgical 
group. The group had mean age of 50.7± 1.0, median duration of diabetes 10.0 (5.0-
16.0) years, BMI of 43.6 (40.6-49.7) kg/m2. HbA1c was 9.6 (8.0-10.4) % [81 (64-90)] 
mmol/mol before surgery. 
There were 25 subjects in the medical group, of which 11 were males. Their mean age 
was 52.6± 1.9, median duration of diabetes 13.0 (8.5-17.0), BMI of 42.0 (37.8-47.3) 
kg/m2. HbA1c was 7.8 (7.0-10.9) % [62 (53-96) mmol/mol] at baseline.  There were no 
significant baseline differences in gender, age, HbA1c and duration of diabetes 
between the surgical and medical groups. 
Body mass index 
BMI reduced to 32.9 (28.6-37.9) kg/m2 in the surgical group at 1 year follow up 
(p<0.0001). This has not changed significantly in medical group, 41.9 (38.7-46.6) 
(p=0.39). There was significant difference in the change of BMI between both groups 
(p<0.0001). 
Blood pressure 
There was significant reduction in SBP from 143± 2 mmHg to 130± 3 mmHg in the 
surgical group (p<0.0001), whereas no significant reduction in SBP was observed in 
the medical group, 139± 4 mmHg to 134± 3 mmHg (p=0.34). The changes in SBP 
between the medical and surgical group was significant (p=0.04). 
There was no significant change in DBP in both groups, 83 (79-90) mmHg to 80 (75-
88) mmHg (p=0.08); 80 (76-88) mmHg to 77 (71-86) mmHg (p=0.16) respectively. 
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8.2 Glycaemic control at 1 year 
Surgical group achieved significant reduction in HbA1c, from 9.6 (8.0-10.4) % [81 (64-
90)] mmol/mol to 6.3 (5.9-7.0) % [45(41-53) mmol/mol] at one year (p=0.03). No 
significant change was observed in medical group, HbA1c was 7.8 (7.0-10.9) % [62 
(53-96) mmol/mol] before and 8.5 (7.6-9.9) % [69 (60-85) mmol/mol] at 1 year 
(p=0.22). The difference in HbA1c changes between both groups was significant 
(p<0.0001). 
Remission of diabetes 
Twenty (29%) of the surgical group achieved HbA1c <6%. Of this, 7 (10.1%) were in 
remission of diabetes. No subject in medical group achieved HbA1c of <6%. 
Medication usage 
Glucose lowering medication 
The use of glucose lowering medication was reduced in surgical group, from 2 (2-3) 
per patient to 1 (1-1), (P<0.0001). There was no significant change in medical group, 
3 (2-3) to 3 (2-3) at one year (p=0.85). 
Blood pressure lowering medication 
Surgical group had significant reduction in use of blood pressure lowering medication, 
from 1 (1-2) to 0(0-1) at 1 year (P<0.0001) as compared to medical group which has 
not changed (p=1.00). 
Table 20 showed the changes in glucose lowering medication classes and blood 
pressure lowering medication classes before and 1 year after intervention in surgical 
and medical groups. 
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8.3 Microvascular complications 
8.3.1 Albuminuria 
Fifty-three subjects of the surgical group had complete urine ACR datasets. Urine ACR 
decreased from 3.6 (1.7-9.3) mg/mmol to 1.7 (1.0-4.9) mg/mmol in the surgical group 
(p=0.02). 
Subgroup analysis of the 27 surgical subjects who had pre-existing albuminuria at 
baseline showed a significant improvement from 8.5 (5.7-17.4) mg/mmol to 1.7 (1.0-
6.1) mg/mmol at 1 year (p=0.009). Twenty-two subjects showed improvement, of 
which 16 normalised their ACR at 1 year.  Four subjects had deterioration in ACR, and 
1 had no change. Of the 26 subjects who had normal baseline ACR, 5 developed 
albuminuria at 1 year post-surgery. 
Nineteen subjects from the medical group had complete urine ACR datasets. Urine 
ACR increased from 1.7 (1.1- 4.9) mg/mmol to 4.8 (2.6-10.9) mg/mmol in the medical 
group at 1 year (p=0.03). Six subjects had pre-existing albuminuria, all of them still 
had albuminuria post intervention, from 17.8 (4.6-43.7) mg/mmol to 20.9 (9.5-47.0) 
mg/mmol (p=0.84). Of the 13 subjects with normal albuminuria at baseline, 5 
developed albuminuria post-intervention. There was a significant difference between 
the surgical and medical group for the remission of albuminuria (p<0.005), but not for 
the deterioration of albuminuria (p=0.50), or the new incidence of albuminuria (p=0.25) 
at 1 year (see Figure 11). 
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Figure 11. Proportion of subjects who had changes in albuminuria from baseline to 
one year follow up. 
8.3.2 Retinopathy 
In the group of 56 surgical patients with complete retinal photograph datasets, there 
was no significant change in retinal score between both surgical and medical groups. 
Surgical group had no change in retinal score, from 1 (0-2) to 1 (0-2) at 1 year (p=0.40). 
There were 17 subjects who had no diabetic retinopathy, 32 had mild to moderate 
non-proliferative diabetic retinopathy, 6 had severe non proliferative diabetic 
retinopathy, and 1 had proliferative diabetic retinopathy. At 1 year after surgery, 44 
(78%) subjects had no change, 6 (11%) improved, and 6 (11%) deteriorated. Of the 6 
subjects who deteriorated, 4 had pre-existing diabetic retinopathy. 
In the medical group, 21 subjects had complete retinal datasets. Medical group had 
retinal score of 2 (1-4) at baseline, and 3 (1-4) at follow up (p=0.38). Ten subjects had 
no retinopathy, 8 had mild to moderate non-proliferative diabetic retinopathy, 2 had 
severe non-proliferative diabetic retinopathy, and 1 had proliferative diabetic 
retinopathy.  After intervention, 17 subjects (81%) had no change; 1 (5%) improved; 
and 3 (14%) deteriorated. One patient required photocoagulation at follow up. All 3 
subjects who deteriorated had pre-existing retinopathy. There were no significant 
differences between the surgical and medical groups in the rates of patients who 
108 
 
deteriorated or improved after intervention [(p=0.70 and 0.67 respectively). See Figure 
12] 
 
Figure 12. Proportion of subjects who had at least two steps changes in retinal disease 
score from baseline to one year follow up. 
8.3.3 Peripheral neuropathy 
Nerve conduction study 
Fifty-four subjects in the surgical group underwent nerve conduction studies. There 
was statistically significant changes in minimal latency tibial F-response which 
increased from 54.6 ± 0.9 ms to 56.3 ± 1.0 ms (p= 0.0028) at 1 year. This was not 
clinically significant. There were no statistically significant changes in other nerve 
conduction parameters (Table 20). 
Qualitative analysis showed that 21 of the 54 surgical subjects had pre-existing 
neuropathy, of which 7 deteriorated over 1 year. No change was observed in the 14 
subjects with pre-existing neuropathy, 33 subjects that had no neuropathy remained 
stable. 
  
109 
 
Thermal threshold testing 
Forty-one subjects completed thermal threshold testing. Upper limb warm perception 
threshold improved from 36.0 (34.7-38.5) °C to 35.1 (33.7-36.7) °C (p=0.008), and 
lower limb cool perception threshold deteriorated from 29.5 (27.2-30.5) °C to 27.2 
(23.7-30.2) °C, (p=0.0028). No other statistically significant changes were observed in 
other perception threshold parameters (Table 21). 
Qualitative analysis showed that 18 (43.9%) subjects had normal thermal threshold 
perception, 23 (56.1%) had abnormal thermal threshold perception preoperatively. At 
1 year after surgery, 17 subjects with known abnormal thermal threshold had 
worsened cool perception threshold in lower limb. Table 23 showed changes in 
thermal threshold perception in subjects with pre-existing abnormality. 
There were no significant correlations between the changes in ACR and change in 
HbA1c (r=-0.046, p=0.75), BMI (r=-0.058, p=0.70), systolic (r=-0.079, p=0.61) and 
diastolic blood pressure (r=0.042, p=0.79) in either group. 
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Table 19. GLUCOSURG -Combine. Baseline characteristics and clinical parameters before and 1 year after RYGB surgery 
between surgical and medical groups. 
 
 
 
RYGB group 
(n=69) 
Medical group 
(n=25) 
  
 Pre-operative Post-
operative 
P value 
(change 
within 
group) 
Pre-operative Post-
operative 
P value 
(change within 
group) 
P value 
(between 
groups at 
baseline) 
P value 
(of change 
between 
groups) 
n 69 69 - 25 25 - -  
Age (years) 50.7 ± 1.0 - - 52.6 ± 1.9 - - 0.26  
Gender  (% male, n) 51%, 35 - - 44.0%, 11 - - 0.65  
Duration of T2DM 
(years) 
10.0 (5.0 - 16.0) - - 13.0 ( 8.5 - 17.0) - - 0.12  
BMI (kg/m²) 43.6 (40.6 - 
49.7) 
32.9 (28.6 - 
37.9) 
<0.0001 42.0 (37.8 - 47.3) 41.9 (38.7-
46.6) 
0.39 0.08 <0.0001 
SBP  (mmHg) 143 ± 2 130 ± 3 <0.0001 139 ± 4 134 ± 3.1 0.34 0.26 0.04 
DBP (mmHg) 83 (79-90) 80 (75-88) 0.08 80 (76 - 88) 77 (71 - 86) 0.16 0.42 0.91 
HbA1c (IFCC-mmol/mol) 
 
HbA1c (%) 
81 (64 - 90) 
 
9.6 (8.0 - 10.4) 
45 ( 41 - 53) 
 
6.3 ( 5.9 - 7.0) 
0.03 62 (53 - 96) 
 
7.8 (7.0 - 10.9) 
69 (60 - 85) 
 
8.5 (7.6 - 9.9) 
0.22 0.07 <0.0001 
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BMI body mass index, HbA1c glycated haemoglobin, N/A not applicable, SBP systolic blood pressure, DBP diastolic blood pressure. 
Urine ACR (mg/mmol) 
 
3.6 (1.7 - 9.3) 1.7 (1.0 - 4.9 ) <0.05 1.7 (1.1 – 4.9) 4.8 (2.6 - 10.9) 0.03 0.17 0.0002 
Retinal score 1 (0-2) 1 (0-2) 0.40 2 (1-4) 3 (1-4) 0.38 0.46  
Glucose lowering 
medications per patient 
2 (2-3) 1 (1-1) P<0.0001 3 (2-3) 3 (2-3) 0.85 0.32  
Blood pressure lowering 
medications per patient 
1 (1-2) 0 (0-1) P<0.0001 2 (1-3) 2 (1-3) 1.00 0.27  
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Table 20. Changes in medication classes before and 1 year after intervention 
in surgical and medical groups. 
 
 RYGB group 
(n=69) 
Medical group 
(n=25) 
 Pre-operative Post-operative Pre-operative Post-operative 
Patient use of glucose-
lowering medications 
classes, n (%) 
    
Metformin 58 (83%) 41 (59%) 19 (76%) 18 (72%) 
Sulphonylurea 15 (21%) 0(0%) 7(28%) 9 (36%) 
Pioglitazone 4 (6%) 0 (0%) 3 (12%) 2 (8%) 
DPP4i/GLP-1 26 (37%) 1 (1%) 10 (40%) 13 (52%) 
Insulin 46 (66%) 20 (29%) 15 (60%) 17 (68%) 
Patient use of BP-lowering 
medications, n (%) 
    
ACEi/A2B 48 (69%) 26 (37%) 16 (64%) 18 (72%) 
Calcium channel blocker 18 (26%) 15 (21%) 1 (4%) 2 (8%) 
Alpha blocker 7 (10%) 2 (3%) 8 (32%) 7 (28%) 
Diuretics 18 (26%) 2 (3%) 6 (24%) 6 (24%) 
Beta blocker 6 (9%) 5 (7%) 6 (24%) 7 (28%) 
 
n refers to the number of patients in the cohort that were on the class of medications 
A2B, angiotensin receptor 2 blocker; ACEi, ACE inhibitors; DPP4i, dipeptidyl peptidase-4 
inhibitors; GLP-1, glucagon-like peptide 1 
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Table 21. Nerve conduction studies in the RYGB group: Baseline and one year 
follow-up. 
 
 
RYGB  group 
(n=54) 
 
P value (change 
within group) 
 Pre-operative Post-operative  
Sup radial SNAP(µV) 17.0 (11.0-23.3) 18.5 ( 12.2-25.6) 0.56 
Sup radial CV(m/s) 62.0 (57.9-66.7) 61.3 (57.8-64.3) 0.14 
Sural SNAP (µV) 9.0 ( 5.0-13.9) 9.9 ( 6.9-16.1) 1.00 
Sural CV (m/s) 48.6 ± 0.8 48.6 ±0.8 1.00 
Common Peroneal CV (m/s) 44.6 ± 0.7 45.6 ± 0.7 1.00 
Tibial CMAP (mV) 5.0 ±0.4 5.2 ± 0.4 1.00 
Minimal latency tibial F-response 
(ms) 
54.6 ± 0.9 56.3 ± 1.0 0.0028 
SNAP, sensory nerve action potential; CV, conduction velocity; CMAP, compound muscle 
action potential 
 
Table 22. Result of thermal threshold testing in the RYGB group: Baseline and 
one year follow-up. 
 
 
RYGB  group 
(n=41) 
 
P value 
(within 
group) 
 Pre-operative Post-operative  
UL-WPT(°C) 36.0 (34.7-38.5) 35.1 ( 33.7-36.7) 0.008 
UL- CPT(°C) 30.5 (29.5-31.0) 30.4 ( 30.0- 
31.0) 
1.00 
LL- WPT(°C) 40.1 ( 36.1-43.5) 39.8 (36.6- 43.0) 1.00 
LL- CPT(°C) 29.5 (27.2-30.5) 27.2 ( 23.7-30.2) 0.0028 
UL, upper limb; LL, lower limb; WPT, warm perception threshold; CPT, cool perception 
threshold 
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Table 23. Changes within each thermal threshold parameters in subjects with 
pre-existing abnormal thermal threshold result 1 year post surgery (n=23). 
 
 Deterioration, n (%) No deterioration, n (%) 
Upper limb WPT 4 (17.4%) 19 (82.6%) 
Upper limb CPT 5 (27.8%) 18 (78.2%) 
Lower limb WPT 6 (26.1%) 17 (73.9%) 
Lower limb CPT 17 (73.9%) 6 (26.1%) 
 
n refers to the number of patients within the each perception threshold parameter. 
WPT, warm perception threshold; CPT, cool perception threshold 
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Chapter 9. Discussion 
9.1 GLUCOSURG-pre 
The intention to treat and as per protocol analysis shared similar results. 
9.1.1 Summary of main findings 
This study has shown that, 
1. Intensive pre-operative glycaemic management of obese T2DM patients undergoing 
RYGB was not superior to conservative management in terms of glycaemic control at 
1 year after surgery. 
 
2. Intensive pre-operative glycaemic management of obese T2DM patients undergoing 
RYGB was not superior to conservative management in terms of 30-day peri-operative 
surgical complication and LOS. 
 
Other findings 
Both conservative and intensive groups showed significant reduction in BMI and 
HbA1c. SBP was significantly reduced in the conservative group only. The use of 
glucose–lowering medications and BP lowering medications were reduced in both 
groups of patients. There was no difference in hypoglycaemic event between both 
groups. 
ACR was significantly reduced in the conservative group only. There were no 
significant changes in retinal score and NCS parameters in both groups. TTT showed 
worsening of lower limb cool perception threshold in the conservative group. The 
change is statistically significant but not clinically significant, as it is still within normal 
limits. 
Overall, there were no statistically differences when compared the changes between 
the conservative and intensive groups. The postoperative glucose trend in both groups 
were not significantly different. The reduction in BMI, HbA1c, SBP, use of glucose and 
BP lowering medications, and urine ACR were the result of the RYGB, as evidenced 
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by other studies(Schauer et al., 2012b, Heneghan et al., 2013, Miras et al., 2012, 
Ribaric et al., 2014). Further intensive optimisation had not yielded added benefit. 
9.1.2 Factors influencing the result 
This study suggested that the reduction of “glycaemic burden” in the months preceding 
bariatric surgery did not translate to better clinical outcomes either in the short or the 
medium term. This might be influenced by the following factors: 
Pre-op low calorie diet 
Despite glucose optimisation in the intensive cohort 3 months before surgery, both 
conservative and intensive groups underwent a low-calorie diet for 2 weeks pre-
operatively. Although the two groups were exposed to different glucose levels for the 
3 months pre-surgery, it is likely that glucose readings were similar on the day of 
surgery. This may explain the lack of difference in the rates of peri-operative 
complications. 
At 1 year, there was a non-significant trend for the conservatively treated group to 
have a greater reduction in glycaemia; this may be due to the non-significantly higher 
baseline HbA1c. Nonetheless, glycaemic optimisation remains crucial in T2DM. 
Challenge in optimising glucose control 
Even though in our study the intensively treated group managed to improve glycaemic 
control, on the day of surgery their HbA1c was still elevated at 8.4% (68mmol/mol). 
This reflects real life practice in that the vast majority of diabetes patients referred for 
bariatric surgery have exhausted non-surgical glucose-lowering treatments and there 
is less room for additional optimisation. Instead, any pre-operative interventions could 
be focused on improving other obesity-associated comorbidities. 
Lack of difference in microvascular complications 
Albuminuria improved in the conservative group but no significant change in intensive 
group at 1 year. This could be explained by the smaller sample size in intensive group. 
We did not observe improvement in retinopathy or NCS parameters at 1 year follow 
up. This might be limited by the small sample size, and short duration of follow up. 
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9.1.3 Comparison with similar work 
The finding of this study is in contrast to the study by Perna et al. who retrospectively 
categorised 468 patients by their pre-operative HbA1c, and compared it to the 
outcomes. The study reported that the cohort with poor glycaemic control (HbA1c>8%) 
before bariatric surgery was associated with worse glucose control postoperatively, 
with fewer diabetes remission and less weight loss by 18 months (Perna et al., 2012).  
In another of our retrospective cohort study we found no difference in post-operative 
complications between patients with or without diabetes (Neff K, 2013).  The 
discrepancies may be due to differences in study design (i.e. retrospective vs. 
prospective randomised trials).  
There were many studies assessing effect of perioperative glucose control on surgical 
outcomes but these were limited to non-bariatric surgery cohorts. No study has 
compared effect of intensive and conservative glucose management before bariatric 
surgery on diabetic nephropathy, retinopathy and neuropathy. 
9.1.4 Originality 
This is the first prospective RCT comparing the effect of intensive glucose control 3 
months before RYGB on glycaemic outcome and microvascular complications of 
T2DM. 
9.1.5 Translation to clinical practice 
I expected to find that intensification of glucose-lowering regimes pre-operatively 
would be beneficial for longer term glycaemic control, but my pilot study did not support 
this. However, my study data do not support withholding or delaying surgery from 
patients with poorly controlled glycaemia when all medical and lifestyle interventions 
have already been optimised.  Physicians and anaesthetists who are not familiar with 
the impact of bariatric surgery may be turned down patients with poorly controlled 
diabetes for bariatric surgery.  Although their approach is understandable, given the 
wealth of data on poor outcomes in patients with poorly controlled T2DM undergoing 
non-bariatric surgery, our data questions whether this is the case for bariatric surgery. 
The only option available currently for this group of patients may be bariatric surgery 
when all other interventions failed. 
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9.1.6 Future directions 
1. This study could be used to pilot a larger sample size RCT with at least 6 months 
of intensive therapy compared against best medical therapy before RYGB. Both 
conservative and intensive groups should avoid pre-operative LCD, to maintain the 
difference in blood glucose control at time of surgery.  However, taking into account 
the effect size was small, a larger trial focussing on glycaemic outcome may thus be 
challenging.  In order to assess if better perioperative glycaemic control improves post-
operative complications, a very large RCT will be required, because even if the effect 
size of the intervention is large, the number of post-operative complications is low. The 
lack of any statistical trends suggests that a larger number of subjects may not have 
altered the final result. 
2. It would be interesting to follow up the group of patients with abnormal NCS to 
assess if peripheral neuropathy become symptomatic, and whether NCS helped to 
identify those at high risk of developing neuropathy. Effect of RYGB on reversibility of 
neuropathy would warrant longer term follow up given UKPDS only showed beneficial 
effect of intensive glycaemic control on neuropathy at 15 years follow up. 
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9.2 GLUCOSURG-post 
The similarities and differences between intention to treat and as per protocol analysis 
were discussed below. 
9.2.1 Summary of main findings 
In this study I have shown that: 
1. Intensive post-operative glycaemic management of obese T2DM patients undergoing 
RYGB was not superior to conservative management in terms of glycaemic control at 
1 year after surgery. 
 
2. Intensive post-operative glycaemic management of obese T2DM patients undergoing 
RYGB was not superior to conservative management in terms of 30-day peri-operative 
surgical complication and LOS. 
Other findings 
Intention to treat analysis 
Intensive group had T2DM for 5 year longer than the conservative group following 
randomisation. Both conservative and intensive groups showed significant reduction 
in BMI and HbA1c. The use of glucose–lowering medications and BP lowering 
medications were reduced in both groups of patients. 
There were no significant reduction in urine ACR, retinal score and TTT at 1 year. 
Within NCS, superficial radial conduction velocity reduced. This was not clinically 
significant as it was still within the normal range. 
The postoperative glucose trend in both groups were not significantly different, despite 
best effort to control glucose within conservative group post-surgery. 10 subjects in 
conservative group achieved intensive glucose target post-surgery, which is the result 
of RYGB. 
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As per protocol analysis 
There was no difference in duration of diabetes when the group was analysed using 
as per protocol analysis. SBP showed significant reduction at 1 year. This was 
explained by the significantly higher SBP at baseline. There was no significant 
reduction in use of BP lowering medications in conservative group, likely due to the 
small sample size of 10 subjects. Except this, all groups showed reduction in glucose 
and BP lowering medications. 
There were no significant reduction in urine ACR, retinal score, NCS and TTT at 1 
year. Overall, there were no significant differences when compared the changes 
between the conservative and intensive groups. The postoperative glucose trend in 
both groups were only different in as per protocol analysis. 
9.2.2 Factors influencing the result 
Effect of RYGB on postoperative glucose control 
Unlike other elective surgical procedures following which hyperglycaemia is common 
and predominantly due to surgical stress, RYGB is different in that it has a substantial 
effect in improving glucose levels within days after surgery. Consequently, the glucose 
levels of our conservatively treated group were still in the intensive glucose range. This 
may explain the lack of significant difference in the short and medium term clinical 
outcomes between the groups. 
The hypoglycaemic rate was low, a post-operative glucose management algorithm 
that maintain fasting glucose <7.5mmol/L therefore appears to be safe. Further 
intensification may not therefore confer clinical benefits nor does it decrease 
complications. An overzealous glucose management approach may increase 
hypoglycaemic risk. 
The reduction in BMI, HbA1c, use of glucose and BP lowering medications were the 
result of RYGB, as evidenced by other studies (Schauer et al., 2012b, Heneghan et 
al., 2013, Miras et al., 2012, Ribaric et al., 2014). Significant reduction in SBP was 
only observed in the group with higher baseline SBP. 
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Lack of difference in microvascular complications 
Urine ACR had not shown improvement as they were within normal range at baseline. 
Retinal and neuropathy changes as discussed in 9.1.2 
9.2.3 Comparison with similar work 
A retrospective study by Perna et al. reported that the cohort with poor glycaemic 
control (HbA1c>8%) before bariatric surgery was associated with worse glucose 
control postoperatively, fewer diabetic remission and less weight loss by 18 months 
(Perna et al., 2012). In my study, I had not observed any worsening in HbA1c, 
remission of diabetes or BMI differences between both groups. The discrepancies may 
be due to differences in study design (i.e. retrospective vs. prospective RCT), the 
different target glucose range for intensive and conservative groups postoperatively.  
In another of our prospective cohort study comparing postoperative protocol driven 
glucose management to a standard glycaemic regime; the protocol driven group which 
aimed for fasting capillary glucose of 5.5-6.9mmol/L achieved better glycaemic control 
and remission of diabetes at 1 year (Fenske et al., 2012). The lack of significant 
difference in my study could be due to the narrow range of target fasting capillary 
glucose, and the substantial effect of RYGB on glycaemic control. 
9.2.4 Originality 
Management of T2DM post RYGB varied extensively across different centres. There 
are limited prospective studies that assess if perioperative glucose optimisation would 
have favourable glycaemic outcomes in the future. This study is the first study that 
assess if postoperative glucose optimisation would have an impact on diabetic 
nephropathy, retinopathy and neuropathy. 
9.2.5 Translation to clinical practice 
I expected to find that intensification of glucose-lowering regimes post-operatively 
would be beneficial for longer term glycaemic control, but my study did not support 
this. The effect of RYGB is substantial and therefore further intensification of glucose 
management will not confer further benefits. It shows that the use of a post-operative 
glucose management algorithm that maintain fasting glucose <7.5mmol/L appears to 
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be safe. This study, in conjunction with GLUCOSURG-pre support that RYGB as a 
metabolic surgery, should be distinguished from other gastrointestinal surgery. RYGB 
should therefore warrant its own preoperative glucose management recommendation 
rather than a generalised guideline based on prior studies on non-bariatric surgeries. 
This would have implication on patients’ access for surgeries as some patients might 
have been denied surgery due to their poor control. 
9.2.6 Future directions 
1. This study could be used as a pilot to compare different glucose management 
protocols between centres to assess its effect on diabetes outcomes. 
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9.3 GLUCOSURG-combine 
9.3.1 Summary of main findings 
In this study I have shown that: 
1. RYGB had beneficial effect on progression of diabetic nephropathy at 1 year when 
compared to medical group that received best medical care. 
2. RYGB had not shown significant beneficial effect on progression of retinopathy at 1 
year when compared to medical group that received best medical care. 
3. RYGB had not shown significant beneficial effect on progression of neuropathy at 1 
year. 
4. RYGB had not shown significant deterioration in retinopathy and neuropathy 1 year 
after surgery. 
Other findings 
RYGB group showed significant reduction in BMI, HbA1c, and SBP when compared 
to the medical group at 1 year following intervention. There was also a large proportion 
of RYGB subjects that achieved remission of diabetes. Significant reduction in glucose 
lowering and blood pressure lower medications were also observed in the surgical 
group. These results are consistent with other studies (Mingrone et al., 2012a, Ribaric 
et al., 2014, Schauer et al., 2012b) 
Urine ACR improved significantly in the surgical group, whereas medical group 
showed significant deterioration at 1 year. Eighty-one percent of those with pre-
existing albuminuria in the surgical group showed improvement, of which 73% 
normalised their ACR at 1 year. This was not observed in the medical group. The 
deterioration of albuminuria and the new incidence of albuminuria were not 
significantly different between surgical and medical groups. 
There was no significant difference in the changes of retinal score between surgical 
and medical groups. Most subjects in both groups had no change in retinal score. Four 
of the 6 subjects in surgical group and all 3 subjects in medical group who deteriorated, 
had pre-existing retinopathy. There were no differences between the groups in the 
rates of deterioration and improvement. 
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NCS showed statistically significant change in minimal latency tibial F response, which 
was not clinically significant. There was no change in other nerve parameters. On 
qualitative analysis, 2 of the 11 subjects with pre-existing peripheral neuropathy 
showed deterioration; no change was observed in those without neuropathy.  
TTT showed improvement in upper limb warm perception threshold; but deterioration 
in lower limb cool perception threshold. The change in upper limb was within normal 
range. Qualitative analysis showed 13 subjects who had pre-existing abnormal 
thermal threshold perception had deterioration in lower limb cool perception threshold. 
There were no significant correlations between the changes in ACR and change in 
HbA1c, BMI, SBP, and DBP in surgical group. 
 
9.3.2 Factors influencing the result 
Effect of RYGB on BMI, HbA1c and SBP are well known. Numerous studies have 
looked into metabolic effect of RYGB on weight loss and remission of diabetes. The 
proposed mechanisms include weight dependent and weight independent factors. 
These have been discussed in Chapter 1.3.4. These mechanisms, working in 
concerted manner reduce weight, improves hepatic insulin sensitivity and reverse islet 
cell dysfunction. Immediately post-surgery, hepatic sensitivity improved secondary to 
energy restriction (Dirksen et al., 2012, Lim et al., 2011); exaggerated postprandial 
insulin response which restored the impaired acute phase insulin response in T2DM 
is also observed. This is in conjunction with altered gut hormone response including 
exaggerated release of postprandial GLP-1. Peripheral insulin sensitivity improves 
later after established weight loss. Other mechanisms such as altered bile acid 
passage, altered gut microflora, altered food preferences to less energy dense diet 
had been observed (Dirksen et al., 2012, Behary and Miras, 2015). Many studies 
continue to explore the mechanisms of RYGB on remission of diabetes. 
Diabetic nephropathy 
Effects of RYGB on microvascular complications are less known. Among the 
microvascular complications, diabetic nephropathy is the best studied. Mechanisms of 
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obesity and kidney disease are less well known. Renal lipotoxicity, inflammatory 
cytokines, altered renal hemodynamics had been proposed (Wahba and Mak, 2007, 
Currie et al., 2011). 
UKPDS study reported that intensive blood glucose control resulted in 33 % reduction 
in relative risk of developing microalbuminuria or proteinuria at 12 years (Bilous, 2008). 
Kumamoto study also reported a lower incidence of nephropathy in intensive 
glycaemic group after 6 years (Ohkubo et al., 1995). This was also supported by 
ADVANCE trial where intensive glycaemic group had less incidence of 
microalbuminuria (Patel et al., 2008).  
Obesity is associated with renal hyperfiltration and hyperperfusion, independent of 
hypertension (Currie et al., 2011). Animal studies suggested that obesity is associated 
with increase intra-abdominal pressure leading to increase renal venous pressure, 
systemic blood pressure and vascular resistance. This activated the juxtaglomerular 
apparatus and the renin-aldosterone system, leading to hypertension, hyperfiltration, 
and proteinuria (Currie et al., 2011, Heneghan et al., 2013). Chagnac et al reported 
that study on non-diabetic subjects with obesity-related glomerular hyperfiltration 
ameliorated after weight loss further supported the critical role that obesity played in 
nephropathy (Chagnac et al., 2003). Amor et al. also reported that a stepwise logistic 
regression analysis on 255 subjects who had bariatric surgery, of which 96 had T2DM, 
weight loss was the only independent predictor of ACR normalisation at 12 months 
post-surgery (Amor et al., 2013) . 
Fenske et al showed reduction in CRP, urinary ACR and cytokines at 12 months after 
RYGB, AGB or SG. The study proposed that the reduction in inflammatory marker is 
due to weight loss rather than type of procedures (Fenske et al., 2013). Reduction in 
total body fat and visceral fat post RYGB may also have impact on renal function and 
inflammatory state. The presence of GLP-1 receptors on kidney and animal study 
suggested that GLP-1 might have renoprotective effect independent of glucose 
homeostatsis (Kodera et al., 2011). 
My study reported an improvement in albuminuria after RYGB. Of this, 73% of the 
subjects in fact normalised their ACR at 1 year. This showed the combination effects 
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of weight loss, improved glucose control, as well as weight independent factors 
achieved by RYGB. 
Diabetic retinopathy 
There were no significant changes in retinal score between the surgery and medical 
groups. This was surprising considering UKPDS (1998b), Kumamoto study (Ohkubo 
et al., 1995) and ACCORD Eye study (2010) had all shown that intensive glucose 
management reduce the risk of diabetic retinopathy. VADT trial had not observed 
similar effect and this might be due to limited numbers of subjects and follow up time 
as compared to UKPDS(Duckworth et al., 2009). Other factors such as hypertension 
are also critical in influencing progression of retinopathy.  
My study showed that those with pre-existing retinopathy were more at risk of 
deterioration and would therefore warrant more intensive retinal surveillance. It was 
reassuring that none of the subjects reported worsening vision or retinopathy post-
surgery. The lack of changes in my study is limited by the number of subjects and the 
short follow up period. 
Diabetic neuropathy 
There were no clinically significant changes in NCS parameters in the surgical groups. 
The change in lower limb cool perception threshold, however, was unexpected. In 
diabetic neuropathy, lower limb small nerve fibres are affected before upper limb. 
However, the first thermal modality usually affected is lower limb warm perception 
threshold which is innervated by unmyelinated small fibres, and followed by lower limb 
cool perception threshold, which is innervated by thinly myelinated small fibres. This 
would then followed by warm perception threshold changes in hand (Personal 
communication, Dr Alessia Nicotra). The change in thermal threshold perception was 
out of what is expected in clinical practice. An abstract reporting quantitative sensory 
testing on 10 subjects who had bariatric surgery had not reported any changes in their 
parameters although the type of quantitative sensory testing was not known. There 
was no other publication on assessment of small nerve fibres post bariatric surgery so 
far.   
127 
 
Thermal threshold testing, however, is a psychophysical test which could be 
influenced by patient’s perception of the change in temperature, patient’s response to 
the changes, and interoperator variability (Heldestad et al., 2010, Devigili et al., 2008). 
We have attempted to limit the variability by having a single operator, using the same 
machine and conduct the test in a temperature controlled room. 
 
It appeared that deterioration in NCS were more likely in the group that had pre-
existing neuropathy. There was no worsening of symptoms in those with normal NCS 
at baseline. The changes in TTT and NCS were subclinical. Although we had not 
undertaken a formal clinical neurological evaluation assessment, all patients were 
asked if they have neuropathy symptom before surgery and at one year follow up. 
There were 3 subjects that had symptom consistent with carpal tunnel syndrome, but 
none have reported neuropathy previously or during follow up. The changes we 
detected on NCS and TTT might precede the development of symptoms, therefore 
future longer term follow up of this group of patients to assess progression of symptom 
would be warranted. The tests might be a useful tool to predict the proportion of subject 
that would develop neuropathic symptoms in the future. 
 
NCS is an objective test, and we have attempted to limit the interoperator variability 
by having only single neurophysiologist to carry out the testing. Although some nerve 
conduction parameters showed statistically significant changes, the changes were 
within normal limit, and hence of no clinical significance.  
 
As compared to T1DM where EDIC study showed intensive glycaemic control reduced 
the risk of neuropathy by 64%, its effect on T2DM is not as robust (Martin et al., 2006). 
Of the T2DM studies, UKPDS is the only study that showed intensive glycaemic 
control was associated with reduction in neuropathy, albeit only at 15 years follow 
up(1998c). It is therefore likely that factors other than glycaemic control is more critical 
in influencing progress of neuropathy. Other factors such as obesity, lipids, and 
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inflammation had been implicated previously. Given the duration of time it takes to 
show beneficial effect in UKPDS study, it might be that the nerve fibres take longer 
time to recover. 
Although the 3 microvascular complications shared similar pathogenesis, their rate of 
progression and reversibility appeared to differ, and factors influencing their recovery 
may not be similar either. Nutritional deficiency has been implicated in a few trials post 
bariatric surgery (Thaisetthawatkul et al., 2004). We haven’t observed this in our 
cohort. The group of patients that showed worsening in neuropathy all had pre-existing 
neuropathy on electrophysiology testing even before the surgery. All our patients were 
prescribed multivitamins and minerals supplement after RYGB. 
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9.3.3 Comparison with similar work 
Diabetic nephropathy 
Several retrospective and prospective studies including our own, had reported 
improvement in albuminuria following RYGB (Miras et al., 2012, Heneghan et al., 
2013, Navaneethan et al., 2010). Iaconelli et al followed up newly diagnosed T2DM 
for 10 years following BPD reported that all 7 patients with microalbuminuria had 
normalised ACR, whereas microalbuminuria progressed to macroalbuminuria in 
control group (Iaconelli et al., 2011). 
Navaneethan et al compared effect of different bariatric surgery on 15 subjects and 
reported RYGB improved albuminuria and insulin sensitivity as compared to other 
procedures (Navaneethan et al., 2010).  Heneghen et al retrospectively reviewed 
changes in urine ACR in T2DM subjects completed 5 years follow up, and reported 
diabetic nephropathy resolved in 58.3%   at 5 year follow up (Heneghan et al., 2013). 
The study also reported a significant correlation between postoperative urine ACR and 
systolic blood pressure. 
My study confirmed similar finding that RYGB improves diabetic nephropathy at 1 year 
follow up. However, I did not find correlation between changes in ACR and SBP. The 
discrepancy might be associated with different design in study (retrospective vs 
prospective). 
Diabetic retinopathy 
STAMPEDE trial which randomised 150 T2DM subjects to either RYGB, VSG and 
medical therapy reported no change in retinopathy score at 2 years. Longer term follow 
up data is awaited (Singh et al., 2015). 
Murphy et al retrospectively reviewed 318 T2DM subjects who had bariatric surgery 
and reported that 73% of subjects had no change in retinopathy 11 % regressed, and 
16% progressed. The probability of progression of retinopathy was associated with the 
magnitude of change in HbA1c, more severe pre-existing eye disease (Murphy et al., 
2015). Similar finding was also reported by Thomas et al (Thomas et al., 2014). 
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This is consistent with my finding that majority of subjects had no change in retinopathy 
at 1 year follow up. 
Diabetic neuropathy 
Muller-Stich et al reported a study of 20 non-severely obese subjects who had RYGB 
which showed significant improvement in neuropathy symptom score and neuropathy 
deficit score post-surgery. All patients had shown improvement (Muller-Stich et al., 
2013). 
My study had not shown similar result. This is interesting as the subjects in my study 
were not symptomatic, hence the abnormal findings on NCS were subclinical, yet the 
results had not improved after intensive glycaemic control following RYGB. Muller-
Stich et al, however studied a group of subjects who were symptomatic, by definition 
would be more severe in degree of neuropathy. The major discrepancy in the study 
would be the investigations used. Electrophysiological study is an objective 
measurement of large nerve fibres, whereas neuropathy score is a subjective test. 
Secondly, both studies were limited by the small sample size. Thirdly, the other study 
had a cohort with lower BMI of 25-35kg/m2. 
9.3.4 Originality 
This study is the first study that prospectively assessed the effect of RYGB on all 3 
components of microvascular complications (diabetic nephropathy, retinopathy and 
neuropathy) using objective measurements. 
9.3.5 Translation to clinical practice 
Results of this study showed that despite improved glycaemic control following RYGB, 
only diabetic nephropathy improved at 1 year follow up.  Diabetic retinopathy and 
subclinical changes in diabetic neuropathy had not altered. The study has clinical 
implications on follow up of this group of patients. Patients as well as physician need 
to be aware of the importance of continuing with annual retinal and foot surveillance 
despite   improvement or remission of diabetes. 
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9.3.6 Future directions: 
1. A longer term follow up to assess changes in retinopathy and neuropathy would allow 
assessment on reversibility of the complications. 
 
2. Future study should include NCS and TTT assessment in the obese T2DM medical 
treated group as control. 
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9.4 Limitations 
GLUCOSURG -pre and GLUCOSURG -post 
Due to the design of both studies, limitations on both studies are similar. These include 
the number of patients in each group being relatively small, but even so, the effect size 
was small, which suggests that there was only a small chance of the data representing 
a type II statistical error. A larger trial focussing on glycaemic outcome may thus be 
challenging. Whether better perioperative glycaemic control improves post-operative 
complications requires a very large RCT, because even if the effect size of the 
intervention is large, the number of post-operative complications are low. The lack of 
any statistical trends suggests that a larger number of subjects may not have altered 
the final result. In both trials the follow-up was limited to 1 year, and therefore 
differences in clinical outcomes between the groups in the longer term cannot be 
excluded. My study based the post-operative management of patients on fasting CG 
readings only and continuous glucose monitoring may have been superior for 
assessing glycaemic excursions and enabled detection of hypoglycaemia more 
effectively. Despite randomisation in the GLUCOSURG-post trial, the intensively 
treated group had a longer duration of T2DM. This may have limited the impact of the 
intervention on the 1 year glycaemic outcome endpoint, although my study did not 
detect any trends that would have suggested this even in the smaller number of 
patients that had similar duration of diabetes. 
GLUCOSURG -combine 
This study is limited by the small sample size, the non-randomised design and lack of 
information on peripheral neuropathy for the medically treated patients. I cannot 
exclude that some patients may have had an acute deterioration in retinopathy which 
occurred before 12 months and then partially recovered. I am however, reassured that 
the surgical patients who were all followed at 3, 6 and 9 months after surgery did not 
complain of deteriorating vision. Moreover the retinopathy findings at one year were 
also reassuring. The study is also limited by its short follow up of 1 year, which is not 
adequate to assess changes in microvascular complications. However, my findings 
could be used to power larger randomised controlled trials with longer term follow up 
that are necessary in this field. 
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Chapter 10 Conclusion 
In summary, I have shown that RYGB had an early and substantial effect on glucose 
control, and additional intensive glucose-lowering interventions before and after RYGB 
did not appear to confer any clinical benefits. My pilot randomised controlled trials did 
not confirm the two previous cohort studies that intensive management of glycaemia 
for the first two weeks after RYGB resulted in better glycaemic control one year after 
surgery. I also did not find evidence that intensive management of glycaemia in the 3 
months before surgery made a difference. There was no difference in LOS or 
incidence of surgical complications between the conservative and intensive groups. 
My study did show improving peri-operative glycaemia was feasible, but a much larger 
randomized controlled trial would be required to address whether such an approach 
reduces the already low post-operative complications of RYGB.  
The combine study has shown that, as compared to a group of patients receiving best 
medical care, patients treated with bariatric surgery experience substantial reductions 
in albuminuria. The rates of retinopathy progression were similar to those observed in 
a medically treated group whilst there were no significant changes in peripheral nerve 
function 1 year after RYGB surgery. A longer term follow up on retinopathy and 
neuropathy changes would provide insightful information on the disease progression. 
The result of my studies reaffirm the importance of retinal and neuropathy surveillance 
in the face of improving glycaemic control following RYGB. 
 
 
 
 
 
 
 
134 
 
Chapter 11 References 
 
 
. 
1993. The effect of intensive treatment of diabetes on the development and progression of long-
term complications in insulin-dependent diabetes mellitus. The Diabetes Control and 
Complications Trial Research Group. N Engl J Med, 329, 977-86. 
1998a. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch 
Ophthalmol, 116, 874-86. 
1998b. Effect of intensive blood-glucose control with metformin on complications in overweight 
patients with type 2 diabetes (UKPDS 34). The Lancet, 352, 854-865. 
1998c. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional 
treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK 
Prospective Diabetes Study (UKPDS) Group. Lancet, 352, 837-53. 
2003. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and 
progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and 
Complications (EDIC) study. JAMA, 290, 2159-67. 
2009. Perioperative Safety in the Longitudinal Assessment of Bariatric Surgery. New England Journal 
of Medicine, 361, 445-454. 
2010. Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes. New England 
Journal of Medicine, 363, 233-244. 
(WHO), W. H. O. 2011. Diabetes Fact sheet No312. August 2011 ed. 
ADAMS, T. D., GRESS, R. E., SMITH, S. C., HALVERSON, R. C., SIMPER, S. C., ROSAMOND, W. D., 
LAMONTE, M. J., STROUP, A. M. & HUNT, S. C. 2007. Long-term mortality after gastric bypass 
surgery. N Engl J Med, 357, 753-61. 
ADRIANZEN VARGAS, M., CASSINELLO FERNANDEZ, N. & ORTEGA SERRANO, J. 2011. Preoperative 
weight loss in patients with indication of bariatric surgery: which is the best method? Nutr 
Hosp, 26, 1227-30. 
AMOR, A., JIMENEZ, A., MOIZE, V., IBARZABAL, A., FLORES, L., LACY, A. M. & VIDAL, J. 2013. Weight 
loss independently predicts urinary albumin excretion normalization in morbidly obese type 
2 diabetic patients undergoing bariatric surgery. Surg Endosc, 27, 2046-51. 
ANDERSON, J. W., KENDALL, C. W. & JENKINS, D. J. 2003. Importance of weight management in type 
2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr, 22, 331-9. 
ASTRUP, A. & FINER, N. 2000. Redefining type 2 diabetes: 'diabesity' or 'obesity dependent diabetes 
mellitus'? Obes Rev, 1, 57-9. 
AZAD, N., EMANUELE, N. V., ABRAIRA, C., HENDERSON, W. G., COLWELL, J., LEVIN, S. R., NUTTALL, F. 
Q., COMSTOCK, J. P., SAWIN, C. T., SILBERT, C. & RUBINO, F. A. 1999. The effects of intensive 
glycemic control on neuropathy in the VA cooperative study on type II diabetes mellitus (VA 
CSDM). J Diabetes Complications, 13, 307-13. 
BEHARY, P. & MIRAS, A. D. 2015. Food preferences and underlying mechanisms after bariatric 
surgery. Proc Nutr Soc, 1-7. 
BERGENSTAL, R. M., BAILEY, C. J. & KENDALL, D. M. 2010. Type 2 diabetes: assessing the relative risks 
and benefits of glucose-lowering medications. Am J Med, 123, 374 e 9 -18. 
BILOUS, R. 2008. Microvascular disease: what does the UKPDS tell us about diabetic nephropathy? 
Diabet Med, 25 Suppl 2, 25-9. 
BRAY, G. A. 2008. Lifestyle and pharmacological approaches to weight loss: efficacy and safety. J Clin 
Endocrinol Metab, 93, S81-8. 
BRETHAUER, S. A., AMINIAN, A., ROMERO-TALAMÁS, H., BATAYYAH, E., MACKEY, J., KENNEDY, L., 
KASHYAP, S. R., KIRWAN, J. P., ROGULA, T., KROH, M., CHAND, B. & SCHAUER, P. R. 2013. 
Can Diabetes Be Surgically Cured?: Long-Term Metabolic Effects of Bariatric Surgery in 
Obese Patients with Type 2 Diabetes Mellitus. Ann Surg, 258, 628-37. 
135 
 
BRETZEL, R. G., BRANDHORST, D., BRANDHORST, H., ECKHARD, M., ERNST, W., FRIEMANN, S., RAU, 
W., WEIMAR, B., RAUBER, K., HERING, B. J. & BRENDEL, M. D. 1999. Improved survival of 
intraportal pancreatic islet cell allografts in patients with type-1 diabetes mellitus by refined 
peritransplant management. J Mol Med (Berl), 77, 140-3. 
BROWNLEE, M. 2001. Biochemistry and molecular cell biology of diabetic complications. Nature, 
414, 813-20. 
BUCHWALD, H., AVIDOR, Y., BRAUNWALD, E., JENSEN, M. D., PORIES, W., FAHRBACH, K. & 
SCHOELLES, K. 2004. Bariatric surgery: a systematic review and meta-analysis. JAMA, 292, 
1724-37. 
BUCHWALD, H., ESTOK, R., FAHRBACH, K., BANEL, D., JENSEN, M. D., PORIES, W. J., BANTLE, J. P. & 
SLEDGE, I. 2009. Weight and type 2 diabetes after bariatric surgery: systematic review and 
meta-analysis. Am J Med, 122, 248-256 e5. 
BUSE, J. B., CAPRIO, S., CEFALU, W. T., CERIELLO, A., DEL PRATO, S., INZUCCHI, S. E., MCLAUGHLIN, S., 
PHILLIPS, G. L., ROBERTSON, R. P., RUBINO, F., KAHN, R. & KIRKMAN, M. S. 2009. How Do We 
Define Cure of Diabetes? Diabetes Care, 32, 2133-2135. 
CAI, J. & BOULTON, M. 2002. The pathogenesis of diabetic retinopathy: old concepts and new 
questions. Eye (Lond), 16, 242-60. 
CHAGNAC, A., WEINSTEIN, T., HERMAN, M., HIRSH, J., GAFTER, U. & ORI, Y. 2003. The Effects of 
Weight Loss on Renal Function in Patients with Severe Obesity. Journal of the American 
Society of Nephrology, 14, 1480-1486. 
CHEUNG, N. & WONG, T. Y. 2007. Obesity and Eye Diseases. Surv Ophthalmol, 52, 180-95. 
CHUAH, L. L. & LE ROUX, C. W. 2013. Management of patients with type 2 diabetes before and after 
bariatric surgery: evolution and microvascular complications. Nutr Hosp, 28 Suppl 2, 17-22. 
CHUAH, L. L., MIRAS, A. D., PAPAMARGARITIS, D., JACKSON, S. N., OLBERS, T. & LE ROUX, C. W. 2015. 
Impact of perioperative management of glycemia in severely obese diabetic patients 
undergoing gastric bypass surgery. Surg Obes Relat Dis, 11, 578-84. 
CHUAH, L. L., PAPAMARGARITIS, D., PILLAI, D., KRISHNAMOORTHY, A. & LE ROUX, C. W. 2013. 
Morbidity and mortality of diabetes with surgery. Nutr Hosp, 28 Suppl 2, 47-52. 
CIULLA, T. A., AMADOR, A. G. & ZINMAN, B. 2003. Diabetic retinopathy and diabetic macular edema: 
pathophysiology, screening, and novel therapies. Diabetes Care, 26, 2653-64. 
CLEMENT, S., BRAITHWAITE, S. S., MAGEE, M. F., AHMANN, A., SMITH, E. P., SCHAFER, R. G., HIRSCH, 
I. B. & AMERICAN DIABETES ASSOCIATION DIABETES IN HOSPITALS WRITING, C. 2004. 
Management of diabetes and hyperglycemia in hospitals. Diabetes Care, 27, 553-91. 
COLLES, S. L., DIXON, J. B., MARKS, P., STRAUSS, B. J. & O'BRIEN, P. E. 2006. Preoperative weight loss 
with a very-low-energy diet: quantitation of changes in liver and abdominal fat by serial 
imaging. Am J Clin Nutr, 84, 304-11. 
COLQUITT, J. L., PICOT, J., LOVEMAN, E. & CLEGG, A. J. 2009. Surgery for obesity. Cochrane Database 
Syst Rev, CD003641. 
CUMBIE, B. C. & HERMAYER, K. L. 2007. Current concepts in targeted therapies for the 
pathophysiology of diabetic microvascular complications. Vasc Health Risk Manag, 3, 823-
32. 
CURRIE, A., CHETWOOD, A. & AHMED, A. R. 2011. Bariatric surgery and renal function. Obes Surg, 
21, 528-39. 
DAROUICH, S., GOUCHA, R., JAAFOURA, M. H., ZEKRI, S., BEN MAIZ, H. & KHEDER, A. 2011. 
Clinicopathological characteristics of obesity-associated focal segmental glomerulosclerosis. 
Ultrastruct Pathol, 35, 176-82. 
DCCT 1995. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in 
insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial. Arch 
Ophthalmol, 113, 36-51. 
136 
 
DEVIGILI, G., TUGNOLI, V., PENZA, P., CAMOZZI, F., LOMBARDI, R., MELLI, G., BROGLIO, L., GRANIERI, 
E. & LAURIA, G. 2008. The diagnostic criteria for small fibre neuropathy: from symptoms to 
neuropathology. Brain, 131, 1912-25. 
DHATARIYA, K., LEVY, N., KILVERT, A., WATSON, B., COUSINS, D., FLANAGAN, D., HILTON, L., JAIRAM, 
C., LEYDEN, K., LIPP, A., LOBO, D., SINCLAIR-HAMMERSLEY, M., RAYMAN, G. & JOINT BRITISH 
DIABETES, S. 2011. Management of adults with diabetes undergoing surgery and elective 
procedures: improving standards. Diabet Med. 2012/02/01 ed. 
DIRKSEN, C., JORGENSEN, N. B., BOJSEN-MOLLER, K. N., JACOBSEN, S. H., HANSEN, D. L., WORM, D., 
HOLST, J. J. & MADSBAD, S. 2012. Mechanisms of improved glycaemic control after Roux-en-
Y gastric bypass. Diabetologia, 55, 1890-901. 
DIXON, J. B., ZIMMET, P., ALBERTI, K. G. & RUBINO, F. 2011. Bariatric surgery: an IDF statement for 
obese Type 2 diabetes. Diabet Med, 28, 628-42. 
DUCKWORTH, W., ABRAIRA, C., MORITZ, T., REDA, D., EMANUELE, N., REAVEN, P. D., ZIEVE, F. J., 
MARKS, J., DAVIS, S. N., HAYWARD, R., WARREN, S. R., GOLDMAN, S., MCCARREN, M., VITEK, 
M. E., HENDERSON, W. G. & HUANG, G. D. 2009. Glucose control and vascular complications 
in veterans with type 2 diabetes. N Engl J Med, 360, 129-39. 
ERIKSSON, K. F. & LINDGARDE, F. 1991. Prevention of type 2 (non-insulin-dependent) diabetes 
mellitus by diet and physical exercise. The 6-year Malmo feasibility study. Diabetologia, 34, 
891-8. 
FEIT, H., GLASBERG, M., IRETON, C., ROSENBERG, R. N. & THAL, E. 1982. Peripheral Neuropathy and 
Starvation After Gastric Partitioning for Morbid Obesity. Annals of Internal Medicine, 96, 
453-455. 
FENSKE, W. K., DUBB, S., BUETER, M., SEYFRIED, F., PATEL, K., TAM, F. W., FRANKEL, A. H. & LE ROUX, 
C. W. 2013. Effect of bariatric surgery-induced weight loss on renal and systemic 
inflammation and blood pressure: a 12-month prospective study. Surg Obes Relat Dis, 9, 
559-68. 
FENSKE, W. K., POURNARAS, D. J., AASHEIM, E. T., MIRAS, A. D., SCOPINARO, N., SCHOLTZ, S. & LE 
ROUX, C. W. 2012. Can a protocol for glycaemic control improve type 2 diabetes outcomes 
after gastric bypass? Obes Surg, 22, 90-6. 
FIORETTO, P., STEFFES, M. W., SUTHERLAND, D. E., GOETZ, F. C. & MAUER, M. 1998. Reversal of 
lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med, 339, 69-75. 
FOWLER, M. J. 2008. Microvascular and macrovascular complications of diabetes. Clinical Diabetes, 
26, 77-82. 
FRISCH, A., CHANDRA, P., SMILEY, D., PENG, L., RIZZO, M., GATCLIFFE, C., HUDSON, M., MENDOZA, J., 
JOHNSON, R., LIN, E. & UMPIERREZ, G. E. 2010. Prevalence and clinical outcome of 
hyperglycemia in the perioperative period in noncardiac surgery. Diabetes Care, 33, 1783-8. 
GAEDE, P., LUND-ANDERSEN, H., PARVING, H. H. & PEDERSEN, O. 2008. Effect of a multifactorial 
intervention on mortality in type 2 diabetes. N Engl J Med, 358, 580-91. 
GARG, A. & GRUNDY, S. M. 1994. Cholestyramine therapy for dyslipidemia in non-insulin-dependent 
diabetes mellitus. A short-term, double-blind, crossover trial. Ann Intern Med, 121, 416-22. 
GERSTEIN, H. C., MILLER, M. E., BYINGTON, R. P., GOFF, D. C., JR., BIGGER, J. T., BUSE, J. B., 
CUSHMAN, W. C., GENUTH, S., ISMAIL-BEIGI, F., GRIMM, R. H., JR., PROBSTFIELD, J. L., 
SIMONS-MORTON, D. G. & FRIEDEWALD, W. T. 2008. Effects of intensive glucose lowering in 
type 2 diabetes. N Engl J Med, 358, 2545-59. 
GOLDMAN-LEVINE, J. D. 2011. Beyond metformin: initiating combination therapy in patients with 
type 2 diabetes mellitus. Pharmacotherapy, 31, 44S-53S. 
HAINES, L., WAN, K. C., LYNN, R., BARRETT, T. G. & SHIELD, J. P. 2007. Rising incidence of type 2 
diabetes in children in the U.K. Diabetes Care, 30, 1097-101. 
HANDELSMAN, Y., GOLDBERG, R. B., GARVEY, W. T., FONSECA, V. A., ROSENSTOCK, J., JONES, M. R., 
LAI, Y. L., JIN, X., MISIR, S., NAGENDRAN, S. & ABBY, S. L. 2010. Colesevelam hydrochloride to 
137 
 
treat hypercholesterolemia and improve glycemia in prediabetes: a randomized, prospective 
study. Endocr Pract, 16, 617-28. 
HELDESTAD, V., LINDER, J., SELLERSJO, L. & NORDH, E. 2010. Reproducibility and influence of test 
modality order on thermal perception and thermal pain thresholds in quantitative sensory 
testing. Clin Neurophysiol, 121, 1878-85. 
HENEGHAN, H. M., CETIN, D., NAVANEETHAN, S. D., ORZECH, N., BRETHAUER, S. A. & SCHAUER, P. R. 
2013. Effects of bariatric surgery on diabetic nephropathy after 5 years of follow-up. Surgery 
for Obesity and Related Diseases, 9, 7-14. 
HENRICSSON, M., NYSTROM, L., BLOHME, G., OSTMAN, J., KULLBERG, C., SVENSSON, M., SCHOLIN, 
A., ARNQVIST, H. J., BJORK, E., BOLINDER, J., ERIKSSON, J. W. & SUNDKVIST, G. 2003. The 
incidence of retinopathy 10 years after diagnosis in young adult people with diabetes: 
results from the nationwide population-based Diabetes Incidence Study in Sweden (DISS). 
Diabetes Care, 26, 349-54. 
HEYMSFIELD, S. B., SEGAL, K. R., HAUPTMAN, J., LUCAS, C. P., BOLDRIN, M. N., RISSANEN, A., 
WILDING, J. P. & SJOSTROM, L. 2000. Effects of weight loss with orlistat on glucose tolerance 
and progression to type 2 diabetes in obese adults. Arch Intern Med, 160, 1321-6. 
HOLMAN, R. R., PAUL, S. K., BETHEL, M. A., MATTHEWS, D. R. & NEIL, H. A. 2008. 10-year follow-up 
of intensive glucose control in type 2 diabetes. N Engl J Med, 359, 1577-89. 
HUSAIN, K., HERNANDEZ, W., ANSARI, R. A. & FERDER, L. 2015. Inflammation, oxidative stress and 
renin angiotensin system in atherosclerosis. World J Biol Chem, 6, 209-17. 
IACONELLI, A., PANUNZI, S., DE GAETANO, A., MANCO, M., GUIDONE, C., LECCESI, L., GNIULI, D., 
NANNI, G., CASTAGNETO, M., GHIRLANDA, G. & MINGRONE, G. 2011. Effects of bilio-
pancreatic diversion on diabetic complications: a 10-year follow-up. Diabetes Care, 34, 561-
7. 
ISMAIL-BEIGI, F., CRAVEN, T., BANERJI, M. A., BASILE, J., CALLES, J., COHEN, R. M., CUDDIHY, R., 
CUSHMAN, W. C., GENUTH, S., GRIMM, R. H., JR., HAMILTON, B. P., HOOGWERF, B., KARL, 
D., KATZ, L., KRIKORIAN, A., O'CONNOR, P., POP-BUSUI, R., SCHUBART, U., SIMMONS, D., 
TAYLOR, H., THOMAS, A., WEISS, D. & HRAMIAK, I. 2010. Effect of intensive treatment of 
hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD 
randomised trial. Lancet, 376, 419-30. 
K, M. 2009. The History of Diabetes [Online]. Available: 
http://www.everydayhealth.com/diabetes/understanding/diabetes-mellitus-through-
time.aspx [Accessed 20/07/2012 2012]. 
KAHN, S. E. 2003. The relative contributions of insulin resistance and beta-cell dysfunction to the 
pathophysiology of Type 2 diabetes. Diabetologia, 46, 3-19. 
KELLY, T. N., BAZZANO, L. A., FONSECA, V. A., THETHI, T. K., REYNOLDS, K. & HE, J. 2009. Systematic 
Review: Glucose Control and Cardiovascular Disease in Type 2 Diabetes. Annals of Internal 
Medicine, 151, 394-403. 
KODERA, R., SHIKATA, K., KATAOKA, H. U., TAKATSUKA, T., MIYAMOTO, S., SASAKI, M., KAJITANI, N., 
NISHISHITA, S., SARAI, K., HIROTA, D., SATO, C., OGAWA, D. & MAKINO, H. 2011. Glucagon-
like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action 
without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia, 54, 
965-78. 
KUGELBERG, E. 2013. Surgery: Altered gut microbiota trigger weight loss. Nat Rev Gastroenterol 
Hepatol, 10, 259-259. 
LEOW, M. K. & WYCKOFF, J. 2005. Under-recognised paradox of neuropathy from rapid glycaemic 
control. Postgrad Med J, 81, 103-7. 
LIM, E. L., HOLLINGSWORTH, K. G., ARIBISALA, B. S., CHEN, M. J., MATHERS, J. C. & TAYLOR, R. 2011. 
Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased 
pancreas and liver triacylglycerol. Diabetologia, 54, 2506-14. 
138 
 
MACDONALD, K. G., JR., LONG, S. D., SWANSON, M. S., BROWN, B. M., MORRIS, P., DOHM, G. L. & 
PORIES, W. J. 1997. The gastric bypass operation reduces the progression and mortality of 
non-insulin-dependent diabetes mellitus. J Gastrointest Surg, 1, 213-20; discussion 220. 
MARTIN, C. L., ALBERS, J., HERMAN, W. H., CLEARY, P., WABERSKI, B., GREENE, D. A., STEVENS, M. J. 
& FELDMAN, E. L. 2006. Neuropathy Among the Diabetes Control and Complications Trial 
Cohort 8 Years After Trial Completion. Diabetes Care, 29, 340-4. 
MARTYN, C. N. & HUGHES, R. A. 1997. Epidemiology of peripheral neuropathy. J Neurol Neurosurg 
Psychiatry, 62, 310-8. 
MARYNIAK, O. 1984. Severe peripheral neuropathy following gastric bypass surgery for morbid 
obesity. Can Med Assoc J, 131, 119-20. 
MINGRONE, G., PANUNZI, S., DE GAETANO, A., GUIDONE, C., IACONELLI, A., LECCESI, L., NANNI, G., 
POMP, A., CASTAGNETO, M., GHIRLANDA, G. & RUBINO, F. 2012a. Bariatric surgery versus 
conventional medical therapy for type 2 diabetes. N Engl J Med, 366, 1577-85. 
MINGRONE, G., PANUNZI, S., DE GAETANO, A., GUIDONE, C., IACONELLI, A., LECCESI, L., NANNI, G., 
POMP, A., CASTAGNETO, M., GHIRLANDA, G. & RUBINO, F. 2012b. Bariatric Surgery versus 
Conventional Medical Therapy for Type 2 Diabetes. N Engl J Med. 
MIRAS, A., AASHEIM, E., PARPAMAGARITIS, D., CHUAH, L., JACKSON, S. & LE ROUX, C. 2011. Is gastric 
bypass surgery safe for patients with Type 2 diabetes mellitus and microvascular disease? A 
case report. International Diabetes Federation. Dubai. 
MIRAS, A. D., CHUAH, L. L., LASCARATOS, G., FARUQ, S., MOHITE, A. A., SHAH, P. R., GILL, M., 
JACKSON, S. N., JOHNSTON, D. G., OLBERS, T. & LE ROUX, C. W. 2012. Bariatric surgery does 
not exacerbate and may be beneficial for the microvascular complications of type 2 
diabetes. Diabetes Care, 35, e81. 
MULLER-STICH, B. P., FISCHER, L., KENNGOTT, H. G., GONDAN, M., SENFT, J., CLEMENS, G., NICKEL, 
F., FLEMING, T., NAWROTH, P. P. & BUCHLER, M. W. 2013. Gastric bypass leads to 
improvement of diabetic neuropathy independent of glucose normalization--results of a 
prospective cohort study (DiaSurg 1 study). Ann Surg, 258, 760-5; discussion 765-6. 
MURPHY, R., JIANG, Y., BOOTH, M., BABOR, R., MACCORMICK, A., HAMMODAT, H., BEBAN, G., 
BARNES, R. M. & VINCENT, A. L. 2015. Progression of diabetic retinopathy after bariatric 
surgery. Diabet Med, 32, 1212-20. 
NÄSLUND, E. & KRAL, J. G. 2006. Impact of Gastric Bypass Surgery on Gut Hormones and Glucose 
Homeostasis in Type 2 Diabetes. Diabetes, 55, S92-S97. 
NAVANEETHAN, S. D., KELLY, K. R., SABBAGH, F., SCHAUER, P. R., KIRWAN, J. P. & KASHYAP, S. R. 
2010. Urinary albumin excretion, HMW adiponectin, and insulin sensitivity in type 2 diabetic 
patients undergoing bariatric surgery. Obes Surg, 20, 308-15. 
NAVANEETHAN, S. D., YEHNERT, H., MOUSTARAH, F., SCHREIBER, M. J., SCHAUER, P. R. & BEDDHU, 
S. 2009. Weight Loss Interventions in Chronic Kidney Disease: A Systematic Review and 
Meta-analysis. Clinical Journal of the American Society of Nephrology, 4, 1565-1574. 
NAVARRO-DIAZ, M., SERRA, A., ROMERO, R., BONET, J., BAYES, B., HOMS, M., PEREZ, N. & BONAL, J. 
2006. Effect of drastic weight loss after bariatric surgery on renal parameters in extremely 
obese patients: long-term follow-up. J Am Soc Nephrol, 17, S213-7. 
NEFF K, L. T., CHUAHL ET AL 2013. Body mass index and diabetes status do not affect post-operative 
infection rates after bariatric surgery. Surgery for Obesity and Related Diseases. in press ed. 
NEFF, K. J. & LE ROUX, C. W. 2013. Bariatric surgery: a best practice article. J Clin Pathol, 66, 90-8. 
NICOTRA A, N. R., NEWMAN C, SILLS R, JOHNSON M, EREMIN O, MALIK O. 2012. Do Patients born 
with Thalidomide induced limb malformations have peripheral neuropathy? . The British 
Society for Clinical Neurophysiology Scientific meeting,  13 Oct 2012. . London: Epub Clinical 
Neurophysiology. 
OHKUBO, Y., KISHIKAWA, H., ARAKI, E., MIYATA, T., ISAMI, S., MOTOYOSHI, S., KOJIMA, Y., 
FURUYOSHI, N. & SHICHIRI, M. 1995. Intensive insulin therapy prevents the progression of 
diabetic microvascular complications in Japanese patients with non-insulin-dependent 
139 
 
diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract, 28, 103-
17. 
ORGANISATION, W. H. 1999. Definition, Diagnosis and Classification of Diabetes Mellitus and its 
Complications. Part 1: Diagnosis and Classification of Diabetes Mellitus Geneva: World 
Health Organisation. 
ORGANISATION), W. W. H. 2012. Obesity and overweight [Online]. Available: 
http://www.who.int/mediacentre/factsheets/fs311/en/index.html Fact sheet 311]. 
PATEL, A., MACMAHON, S., CHALMERS, J., NEAL, B., BILLOT, L., WOODWARD, M., MARRE, M., 
COOPER, M., GLASZIOU, P., GROBBEE, D., HAMET, P., HARRAP, S., HELLER, S., LIU, L., 
MANCIA, G., MOGENSEN, C. E., PAN, C., POULTER, N., RODGERS, A., WILLIAMS, B., 
BOMPOINT, S., DE GALAN, B. E., JOSHI, R. & TRAVERT, F. 2008. Intensive blood glucose 
control and vascular outcomes in patients with type 2 diabetes. N Engl J Med, 358, 2560-72. 
PERNA, M., ROMAGNUOLO, J., MORGAN, K., BYRNE, T. K. & BAKER, M. 2011. Preoperative 
hemoglobin A1c and postoperative glucose control in outcomes after gastric bypass for 
obesity. Surg Obes Relat Dis. 
PERNA, M., ROMAGNUOLO, J., MORGAN, K., BYRNE, T. K. & BAKER, M. 2012. Preoperative 
hemoglobin A1c and postoperative glucose control in outcomes after gastric bypass for 
obesity. Surg Obes Relat Dis, 8, 685-90. 
PITALE, S., KERNAN-SCHROEDER, D., EMANUELE, N., SAWIN, C., SACKS, J. & ABRAIRA, C. 2005. 
Health-related quality of life in the VA Feasibility Study on glycemic control and 
complications in type 2 diabetes mellitus. J Diabetes Complications, 19, 207-11. 
PORIES, W. J. 2008. Bariatric surgery: risks and rewards. J Clin Endocrinol Metab, 93, S89-96. 
PORIES, W. J., SWANSON, M. S., MACDONALD, K. G., LONG, S. B., MORRIS, P. G., BROWN, B. M., 
BARAKAT, H. A., DERAMON, R. A., ISRAEL, G., DOLEZAL, J. M. & ET AL. 1995. Who would have 
thought it? An operation proves to be the most effective therapy for adult-onset diabetes 
mellitus. Ann Surg, 222, 339-50; discussion 350-2. 
POURNARAS, D. J., AASHEIM, E. T., SØVIK, T. T., ANDREWS, R., MAHON, D., WELBOURN, R., OLBERS, 
T. & LE ROUX, C. W. 2012a. Effect of the definition of type II diabetes remission in the 
evaluation of bariatric surgery for metabolic disorders. British Journal of Surgery, 99, 100-
103. 
POURNARAS, D. J., GLICKSMAN, C., VINCENT, R. P., KUGANOLIPAVA, S., ALAGHBAND-ZADEH, J., 
MAHON, D., BEKKER, J. H. R., GHATEI, M. A., BLOOM, S. R., WALTERS, J. R. F., WELBOURN, R. 
& LE ROUX, C. W. 2012b. The Role of Bile After Roux-en-Y Gastric Bypass in Promoting 
Weight Loss and Improving Glycaemic Control. Endocrinology, 153, 3613-9. 
POURNARAS, D. J., OSBORNE, A., HAWKINS, S. C., VINCENT, R. P., MAHON, D., EWINGS, P., GHATEI, 
M. A., BLOOM, S. R., WELBOURN, R. & LE ROUX, C. W. 2010. Remission of type 2 diabetes 
after gastric bypass and banding: mechanisms and 2 year outcomes. Ann Surg, 252, 966-71. 
POWER, C. & THOMAS, C. 2011. Changes in BMI, duration of overweight and obesity, and glucose 
metabolism: 45 years of follow-up of a birth cohort. Diabetes Care, 34, 1986-91. 
RASMUSSEN, K. L., LAUGESEN, C. S., RINGHOLM, L., VESTGAARD, M., DAMM, P. & MATHIESEN, E. R. 
2010. Progression of diabetic retinopathy during pregnancy in women with type 2 diabetes. 
Diabetologia, 53, 1076-83. 
RAY, D., MISHRA, M., RALPH, S., READ, I., DAVIES, R. & BRENCHLEY, P. 2004. Association of the VEGF 
gene with proliferative diabetic retinopathy but not proteinuria in diabetes. Diabetes, 53, 
861-4. 
REICHARD, P., NILSSON, B. Y. & ROSENQVIST, U. 1993. The effect of long-term intensified insulin 
treatment on the development of microvascular complications of diabetes mellitus. N Engl J 
Med, 329, 304-9. 
REMUZZI, G., SCHIEPPATI, A. & RUGGENENTI, P. 2002. Clinical practice. Nephropathy in patients with 
type 2 diabetes. N Engl J Med, 346, 1145-51. 
140 
 
RIBARIC, G., BUCHWALD, J. N. & MCGLENNON, T. W. 2014. Diabetes and weight in comparative 
studies of bariatric surgery vs conventional medical therapy: a systematic review and meta-
analysis. Obes Surg, 24, 437-55. 
ROSENSTOCK, J., FONSECA, V. A., GARVEY, W. T., GOLDBERG, R. B., HANDELSMAN, Y., ABBY, S. L., 
LAI, Y. L., JIN, X., MISIR, S., NAGENDRAN, S. & JONES, M. R. 2010. Initial combination therapy 
with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 
diabetes. Endocr Pract, 16, 629-40. 
RUBINO, F., FORGIONE, A., CUMMINGS, D. E., VIX, M., GNULI, D., MINGRONE, G., CASTAGNETO, M. 
& MARESCAUX, J. 2006. The mechanism of diabetes control after gastrointestinal bypass 
surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 
diabetes. Ann Surg, 244, 741-9. 
RUBINO, F., SCHAUER, P. R., KAPLAN, L. M. & CUMMINGS, D. E. 2010. Metabolic surgery to treat 
type 2 diabetes: clinical outcomes and mechanisms of action. Annu Rev Med, 61, 393-411. 
SCHAUER, P. R., BURGUERA, B., IKRAMUDDIN, S., COTTAM, D., GOURASH, W., HAMAD, G., EID, G. 
M., MATTAR, S., RAMANATHAN, R., BARINAS-MITCHEL, E., RAO, R. H., KULLER, L. & KELLEY, 
D. 2003. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann 
Surg, 238, 467-84; discussion 84-5. 
SCHAUER, P. R., KASHYAP, S. R., WOLSKI, K., BRETHAUER, S. A., KIRWAN, J. P., POTHIER, C. E., 
THOMAS, S., ABOOD, B., NISSEN, S. E. & BHATT, D. L. 2012a. Bariatric Surgery versus 
Intensive Medical Therapy in Obese Patients with Diabetes. N Engl J Med. 
SCHAUER, P. R., KASHYAP, S. R., WOLSKI, K., BRETHAUER, S. A., KIRWAN, J. P., POTHIER, C. E., 
THOMAS, S., ABOOD, B., NISSEN, S. E. & BHATT, D. L. 2012b. Bariatric surgery versus 
intensive medical therapy in obese patients with diabetes. N Engl J Med, 366, 1567-76. 
SCOPINARO, N., ADAMI, G. F., PAPADIA, F. S., CAMERINI, G., CARLINI, F., BRIATORE, L., 
D'ALESSANDRO, G., PARODI, C., WEISS, A., ANDRAGHETTI, G., CATALANO, M. & CORDERA, R. 
2011. The effects of biliopancreatic diversion on type 2 diabetes mellitus in patients with 
mild obesity (BMI 30-35 kg/m2) and simple overweight (BMI 25-30 kg/m2): a prospective 
controlled study. Obes Surg, 21, 880-8. 
SEHGAL, R., BERG, A., FIGUEROA, R., PORITZ, L. S., MCKENNA, K. J., STEWART, D. B. & KOLTUN, W. A. 
2011. Risk factors for surgical site infections after colorectal resection in diabetic patients. J 
Am Coll Surg, 212, 29-34. 
SHAW, K., GENNAT, H., O’ROURKE & DEL MA, C. 2006. <Cochrane exercise for overweight or 
obese.pdf>. 
SILVA, R. A., MORTON, J. M. & MOSHFEGHI, D. M. 2013. Severe worsening of diabetic retinopathy 
following bariatric surgery. Ophthalmic Surg Lasers Imaging Retina, 44 Online, E11-4. 
SINGH, R. P., GANS, R., KASHYAP, S. R., BEDI, R., WOLSKI, K., BRETHAUER, S. A., NISSEN, S. E., BHATT, 
D. L. & SCHAUER, P. 2015. Effect of Bariatric Surgery Versus Intensive Medical Management 
on Diabetic Ophthalmic Outcomes. Diabetes Care, 38, e32-e33. 
SINGLETON, J., VOLCKMANN, E., GRAHAM, T. & SMITH, A. 2014. Neuropathy Associated with 
Nondiabetic Obesity (S36.006). Neurology, 82, S36.006. 
SJOSTROM, L., NARBRO, K., SJOSTROM, C. D., KARASON, K., LARSSON, B., WEDEL, H., LYSTIG, T., 
SULLIVAN, M., BOUCHARD, C., CARLSSON, B., BENGTSSON, C., DAHLGREN, S., GUMMESSON, 
A., JACOBSON, P., KARLSSON, J., LINDROOS, A. K., LONROTH, H., NASLUND, I., OLBERS, T., 
STENLOF, K., TORGERSON, J., AGREN, G. & CARLSSON, L. M. 2007. Effects of bariatric surgery 
on mortality in Swedish obese subjects. N Engl J Med, 357, 741-52. 
SJOSTROM, L., PELTONEN, M., JACOBSON, P., SJOSTROM, C. D., KARASON, K., WEDEL, H., AHLIN, S., 
ANVEDEN, A., BENGTSSON, C., BERGMARK, G., BOUCHARD, C., CARLSSON, B., DAHLGREN, S., 
KARLSSON, J., LINDROOS, A. K., LONROTH, H., NARBRO, K., NASLUND, I., OLBERS, T., 
SVENSSON, P. A. & CARLSSON, L. M. 2012. Bariatric surgery and long-term cardiovascular 
events. JAMA, 307, 56-65. 
141 
 
SMITH, A. G., RUSSELL, J., FELDMAN, E. L., GOLDSTEIN, J., PELTIER, A., SMITH, S., HAMWI, J., 
POLLARI, D., BIXBY, B., HOWARD, J. & SINGLETON, J. R. 2006. Lifestyle intervention for pre-
diabetic neuropathy. Diabetes Care, 29, 1294-9. 
STAMLER, J., VACCARO, O., NEATON, J. D. & WENTWORTH, D. 1993. Diabetes, other risk factors, and 
12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention 
Trial. Diabetes Care, 16, 434-44. 
STRATTON, I. M., ADLER, A. I., NEIL, H. A., MATTHEWS, D. R., MANLEY, S. E., CULL, C. A., HADDEN, D., 
TURNER, R. C. & HOLMAN, R. R. 2000. Association of glycaemia with macrovascular and 
microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. 
BMJ, 321, 405-12. 
SWINBURN, B. A., SACKS, G., HALL, K. D., MCPHERSON, K., FINEGOOD, D. T., MOODIE, M. L. & 
GORTMAKER, S. L. 2011. The global obesity pandemic: shaped by global drivers and local 
environments. Lancet, 378, 804-14. 
THAISETTHAWATKUL, P., COLLAZO-CLAVELL, M. L., SARR, M. G., NORELL, J. E. & DYCK, P. J. 2004. A 
controlled study of peripheral neuropathy after bariatric surgery. Neurology, 63, 1462-70. 
THE NHS INFORMATION CENTRE, L. S. 2012. 
<Statistics_on_Obesity_Physical_Activity_and_Diet_England_2012.pdf>. 23 February 2012 
ed. 
THOMAS, D. E., ELLIOTT, E. J. & BAUR, L. 2007. Low glycaemic index or low glycaemic load diets for 
overweight and obesity. Cochrane Database Syst Rev, CD005105. 
THOMAS, R. L., PRIOR, S. L., BARRY, J. D., LUZIO, S. D., EYRE, N., CAPLIN, S., STEPHENS, J. W. & 
OWENS, D. R. 2014. Does bariatric surgery adversely impact on diabetic retinopathy in 
persons with morbid obesity and type 2 diabetes? A pilot study. J Diabetes Complications, 
28, 191-5. 
TORGERSON, J. S., HAUPTMAN, J., BOLDRIN, M. N. & SJOSTROM, L. 2004. XENical in the prevention 
of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct 
to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 
27, 155-61. 
UK, D. 2012. DIABETES IN THE UK 2012 Key statistics on diabetes. UK: Diabetes UK. 
VAN NIEUWENHOVE, Y., DAMBRAUSKAS, Z., CAMPILLO-SOTO, A., VAN DIELEN, F., WIEZER, R., 
JANSSEN, I., KRAMER, M. & THORELL, A. 2011. Preoperative very low-calorie diet and 
operative outcome after laparoscopic gastric bypass: a randomized multicenter study. Arch 
Surg, 146, 1300-5. 
VASILAKOU, D., KARAGIANNIS, T., ATHANASIADOU, E., MAINOU, M., LIAKOS, A., BEKIARI, E., 
SARIGIANNI, M., MATTHEWS, D. R. & TSAPAS, A. 2013. Sodium–glucose cotransporter 2 
inhibitors for type 2 diabetes: a systematic review and meta-analysis. Annals of internal 
medicine, 159, 262-274. 
WAHBA, I. M. & MAK, R. H. 2007. Obesity and Obesity-Initiated Metabolic Syndrome: Mechanistic 
Links to Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology, 2, 
550-562. 
WANG, Y. C., MCPHERSON, K., MARSH, T., GORTMAKER, S. L. & BROWN, M. 2011. Health and 
economic burden of the projected obesity trends in the USA and the UK. Lancet, 378, 815-
25. 
WATKINS, P. J. 2003. Retinopathy. BMJ, 326, 924-6. 
WILD, S., ROGLIC, G., GREEN, A., SICREE, R. & KING, H. 2004. Global prevalence of diabetes: 
estimates for the year 2000 and projections for 2030. Diabetes Care, 27, 1047-53. 
WILKINSON, C. P., FERRIS, F. L., III, KLEIN, R. E., LEE, P. P., AGARDH, C. D., DAVIS, M., DILLS, D., 
KAMPIK, A., PARARAJASEGARAM, R. & VERDAGUER, J. T. Proposed international clinical 
diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology, 
110, 1677-1682. 
142 
 
YOUNG, M. J., BOULTON, A. J., MACLEOD, A. F., WILLIAMS, D. R. & SONKSEN, P. H. 1993. A 
multicentre study of the prevalence of diabetic peripheral neuropathy in the United 
Kingdom hospital clinic population. Diabetologia, 36, 150-4. 
ZIMMET, P., ALBERTI, K. G. & SHAW, J. 2001. Global and societal implications of the diabetes 
epidemic. Nature, 414, 782-7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
143 
 
Appendix 1. Publication arising from the thesis: 
 
1. Miras AD, Chuah LL, Khalil N, Nicotra A, Vusirikala A, Baqai N, Graham C, 
Ravindra S, Lascaratos G, Oliver N, le Roux CW. Type 2 diabetes mellitus and 
microvascular complications 1 year after Roux-en-Y gastric bypass: a case-control 
study. Diabetologia. 2015 Jul;58(7):1443-7 
 
2. Chuah LL, Miras AD, Papamargaritis D, Jackson SN, Olbers T, le Roux CW. 
Impact of perioperative management of glycemia in severely obese diabetic patients 
undergoing gastric bypass surgery. Surgery for Obesity and Related Disease. 2015 
May-Jun;11(3):578-584. 
